Field of the Invention The present invention relates to compounds with vasopressin Vla antagonist activity and to pharmaceutical compositions comprising such compounds. The present invention also relates to the use of vasopressin Vla antagonists for the treatment of certain physiological disorders, such as Raynaud's disease and dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea) .

Priority is claimed from EP patent application number 04104062 and US patent application number 60/603557, both filed 24 August 2004.

Background The neurophyseal hormones vasopressin (VP) and oxytocin (OT) are cyclic nonapeptides secreted by the posterior pituitary gland.

Only one OT receptor has so far been well characterised, while three VP receptors are known. These are designated the Via, Vib and V2 receptors.

Vasopressin acts on the blood vessels, where it is a potent vasoconstrictor, and on the kidneys, where it promotes water reuptake leading to an antidiuretic effect.

The Via, Vib, and V2, as well as the OT receptors, are members of the super-family of seven transmembrane re¬ ceptors known as G-protein coupled receptors. The Via receptor mediates phospholipase C activation and intra¬ cellular calcium mobilisation. Localisation of the re¬ ceptors includes blood platelets, blood vessels, hepa- tocytes, brain and uterus-cervix. Thus a Via antagonist may have effects on any or all of these tissues. For example, selective Vla antagonists have been cited as having clinical utility in dysmenorrhoea, pre-term Ia- bour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.

With respect to dysmenorrhoea it has been proposed that myometrial activity is markedly increased in women with dysmenorrhoea during menstruation. It is proposed that the myometrial ischemia caused by increased uterine contractility might explain the menstrual pain. Fur- thermore, on the first day of menstruation, higher plasma concentrations of vasopressin have been measured in dysmenorroeic women than in controls.

In healthy women without dysmenorrhoea, intravenous in- fusion of lysine-vasopressin resulted in decreased uterine blood flow, increased uterine contractility and slight to moderate dysmenorrhoea-like pain, these ef¬ fects being inhibited by a selective human Vχa receptor antagonist. (Bossmar, T. et al., BRITISH JOURNAL OF OB- STETRICS AND GYNAECOLOGY (1997 Apr), 104(4), 471-7) . Also, it is known that vasopressin contracts human uterine arteries in a dose-dependent and Via-mediated fashion.

The above evidence suggests that a Vi3 antagonist would be an appropriate and effective treatment for dysmenor¬ rhoea (primary dysmenorrhoea and/or secondary dysmenor¬ rhoea) . Further evidence is taken from the clinical study carried out on the selective Via antagonist SR49059 ("Effect of SR49059, an orally active Via vaso¬ pressin receptor antagonist, in the prevention of dys- menorrhea". Brouard, R. et al. , BRITISH JOURNAL OF OB¬ STETRICS AND GYNAECOLOGY (2000), 107(5), 614-619) . It was found that there was a dose-related decrease in pain and a dose-related decrease in the amount of addi- tional pain-killer taken compared to patients taking placebo.

The International Patent Application WO 03/016316 Al, published 27 February 2003, discloses a number of compounds which are claimed to be oxytocin agonists and to find use in the treatment of male erectile dysfunction. No Vχa antagonist activity is reported. The European Patent Application EP 1 449 844 Al, published 25 August 2004, discloses a number of compounds which are claimed to be Vχa antagonists and to find use in the treatment of primary dysmenorrhoea.

There exists a need for treatments for conditions which are associated with the Via receptors. There further continues to exist a need for alternative Vi3 antagonists. Simple synthesis and oral availability are additional desirable characteristics.

Disclosure of the Invention According to an aspect, the present invention relates to compounds, preferably VP antagonists, and in particular specific antagonists of the Via receptor, and pharmaceutically acceptable salts thereof.

According to another aspect, the present invention relates to pharmaceutical compositions comprising these compounds, which compositions are useful for the treatment of, inter alia, dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea) .

According to another aspect, the present invention relates to the use of the compounds for the manufacture of a pharmaceutical composition for treatment of dysmenorrhoea.

According to further aspects, the present invention relates to the medical use and to the use of the above mentioned compounds and compositions in therapy and to therapeutic methods wherein the above mentioned compounds and compositions are used.

Detailed Description of the Invention According to an aspect the invention concerns a compound according to general formula Ia, or a compound which is a tautomer or a pharmaceutically acceptable salt thereof,

Ia

wherein G is a group selected among general formula 2a, 3a, 4a, 5a, and 6a,

wwhπecrietiixnπ:. A1 is selected among CH2, CH(OH), NH, N-alkyl, 0 and S; A2 is selected among CH2, CH(OH), C (=0) and NH; A and A are independently selected among S, NH, N-alkyl, -C(R8)=CH-, -C(FT)=N-, -N=C(R8)- and -CH=C(R8)-; A4 and A13 are independently selected among C(R9) and N; A5 and A14 are independently selected among C(R10) and N; A6 is selected among CH2, NH, N-alkyl and 0; A7 and A11 are independently selected among C and N; A8 and A9 are independently selected among CH, N, NH, N (CH2) bR 11 and S ; A . 1Λ0U is selected among -CH=CH-, CH, N, NH, N- (CH2) h-R 1111 and S ; wherein the ring constituted by A7, A8, A9, A10 and A11 is aromatic; R1, R2 and R3 are independently selected among H, alkyl, O-alkyl, NO2, F, Cl and Br; R4 is selected among H, alkyl , aryl , heteroaryl, - (CH2) c-R % and

R5 and R6 are independently selected among alkyl, aryl, - (CH2) f-aryl, and - (CH2) f-heteroaryl; R7 is selected among H, alkyl, aryl, heteroaryl, and -(CH2)g-R14; R8, R9 and R10 are independently selected among H, alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl), N (alkyl)2; with the provisos that when G is 3a, and R4 is H, alkyl, aryl, heteroaryl or - (CH2)c-R12, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH (alkyl) or N (alkyl) 2; and when G is 4a, R4 is H, alkyl, aryl, heteroaryl or -(CH2)c-R12/ and A8 is NH, NCH3 or S, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH(alkyl) or N (alkyl)2; R11 and R12 are independently selected among H, alkyl, aryl, heteroaryl, F, OH, 0-alkyl, S-alkyl, O-acyl, NH2, NH-alkyl, N (alkyl) 2, NH-acyl, N (alkyl) -acyl, CO2H, CO2-alkyl, CONH2, CONH-alkyl, CON (alkyl)2, CN and CF3; R13 is selected among H, alkyl, aryl, heteroaryl, - (CH2)H-R15 and Z-R16; R14 and R15 are independently selected among H, alkyl, alkenyl, aryl, heteroaryl, F, OH, O-alkyl, S-alkyl, 0- acyl, NH2, NH-alkyl, N (alkyl) 2, NH-acyl, N (alkyl) -acyl, CO2H, C02-alkyl, CO-alkyl, CO-aryl, CONH2, CONH-alkyl, CON (alkyl) 2, alkenyl-CO2-alkyl, alkenyl-aryl, CN and CF3; R16 is selected among H, alkyl, alkenyl, aryl, heteroaryl, 0-aryl, - (CH2) ±-R17 , cyclopropyl-aryl and 0- ( CH2)i-R17 ; R17 is selected among H, alkyl, aryl, heteroaryl, F, OH, O-alkyl, S-alkyl, O-acyl, NH2, NH-alkyl, N (alkyl) 2, NH- acyl, N (alkyl) -acyl, CO2H, C02-alkyl, CONH2, CONH-alkyl, CON (alkyl) 2, CN and CF3; W is selected among 0 and NH; X is selected among (CH2)m, C (=0) and S(=O)j Y is selected among 0, S, NH and N-alkyl; Z is selected among -C(=0), -C(=0)-0 and -S(=0)k; a is selected among 1 and 2; b and c are independently selected among 0, 1, 2 and 3; d, e and f are independently selected among 1 and 2; g, h and i are independently selected among 1, 2 and 3; j and k are independently selected among 1 and 2; and m and n are independently selected among 0, 1 and 2.

According to an aspect, R16 may further be selected among O-alkyl and O-alkenyl, and Z is different from -C(=O)-0.

It appears that the compounds of formula Ia of claim 1 are subject to the following constraints. When G is 3a, and R4 is H, alkyl, aryl, heteroaryl or - (CH2) C-R12, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH (alkyl) or N (alkyl) 2. When G is 4a, R4 is H, alkyl, aryl, heteroaryl or - (CH2)C-R12, and A8 is NH, NCH3 or S, then the ring containing A3, A4 and A5 is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, NO2, NH (alkyl) or N (alkyl) 2. The ring constituted by A7, A8, A9, AlO and All is aromatic, and accordingly the groups must satisfy certain requirements. When AlO is -CH=CH- the ring is a six membered ring. As such, it can only comprise atoms of the type -C(R)= and -N=. Hence A7 and All must both be C and A8 and A9 must be either CH or N. When AlO is not -CH=CH- then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a "trigonal nitrogen" is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five-membered ring. Thus it follows that, when AlO is not -CH=CH- then one (and only one) of A7, A8, A9, AlO and All must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, AlO and All is subject to the following restrictions. If AlO is not -CH=CH- then one of A8, A9 and AlO is NH, N-(CH2)b-Rll or S or one of A7 and All is N. Not more than one of A8, A9 and AlO may be NH, N-(CH2)b-Rll or S. A7 and All may not both simultaneously be N. Neither A7 nor All may be N if one of A8, A9 and AlO is NH, N- (CH2)b-Rll or S.

According to aspects of the invention, additional and preferred embodiments of the invention are as set out below, in the description and the claims.

The term "alkyl" includes saturated hydrocarbon residues including: linear groups up to 10 atoms (Ci-Cio) . Examples of such alkyl groups include, but are not limited to, Ci - methyl, C2 - ethyl, C3 - propyl and C4- n-butyl; - branched groups of between 3 and 10 atoms (C3-Ci0) • Examples of such alkyl groups include, but are not limited to, C3 - iso-propyl, C4 - sec-butyl, C4 - iso- butyl, C4 - tert-butyl and C5 - neo-pentyl; cyclic groups of between 3 and 8 atoms (C3-Ce) • Examples of such groups include but are not limited to, C3 - cyclopropyl, C4 - cyclobutyl, C5 - cyclopentyl and C6 - cyclohexyl; - combinations of linear, branched and cyclic groups. Examples of such groups include, but are not limited to, The term "alkoxy" is used to denote 0-alkyl groups

The term "alkenyl" includes monounsaturated hydrocarbon residues including - linear groups of between two and six atoms (C2-C6) • Examples of such alkenyl groups include, but are not limited to, C2 - vinyl, C3 - 1-propenyl, C3 - allyl and C4 - 2-butenyl; branched groups of between 3 and 8 atoms (C3-C8) . Examples of such alkenyl groups include, but are not limited to, C4 - 2-methyl-2-propenyl and Ce ~ 2,3- dimethyl-2-butenyl; cyclic groups of between 3 and 8 atoms (C3-C8) . Examples of such groups include, but are not limited to, C5 - 3-cyclopentenyl and Ce - 1-cyclohexenyl.

The term "aryl" includes optionally substituted phenyl and optionally substituted naphthyl. Examples of such aryl groups include, but are not limited to, phenyl, 2- tolyl, 3-chlorophenyl, 4-chlorophenyl, 3-fluorophenyl, 2-methoxyphenyl , 3-methoxyphenyl, 4-methoxyphenyl, 2, 5-difluorophenyl, 1-naphthyl and 2-naphthyl.

The term "heteroaryl" includes optionally substituted heterocycles. Such heteroaryl groups include, but are not limited to, pyridyl, 2-chloropyridyl, 4- methylpyridyl, thienyl, 3-chlorothienyl, 2,3- dimethylthiophenyl, furyl, 2-methylfuryl, pyrrole, N- methylpyrrole, oxazole, imidazole, pyrazole and triazole.

The term λλacyl" denotes a group R-C (=0), where R is H, a saturated or unsaturated hydrocarbon moiety of up to seven carbon atoms or an optionally substituted phenyl, optionally substituted pyridyl or optionally substituted thienyl group. Examples of acyl groups include, but are not limited to: formyl, acetyl, pivaloyl, benzoyl and nicotinoyl.

Certain compounds of the present invention are capable of forming salts with acids or bases. For example, compounds containing one or more basic nitrogen atoms can form addition salts with mineral and organic acids such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trifluoroacetic acid, methanesulphonic acid, citric acid and benzoic acid. Compounds containing acidic groups can form salts with bases. Examples of such salts include the sodium, potassium, calcium, triethylammonium and tetraethylammonium salts. Furthermore, compounds that have both acidic and basic groups can form internal salts (zwitterions) . Insofar as these salts are pharmaceutically acceptable, they are included within the scope of the invention.

Certain compounds within the scope of the present invention may exist as tautomers. For example, where G1 is general formula 4a (4b, 4c, 4d) and X2 is NH the resulting imidazole can exist as its tautomer which is defined by G1 as general formula 5a (5b, 5c, 5d) and X2 as NH. All such tautomers are considered to be within the scope of the present invention.

The compounds according to the present invention may have one or more stereogenic centres ("asymmetric carbon atoms") and so may exhibit optical isomerism. The scope of the present invention includes all epimers, enantiomers and diastereomers of compounds according to the present invention, including single isomers, mixtures and racemates. According to an aspect, it is preferred that G is selected among:

According to an aspect, it is further preferred that G is selected among:

According to an aspect, it is preferred that at least one of R1, R2 and R3 is other than hydrogen; preferably- one of R1, R2 and R3 is selected among methyl, chlorine and fluorine, and the others are hydrogen.

According to different aspects, it is preferred that W is NH; R4 is alkyl; d is 2 and e is 2; R13 is alkyl; and/or n is 0.

According to an aspect, it is preferred that R2 is H, R4 is a piperidine where d is 2 and e is 2, W is NH, X is C(=0) and n is 0, as shown in formula 18a:

wherein R1 is selected among methyl, chlorine and fluorine, and R3 is H; or R1 is H, and R3 is selected among methyl, chlorine and fluorine, and R13 is alkyl.

According to an aspect, it is preferred that X is C(=O) , n is 0 and R4 is a piperidine where d is 2 and e is 2, as shown in formula 19a:

wherein G is selected among general formulae 7a to 17a, and R13 is alkyl.

According to an aspect, it is preferred that R2 is H and W is NH as shown in formula 20a:

20a

wherein either R1 is selected among methyl, chlorine and fluorine, and R3 is H; or R1 is H, and R3 is selected among methyl, chlorine and fluorine; and G is selected from general formulae 7a to 17a.

According to an aspect, it is preferred that R2 is H, W is NH and X is C(=0) as shown in formula 21a: 21a

wherein R1 is selected among methyl, chlorine and fluorine, and R3 is H; or R1 is H, and R3 is selected among methyl, chlorine and fluorine; and R4 is alkyl.

According to an aspect, it is preferred that X is C(=O) as shown in formula 22a:

22a

wherein G is selected among general formulae 7a to 17a, and R4 is alkyl.

According to an aspect, it is preferred that R2 and R3 are both H, W is NH and X is C(=0) as shown in formula 23a:

23a wherein G is selected among general formulae 9a, 10a, 15a, 16a and 17a, R1 is selected among methyl, chlorine and fluorine, and R4 is alkyl.

According to an aspect, it is preferred that R2 and R3 are both H, R4 is a piperidine where d is 2 and e is 2, W is NH, X is C(=0) and n is 0 as shown in formula 24a:

wherein G is selected among general formulae 9a, 10a, 15a, 16a and 17a, R1 is selected among methyl, chlorine and fluorine, and R13 is alkyl.

According to an aspect, particularly preferred compounds are provided in claim 17.

According to an aspect of the present invention, it relates to the compounds of claim 18. According to an aspect, the ring containing A3, A4 and A5 according to general formulae 2b and 3b is substituted in at least one position by alkyl, alkoxy, F, Cl, Br, CN, NH2, N02, NH(alkyl) or N (alkyl)2.

It appears that the compounds of formula Ib of claim 18 are subject to following constraints. As the ring constituted by A7, A8, A9, A10 and A11 is aromatic, the groups must satisfy certain requirements. When A10 is - CH=CH- the ring is a six membered ring. As such, it can only comprise atoms of the type -C(R)= and -N=. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not -CH=CH- then the ring is a five- membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a "trigonal nitrogen" is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five- membered ring. Thus it follows that, when A10 is not - CH=CH- then one, and only one, of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not -CH=CH- then one of A8, A9 and A10 is NH, N- (CH2) d-R5 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N- (CH2)d~R5 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is NH, N- (CH2)d-R5 or S.

According to an aspect, particularly preferred compounds are provided in claim 30.

According to an aspect of the present invention, it relates to the compounds of claim 31. It appears that the compounds of formula Ic of claim 31 are subject to following constraints. The ring constituted by A7, A8, A9, A10 and A11 is aromatic, and accordingly the groups must satisfy certain requirements. When A10 is -CH=CH- the ring is a six membered ring. As such, it can only comprise atoms of the type -C(R)= and -N=. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not -CH=CH- then the ring is a five-membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a "trigonal nitrogen" is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five- membered ring. Thus it follows that, when A10 is not - CH=CH- then one (and only one) of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not -CH=CH- then one of A8, A9 and A10 is NH, N- (CH2) C-R6 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N- (CH2)C-R6 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is NH, N-(CH2)c-R6 or S.

According to an aspect, particularly preferred compounds are provided in claim 45.

According to an aspect of the present invention, it relates to the compounds of claim 46. It appears that the compounds of formula Id of claim 46 are subject to the following constraints. The ring constituted by A7, A8, A9, A10 and A11 is aromatic, and accordingly the groups must satisfy certain requirements. When A10 is - CH=CH- the ring is a six membered ring. As such, it can only comprise atoms of the type -C(R)= and -N=. Hence A7 and A11 must both be C and A8 and A9 must be either CH or N. When A10 is not -CH=CH- then the ring is a five- membered ring. In this case one, and only one, of the atoms in the ring must be S or a trigonal nitrogen. In this context, a "trigonal nitrogen" is a nitrogen atom linked covalently to three different atoms. Two of these atoms are the immediate neighbours to the nitrogen atom in the five-membered ring. The third is a hydrogen, carbon or other atom linked to the five- membered ring. Thus it follows that, when A10 is not - CH=CH- then one (and only one) of A7, A8, A9, A10 and A11 must be S or a trigonal nitrogen. Hence the selection of A7, A8, A9, A10 and A11 is subject to the following restrictions. If A10 is not -CH=CH- then one of A8, A9 and A10 is NH, N-(CH2)C-R11 or S or one of A7 and A11 is N. Not more than one of A8, A9 and A10 may be NH, N- (CH2) c- R11 or S. A7 and A11 may not both simultaneously be N. Neither A7 nor A11 may be N if one of A8, A9 and A10 is

According to an aspect, particularly preferred compounds are provided in claim 69.

The particularly preferred compounds of the invention are Vla antagonists of high activity.

According to an aspect, at least one of the compounds, identified as follows, is not part of the present invention: claim 1 and ex. 286 (3-Pyridin-3-yl-4, 5- dihydro-isoxazole-5-carboxylic acid [4- (4- dimethylamino-benzylcarbamoyl) -phenyl] -amide) of US 6 583 141; ex. 5 and 6 of WO 02/04403 (N- [4- (N-Methyl-N- phenylaminocarbonyl) -phenhylmethyl] -3- (4' - trifluormethylbiphenyl-2-carbonylamino)benzoic acid amide and N- [4- (N-Methyl-N-phenylaminocarbonyl) - phenhylmethyl] -3- (biphenyl-2-carbonylamino)benzoic acid amide); abstract, J. Org. Chem. USSR, vol. 18, no. 6, 1982, p. 1115-1119 (p- (N,N-diethylcarbamoyloxy) -N,N- diethylbenzamide) ; p. 3, 1. 16 - p. 4, 1. 11, ex. 1-4, 11, and 14-19 of WO 01/29005; p. 3, 1. 9 - p. 5, 1. 23, ex. 11, 28-31, 38, and 71-77 of WO 02/00626; and p. 3, 1. 1 - p. 4, 1. 17, ex. 12-18 of WO 03/016316.

According to an aspect, the invention concerns a pharmaceutical composition comprising a compound according to the invention as an active agent. The invention is further related to pharmaceutical compositions incorporating a compound according to the invention used as a Vχa antagonist, which compositions are particularly useful for medical indications such as the treatment of dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea) , pre-term labour, hy¬ pertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depres¬ sion, anxiety, hyponatremia, liver cirrhosis and con- gestive heart failure.

Any excipients used will depend on the intended nature of the formulation, which will, in turn, depend on the intended route of administration. Administration may be oral, transmucosal (such as sublingual, buccal, intranasal, vaginal and rectal) , transdermal or by injection (such as subcutaneous, intramuscular and intravenous) . Oral administration is generally preferred. For oral administration, the formulation may be a tablet, a capsule or a sachet. Other formulations include dry powders, solutions, suspensions, suppositories and the like.

According to an aspect, the invention concerns the use of a compound of the invention for the manufacture of a medicament for the treatment of a disease selected among dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea) , pre-term labour, hyperten¬ sion, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxi¬ ety, hyponatremia, liver cirrhosis and congestive heart failure.

The compounds according to the present invention may be useful for treatment of several diseases, disorders or conditions. The term "treatment" used herein relates to both treatment in order to cure or alleviate a disease, disorder or a condition, and to treatment in order to prevent the development of a disease, disorder or a condition. The treatment may either be performed in an acute or in a chronic way. The human or animal to be treated, i.e. the patient, may be any human or non- human mammal in need of treatment according to the invention.

The administration of the compositions of the present invention will generally be under the control of a physician. The physician will determine the amount of composition to be administered and the dosing schedule, taking into account the patient's physical condition and the therapeutic goals.

Further aspects of the invention relates to methods of treatment of the above mentioned diseases, disorders or conditions. According to a method according to the invention a therapeutically effective amount of the compound, or of the pharmaceutical composition described above, is administered to a patient in need of this treatment. According to different aspects of the invention, it concerns a method of treatment of a disorder selected among dysmenorrhoea (primary dysmenorrhoea and/or secondary dysmenorrhoea) , pre-term labour, hypertension, Raynaud's disease, brain oedema, motion sickness, hyperlipemia, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.

The term "therapeutically effective amount" relates to an amount that will lead to the desired therapeutical effect. The therapeutically effective amount will be determined by the attending physician taking into consideration all appropriate factors. Generally a single dose will comprise between 0.1 mg and 1000 mg, preferably between 1 mg and 250 mg, of the active compound according to the invention. The dose may be given on a single occasion or repeatedly. When given repeatedly, it may be given at regular intervals, such as once, twice or three times daily, or on demand, according to the condition being treated.

The pharmaceutical composition according to the present invention may be presented in any form that is known in the art. For example, the formulation may be presented as a tablet, capsule, powder, suppository, cream, solution or suspension, or in a more complex form such as an adhesive patch. The formulation will generally include one or more excipients, such as diluents, bulking agents, binding agents, dispersants, solvents, preservatives, flavouring agents and the like. The formulation may also include one or more additional phar-macologically active species. Preferably the formulation includes no such additional active agents.

When used as therapeutic agents, the compositions of the present invention may be administered by any appropriate route that is known in the art. For example, they may be administered by the oral, buccal, sublingual, rectal, intra-vaginal, nasal, pulmonary or transdermal routes. Alternatively, they may be given by injection, including intravenous, subcutaneous and intramuscular injection.

The compounds of the present invention can be prepared using standard chemical manipulations. These are described in detail in WO 03/016316 Al, pages 12-17. (Hudson, P. J. et al., "Diazacycloalkanes as Oxytocin Agonists") .

The following examples are to be considered as enabling and not limiting for the invention. Examples The following abbreviations are used: AIBN 2, 2" -azobisisobutyronitrile Boc carboxylic acid tert-butyl ester or tert- butoxycarbonylamino Bu butyl - alkyl residues may be further denoted as n (normal, i.e. unbranched) , i (iso) and t (tertiary) DIEA N,I\J-diisopropylethylamine DMAP 4- (dimethylamino)pyridine DMF dimethylformamide Et ethyl EtOAc ethyl acetate HOBt 1-hydroxybenzotriazole HPLC High performance liquid chromatography H hour(s) Me methyl Min minute (s) MS mass spectrum NMR nuclear magnetic resonance spectrum - NMR spec¬ tra were recorded in CDCl3 at a frequency of 270MHz unless otherwise indicated OVA ornithine vasotocin analogue pet. petroleum ether boiling in the range 60-80°C Ether Ph phenyl Pn pentyl Pr propyl THF tetrahydrofuran Tos toluene-4-sulphonyl WSCD water-soluble carbodiimide (W-ethyl-iV- (3- dimethylaminopropyl) carbodiimide hydrochloride Examples El - E125 describe the synthesis of intermedi¬ ates and compounds of the present invention. Example A describes how compounds can be assayed based on their ability to inhibit the cellular consequences of AVP stimulation on intact cells. Example B describes tab¬ lets for oral administration comprising a compound ac¬ cording to the invention.

Example El 6-Chloro-3-methyl-3,4,9,10-tetrahydro-2,3,4,9-tetraaza- benzo[f]azulene

Example El.1 5- (4-Chloro-2-nitro-phenylamino) -1-methyl-lH-pyrazole- 4-carboxylic acid ethyl ester. Sodium hydride (60% dispersion in oil, 7.28g, 180mmol) was added portionwise to a solution of ethyl 5-amino-l- methylpyrazole-4-carboxylate (21.8g, 148mmol) in anhy¬ drous THF at O0C. The mixture was allowed to warm to room temperature and stirred for Ih. A solution of 4- chloro-2-fluoronitrobenzene (22. βg, 129mmol) in anhy¬ drous THF (50ml) was added dropwise. The resultant deep purple solution was stirred at room temperature for 18h then poured into ice-cold IN hydrochloric acid. The re- suiting mixture was extracted with dichloromethane (200ml x 2), and the combined organic extracts were washed with brine and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 60% pet ether: 40% EtOAc) to yield the title compound (27.5g, 62%) .

Example El.2 5- (2-Amino-4-chloro-phenylamino) -1-methyl-lH-pyrazole- 4-carboxylic acid ethyl ester. Zinc powder (26.17g, 400mmol) was added to a suspension of 5- (4-chloro-2-nitro-phenylamino) -1-methyl-lH- pyrazole-4-carboxylic acid ethyl ester from Example El.1 (26.Og, 80mmol) in methanol/acetic acid (10:1, 330ml) at room temperature. After the exothermic reac¬ tion which followed, the resulting suspension was stirred at room temperature for 18h before being fil¬ tered through Celite® filter agent. The filtrate was concentrated in vacuo. The residue was dissolved in EtOAc, and the solution was washed with saturated NaHCO3 and brine, and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 65% EtOAc: 35% pet ether to 80% EtOAc:20% pet ether) to yield the title compound (18.41g, 78.0%) .

Example El.3 6-Chloro-3-methyl-4, 9-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f] azulen-10-one Sodium (methylsulphinyl)methanide (53.4mmol) was pre¬ pared from sodium hydride (60% dispersion in oil, 2.14g, 53.4mmol) and anhydrous dimethyl sulphoxide (35ml) by heating at 650C until a solution was ob¬ served. To this was added a solution of 5- (2-amino-4- chloro-phenylamino) -l-methyl-lH-pyrazole-4-carboxylic acid ethyl ester from Example El.2 (9.02g, 30.5mmol) in anhydrous dimethyl sulphoxide (20ml) , and stirring con- tinued at 650C for 30min. The mixture was poured into ice (200ml) , and the resulting solid collected and pu¬ rified by recrystallisation from methanol/EtOAc to yield the title compound (5.56g, 73.3%) .

Example El.4 6-Chloro-3-methyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f] azulene To a suspension of 6-chloro-3-methyl-4, 9-dihydro-3H- 2, 3, 4, 9-tetraaza-benzo [f] azulen-10-one from Example El.3 (5.56g, 22.4 mmol) in anhydrous THF (200ml) at O0C was added lithium aluminium hydride (4.24g, 112mmol) , and the resulting suspension was heated at reflux for 18h, then allowed to cool to room temperature. A fur¬ ther portion of lithium aluminium hydride (4.24g, 112mmol) was added, and the mixture was heated at re- flux for 18h. The mixture was cooled to 00C, 35% ammo¬ nia solution (10ml) was added dropwise over 15 min and the mixture was stirred at room temperature for 30min. The resulting suspension was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 0.5% 35% ammonia: 5% metha¬ nol:dichloromethane) to yield the title compound (3.88g, 74%) .

Example E2 3,6-Dimethyl-3,4,9,10-tetrahγdro-2,3,4,9-tetraaza- benzo[f]azulene

Example E2.1 l-Methyl-5- (4-methyl-2-nitro-phenylamino) -lH-pyrazole- 4-carboxylic acid ethyl ester. Sodium hydride (60% dispersion in oil, 7.28g, 180mmol) was added portionwise to a solution of ethyl -5-amino-l- methylpyrazole-4-carboxylate (21.8g, 148mmol) in anhy- drous THF at 00C. The mixture was allowed to warm to room temperature and stirred for Ih then a solution of 3-fluoro-4-nitrotoluene (2Og, 129mmol) in anhydrous THF (50ml) was added dropwise. The resultant deep purple solution was stirred at room temperature for 18h then poured into ice-cold IN hydrochloric acid. The result¬ ing mixture was extracted with dichloromethane (200ml x2) , and the combined organic extracts were washed with brine and concentrated in vacuo. The residue was puri¬ fied by flash chromatography on silica gel (eluant; 60% pet ether:40% EtOAc) to yield the title compound (28.0Og, 61%) . Example E2.2 5- (2-Amino-4-methyl-phenylamino) -1-methyl-lH-pyrazole- 4-carboxylic acid ethyl ester Tin (II) chloride (86.65g, 457. Ommol) was added to a solution of l-methyl-5- (4-methyl-2-nitro-phenylamino) - lH-pyrazole-4-carboxylic acid ethyl ester from Example E2.1 (28.0Og, 91.4mmol) in methanol and the mixture heated at reflux for 3 days. The solvent was removed in vacuo and the residue taken up in EtOAc (400ml) and cooled to 0°C. 35% Ammonia solution was added to pH 14, and the mixture was stirred for 15min before being fil¬ tered through Celite® filter agent. The filtrate was washed with 2M NH3 and brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 6% methanol: 94% dichloromethane rising to 10% methanol: 90% dichloromethane) to yield the title compound (12.8g, 52%) .

Example E2.3 3, 6-Dimethyl-4, 9-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulen-10-one Sodium (methylsulphinyl)methanide (22.7mmol) was pre¬ pared from sodium hydride (60% dispersion in oil, 912mg, 22.7mmol) and anhydrous dimethyl sulphoxide (5.5ml) by heating at 650C until a solution was ob¬ served. To this was added a solution of 5- (2-amino-4- methyl-phenylamino) -l-methyl-lH-pyrazole-4-carboxylic acid ethyl ester from Example E2.2 (3.56g, 13.Ommol) in anhydrous dimethyl sulphoxide (10ml) , and stirring con¬ tinued at 65°C for 30 min. The mixture was then poured into ice (200ml) , the resulting solid collected and pu¬ rified by flash chromatography on silica gel (eluant; 10%methanol: 90% dichloromethane) to yield the title compound (1.12g, 38%) . Example E2.4 3, 6-Dimethyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f] azulene To a suspension of 3, 6-dimethyl-4, 9-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulen-10-one from Example E2.3 (2.35g, 10.3mmol) in anhydrous THF (100ml) at 00C was added lithium aluminium hydride (1.56g, 41.2mmol), and the resulting suspension was heated at reflux for 18h then allowed to cool to room temperature. A further portion of lithium aluminium hydride (781 mg, 20.6mmol) was added, and the mixture was heated at reflux for 3h. The mixture was cooled to 00C, 35% ammonia solution (10ml) was added dropwise over 15 min and the mixture was stirred at room temperature for 30min. The result- ing suspension was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol: 90% dichloromethane) to yield the title compound (1.6Og, 72%) .

Examples E2a-g are described in WO 03/016316 Al, (Hud¬ son, P. et al. "Diazacycloalkanes as Oxytocin Ago¬ nists"), pages 26-31.

Example Ξ2h 4-(tert-Butoxycarbonylamino-methyl) -3-methyl-benzoic acid

Example E2h.l 4-Cyano-3-methyl-benzoic acid methyl ester A mixture of 4-cyano-3-methyl-benzoic acid from Example E2d (1.5g, 9.3mmol) and thionyl chloride (5ml, 68.5mmol) in dichloromethane (20ml) was heated at re¬ flux for 2 h then solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (25ml) . Methanol (10ml) was added and the solution was stirred at room temperature for 2h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to yield the title compound (l.βg, 100%) .

Example E2h.2 4-Aminomethyl-3-methyl-benzoic acid methyl ester A solution of 4-cyano-3-methyl-benzoic acid methyl es- ter from Example E2h.l (l.βg, 9.3mmol) in methanol (50ml) to 0°C was treated with cobalt (II) chloride hexahydrate (5.1g, lδ.βmmol) . The mixture was stirred for 15min at room temperature then sodium borohydride (3.5g, 93mmol) was added portionwise. The reaction mixture was stirred for 90min then concentrated NH3 (5ml) was added drop- wise. The mixture was warmed up to room temperature over 30min, filtered through Celite® filter agent, washed with methanol and the filtrate was concentrated in vacuo. The residue was purified by flash chromatog¬ raphy on silica gel (eluant; 1% 35% ammonia: 10% metha¬ nol: 89% dichloromethane) to yield the title compound (670mg, 37%) .

Example E2h.3 4- (tert-Butoxycarbonylamino-methyl) -3-methyl-benzoic acid methyl ester Di-tert-butyl dicarbonate (900mg, 4.1mmol) was added to a solution of 4-aminomethyl-3-methyl-benzoic acid methyl ester from Example E2h.2 (670mg, 3.7mmol) in di¬ chloromethane (50ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for Ih then con¬ centrated in vacuo. The residue was redissolved in EtOAc, washed with 0.3N KHSO4 then brine, dried and con¬ centrated in vacuo to yield the title compound (1.04g, 100%) .

Example E2h.4 4- (tert-Butoxycarbonylamino-methyl) -3-methyl-benzoic acid 4- (tert-Butoxycarbonylamino-methyl) -3-methyl-benzoic acid methyl ester from Example E2h.3 (1.04g, 3.7mmol) was dissolved in dioxan (20ml) . IN NaOH solution (5.6ml, 5.6mmol) was added and the mixture was stirred for 18h at room temperature then concentrated in vacuo. The residue was redissolved in EtOAc, washed with IN KHSO4 then brine, dried and concentrated in vacuo to yield the title compound (800mg, 81%) .

Example E3 4- (tert-Butoxycarbonylamino-methyl) -3-fluoro-benzoic acid

Example E3.1 3-Fluoro-4-methylbenzoic acid methyl ester Thionyl chloride (9.62g, 81mmol) was added to a solu¬ tion of 3-fluoro-4-methylbenzoic acid (5.0 g, 32.4mmol) in toluene (50ml) . The mixture was stirred at room tem¬ perature for 1.5h and heated at reflux for 3h. The sol¬ vent was removed in vacuo and the residue was taken up in methanol (30ml) and CH2Cl2 (30ml) and stirred for 18h. The mixture was evaporated in vacuo and the resi- due was taken up in EtOAc (50ml) , washed with saturated NaHCθ3 solution (3x75ml) , dried and evaporated in vacuo to yield the title compound (4.5g, 83%) .

Example E3.2 4-Bromomethyl-3-fluorobenzoic acid methyl ester 3-Fluoro-4-methylbenzoic acid methyl ester from Example E3.1 (4.5g, 2β.6mmol) was dissolved in carbon tetra¬ chloride (150ml) . AIBN (457mg, 2.7mmol) and N- bromosuccinimide (5.2g, 29.3mmol) were added and the mixture was heated at reflux for 18h. The mixture was allowed to cool and further portions of AIBN (457mg, 2.7πtmol) and W-bromosuccinimide (5.2g, 29.3mmol) were added. The mixture was heated at reflux for 5βh. The mixture was allowed to cool and evaporated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% EtOAc: 90% pet ether) to yield the title compound (2.7g, 41%) .

Example E3.3 4-Azidomethyl-3-fluorobenzoic acid methyl ester Sodium azide (609mg) was added to a solution of 4- bromomethyl-3-fluorobenzoic acid methyl ester from Ex¬ ample E3.2 (2.1g, 8.5mmol) in DMF (30ml) . The mixture was stirred for 18h, diluted with EtOAc, washed with water and brine and concentrated in vacuo to give a colourless oil identified as the title compound (1.8 g, 100%) .

Example E3.4 4-Aminomethyl-3-fluorobenzoic acid methyl ester Hydrogen was passed through a degassed solution of 4- azidomethyl-3-fluorobenzoic acid methyl ester from Ex¬ ample E3.3 (2.11g, lOmmol) in methanol containing 10% palladium on carbon for 2h. The reaction mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a colourless oil identified as the title compound (1.51 g, 83%) .

Example E3.5 4- (tert-Butoxycarbonylamino-methyl) -3-fluorobenzoic acid methyl ester To a solution of 4-aminomethyl-3-fluorobenzoic acid methyl ester from Example E3.4 (1.5g, 8.2mmol) in di- chloromethane (20ml) were added di-tert-butyl dicarbon- ate (2.3g, llmmol) and triethylamine (1.4ml, lOmmol) . The mixture was stirred for 18h, washed with 0.3M KHSO4 and brine and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% EtOAc: 90% pet. ether) to give a white solid identi¬ fied as the title compound (1.4 g, 60%) .

Example E3.6 4- (tert-Butoxycarbonylamino-methyl) -3-fluorobenzoic acid To a solution of 4- (tert-butoxycarbonylamino-methyl) -3- fluorobenzoic acid methyl ester from Example E3.5 (640mg, 2.25mmol) in dioxan (40ml) was added IN NaOH (4.5ml, 4.5mmol) . The mixture was stirred for 18h, di¬ luted with EtOAc, washed with IN KHSO4, water and brine and concentrated in vacuo to give a white solid identi- fied as the title compound (608 mg, 100%) .

Example Ξ4 1- (3,3-Dimethyl-butyl) -piperazine dihydrochloride

Example E4.1 4- (3, 3-Dimethyl-butyl) -piperazine-1-carboxylic acid tert-butyl ester To a solution of 1-boc-piperazine (8.19g, 43.9mmol) in methanol/acetic acid (99:1, v/v, 100ml) was added 3,3- dimethylbutyraldehyde (4.Og, 40.0mmol) and the result¬ ing mixture was stirred at room temperature for Ih. So¬ dium cyanoborohydride (3.27g, 51.9mmol) was added, and the resulting mixture was stirred at room temperature for 18h then concentrated in vacuo. The residue was dissolved in EtOAc and the resulting solution was washed with saturated NaHCO3, water and brine, dried and concentrated in vacuo. The residue was purified by- flash chromatography on silica gel (eluant; 5% metha¬ nol: 95% EtOAc) to yield the title compound (9.1g, 84%) .

Example E4.2 1-(3,3-Dimethyl-butyl)-piperazine dihydrochloride A solution of 4- (3,3-dimethyl-butyl) -piperazine-1- carboxylic acid tert-butyl ester from Example E4.1 (9.1g, 31.8mmol) in methanol (100ml) was treated with 4N HCl/dioxan (100ml) and the mixture was stirred at room temperature for 30min then concentrated in vacuo. The residue was triturated with diethyl ether and the resulting solid recrystallised from methanol/diethyl ether to yield 1- (3,3-dimethyl-butyl)-piperazine dihy¬ drochloride (7.4g, 90%).

Example Ξ5 2-Methγl-l,4,5,6-tetrahydro-l,3,6-triaza- benzo[e]azulene

Example E5.1 2-(Toluene-4-sulfonylamino)-benzoic acid methyl ester Methyl anthranilate (llOg, 0.73mol) was dissolved in dichloromethane (1 litre) at 0°C and triethylamine (115ml, O.δmol) was added. Tosyl chloride (133g, 0.745mol) was added portionwise at 0°C. The reaction mixture was stirred for 30min at 0°C and 64h at room temperature. The mixture was reduced in vacuo. The residue was dissolved in EtOAc and the organic layer was washed with 5% KHCO3(aq) solution, IN HCl solution and brine, dried, filtered and concentrated in vacuo. The residue was crystallised from EtOAc/hexane to yield the title compound (181g, 81%) .

Example E5.2 2- [ (3-Ethoxycarbonyl-propyl) - (toluene-4-sulfonyl) - amino] -benzoic acid methyl ester 2- (Toluene-4-sulfonylamino) -benzoic acid methyl ester from Example E5.1 (10Og) was dissolved in DMF (250ml) . Potassium carbonate (125g) and ethyl 4-bromobutanoate (6Og) were added and the mixture was heated at 800C for 18h. The mixture was cooled to room temperature, fil¬ tered and reduced in vacuo. The residue was partitioned between chloroform and IM HCl solution. The aqueous layer was extracted with chloroform. The organic layers were combined, washed with brine, dried, filtered and concentrated in vacuo. The material was crystallised from EtOAc/hexane and dried in a vacuum oven at 600C for 3 hours to yield the title compound (98.6g, 72%) .

Example E5.3 5-Hydroxy-l- (toluene-4-sulfonyl) -2, 3-dihydro-lH- benzo [b] azepine-4-carboxylic acid methyl ester and 5- hydroxy-1- (toluene-4-sulfonyl) -2, 3-dihydro-lH- benzo[b] azepine-4-carboxylic acid ethyl ester 2- [3-Ethoxycarbonyl-propyl) - (toluene-4-sulfonyl) - amino] -benzoic acid methyl ester from Example E5.2 (98. βg, 0.235mol) was taken up in warm toluene (600ml) and was added dropwise to a mixture of potassium tert- butoxide (4Og) in toluene (llitre) refluxing under Dean-Stark conditions. The mixture was heated at reflux under Dean-Stark condidtions for Ih further and cooled to room temperature. It was diluted with EtOAc (500ml) and washed with IM HCl solution, saturated NaHCO3 (aq) and brine. The organic layer was dried, filtered and reduced in vacuo. The residue was precipitated from EtOAc/hexane and dried in a vacuum oven to yield a mix¬ ture of 5-hydroxy-l- (toluene-4-sulfonyl) -2, 3-dihydro- lH-benzo [b] azepine-4-carboxylic acid methyl ester and 5-hydroxy-l- (toluene-4-sulfonyl) -2, 3-dihydro-lH- benzo [b] azepine-4-carboxylic acid ethyl ester (53.5g) . Example E5.4 1- (Toluene-4-sulfonyl) -1,2,3, 4-tetrahydro- benzo[b]azepin-5-one A mixture of 5-hydroxy-l- (toluene-4-sulfonyl) -2, 3- dihydro-lH-benzo [b]azepine-4-carboxylic acid methyl es¬ ter and 5-hydroxy-l- (toluene-4-sulfonyl) -2, 3-dihydro- lH-benzo[b]azepine-4-carboxylic acid ethyl ester from Example E5.3 were heated at reflux in a mixture of ethanol (100ml) , acetic acid (300ml) , concentrated HCl (100ml) and water (50ml) for 18h. The mixture was cooled to room temperature, diluted with water (800ml) and extracted with chloroform. The combined organic ex¬ tracts were dried, filtered and reduced in vacuo. The residue was crystallised twice from methanol to yield the title compound (44g, 60% over two steps) .

Example E5.5 1,2,3, 4-Tetrahydro-benzo [b] azepin-5-one Polyphosphoric acid (25g) was heated at 1000C under ni¬ trogen until it could be stirred. 1- (Toluene-4- sulfonyl) -1,2,3, 4-tetrahydro-benzo[b] azepin-5-one from Example E5.4 (2.6g, 8.2βmmol) was added portionwise and the reaction mixture was heated at 1000C for 1.5h. It was poured into ice and basified with 2M NaOH(aq) . The aqueous layer was extracted twice with dichloromethane. The organic extracts were combined, washed with brine, dried and reduced in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% EtOAc: 60% hexane) to yield the title compound (1.05g, 79%) .

Example E5.6 1-Benzoyl-l,2, 3, 4-tetrahydro-benzo [b] azepin-5-one 1,2, 3, 4-Tetrahydro-benzo [b] azepin-5-one from Example E5.5 (480mg, 2.98mmol) was dissolved in a mixture of dichloromethane (30ml) and triethylamine (1.3ml) . Ben- zoyl chloride (0.46g, 3.28mmol) was added and the reac¬ tion mixture was heated for at reflux for 2h. The mix¬ ture was cooled and reduced in vacuo. The residue was dissolved in EtOAc and washed with IM KHSO4 (aq) , water and brine. The organic layer was dried, filtered and reduced in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc: 50% hexane) to yield the title compound (440mg, 56%) .

Example E5.7 l-Benzoyl-4-bromo-l, 2, 3, 4-tetrahydro-benzo[b]azepin-5- one 1-Benzoyl-l, 2,3, 4-tetrahydro-benzo[b] azepin-5-one from Example E5.6 (54.2g, 205mmol) , iV-bromosuccinimide (3.6g, 20.4mmol) and bromine (11.1ml, 214.7mmol) were dissolved in dichloromethane (l.Olitre) . Triethylamine (30ml, 215mmol) was added dropwise over 30 minutes then the reaction mixture was heated at reflux for 4h. Addi¬ tional bromine (1.1ml, 21.5mmol) and triethylamine (3.0ml, 21.5mmol) were added and the reaction mixture was heated at reflux for a further 4h. Additional bro¬ mine (1.1ml, 21.5mmol) and triethylamine (3.0ml, 21.5mmol) were added again and the reaction mixture was heated at reflux for a further 4h. On cooling to room temperature, the reaction solution was washed with 5% aqueous sodium metabisulfate solution (150ml) and the aqueous phase was diluted with water (600ml) . The or¬ ganic phase was separated, washed with saturated Na- HCO3(aq), dried over sodium sulphate and filtered. The filtrate was diluted with EtOAc (100ml) , filtered through a silica pad (eluant; CH2CI2) and reduced in vacuo to yield the title compound (73.6g) which was used without further purification.

Example E5.8 β-Benzoyl-2-methyl-l, 4, 5, 6-tetrahydro-l, 3, 6-triaza- benzo [e] azulene l-Benzoyl-4-bromo-l,2,3,4-tetrahydro-benzo[b] azepin-5- one (67.5g, 200mmol) from Example E5.7, acetamidine hy- drochloride (92.7g, 980mmol) and potassium carbonate (136. Og, 980mmol) were suspended in acetonitrile (2.01itres) and heated at reflux for 17h under nitro¬ gen. Additional acetamidine hydrochloride (18.5g, 200mmol) and potassium carbonate {21.Ig, 200mmol) were added and the reaction mixture was heated at reflux for a further 6h. Additional acetamidine hydrochloride (18.5g, 200mmol) and potassium carbonate {21.Ig, 200mmol) were added again and the reaction mixture was heated at reflux for a further 6h. On cooling to room temperature, the reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was taken up in dichloromethane (1.41itres), washed with water (500ml) , dried over sodium sulfate, filtered and reduced in vacuo. The crude products were purified by flash chromatography on silica gel (eluant; 45% EtOAc: 45% acetonitrile: 10% methanol) to yield the title com¬ pound (26.7g, 34%) and 6-benzoyl-2-methyl-5, 6-dihydro- 4H-l-oxa-3, 6-diaza-benzo [e] azulene (3.3g, 4%) .

Example E5.9 2-Methyl-l, 4,5, 6-tetrahydro-l, 3, 6-triaza- benzo[e] azulene 6-Benzoyl-2-methyl-l, 4,5, 6-tetrahydro-l, 3, 6-triaza- benzo[e]azulene from Example E5.8 (160mg, 0.53mmol) was dissolved in a 6M HCl/dioxan solution (50ml) and heated at reflux for 18h. The reaction mixture was cooled to room temperature and reduced in vacuo. The residue was partitioned between EtOAc and saturated NaHCO3(aq) and the layers were separated. The organic layer was washed with brine, dried, filtered and reduced in vacuo to yield the title compound (69mg, 66%) . Example E5a l-Benzyl-2-methyl-l,4,5,6-tetrahydro-l,3,6—triaza- benzo[e]azulene

Example E5a.l (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo[e] azulen-6-yl) -phenyl-methanone Sodium hydride (60% dispersion in oil, 905mg, 22.5mmol) was placed in anhydrous THF (200ml) and cooled down to 00C. β-Benzoyl-2-methyl-l,4,5, 6-tetrahydro-l, 3, 6- triaza-benzo[e] azulene from Example E5.8 (4.9g, lδ.lmmol) was added dropwise and the mixture was sti¬ rred for 1 h at room temperature. Benzyl bromide (2.31ml, 19.3mmol) and potassium iodide (1.34g, 8.0mmol) were added and the mixture was stirred for 16h. The solution was diluted with EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title com¬ pound (5.73g, 90%) .

Example E5a.2 l-Benzyl-2-methyl-l, 4,5, 6-tetrahydro-l, 3, 6-triaza- benzo[e]azulene (l-Benzyl-2-methyl-4,5-dihydro-lH-l,3, 6-triaza- benzo[e] azulen-6-yl) -phenyl-methanone from Example E5a.l (5.73g, 14.6mmol) was placed in methanol (50ml) and a 6M HCl aqueous solution (200ml) was added. The reaction mixture was heated at reflux for 18h then con¬ centrated in vacuo. The residue was dissolved in di- chloromethane, basified with saturated NaHCO3 then washed with brine, dried and concentrated in vacuo to yield the title compound (3.3Og, 78%) .

Example Ξ6 2-Methyl-5,6-dihydro-4H-l-oxa-3,6-diaza-benzo[e]azυleπe

6-Benzoyl-2-methyl-5, 6-dihydro-4H-l-oxa-3, 6-diaza- benzo [e] azulene from Example E5.8 (1.Og, 3.25mmol) was reacted with a 6M HCl/dioxan solution (100ml) using an analogous procedure to that described for Example E5.9 to yield the title compound (540mg, 82%) .

Example Ξ7 2-Methyl-5 , 6-dihydro-4H-3-thia-l , 6-diaza- benzo [e] azulene

Example E7 . 1 (2-Methyl-4, 5-dihydro-3-thia-l, 6-diaza-benzo [e]azulen- 6-yl) -phenyl-methanone To a solution of l-benzoyl-4-bromo-l, 2, 3, 4- tetrahydrobenzo [b] azepin-5-one (l.Og, 2.9mmol) from Ex¬ ample E5.7 in ethanol (50 ml) was added thioacetamide (0.75g, lOmmol) . The solution was stirred for 16h. The resultant suspension was reduced in volume by evapora- tion and cooled. The precipitate was collected by fil¬ tration and the solid was washed with cold ethanol and dried to yield the title compound as a white solid (0.65g, 70%) .

Example E7.2 2-Methyl-5, 6-dihydro-4H-3-thia-l, 6-diaza- benzo [e] azulene A suspension of (2-methyl-4, 5-dihydro-3-thia-l, 6-diaza- benzo [e] azulen-6-yl) -phenyl-methanone from Example E7.1 (0.42g, 1.3mmol) in 6M hydrochloric acid (45ml) was heated at reflux for 16h. The solution was cooled and treated with saturated NaHCO3(aq) (100ml) . Additional solid NaHCθ3 was added until the solution was basic. The mixture was extracted with dichloromethane and the or¬ ganic extracts were dried and reduced in vacuo to yield the title compound as a yellow oil (0.21g, 76%) .

Example E8 4- (3,3-Dimethyl-butyl) -piperazine-l-carboxylic acid 4- (3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -2-fluoro-benzylamide

Example E8.1 [4- (3, 6-Dimethyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzyl] -carbamic acid tert-butyl ester A solution of 4- (tert-butoxycarbonylamino-methyl) -3- fluorobenzoic acid from Example E3.1 (538mg, 2.0mmol) and DMAP (220mg, l.δmmol) in dichloromethane (20ml) at room temperature was treated with DIEA (0.93ml, 5.4mmol) and WSCD (460mg, 2.4mmol), and the resulting solution was stirred at room temperature for Ih. 3,6- Dimethyl-3, 4,9, 10-tetrahydro-2,3,4, 9-tetraaza- benzo [f] azulene from Example E2 (385mg, l.δmmol) was added and the resulting solution was heated at reflux for 2Oh and allowed to cool to room temperature. The solution was diluted with dichloromethane, washed with saturated NaHCO3 and brine and concentrated in vacuo. The residue was purified by preparative HPLC (eluant 10% methanol: 90% dichloromethane) to yield the title compound (265mg, 32%) .

Example E8.2 (4-Aminomethyl-3-fluoro-phenyl) - (3, 6-dimethyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride [4- (3, β-dimethyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzyl] -carbamic acid tert-butyl ester from Example E8.1 (237mg, 0.51mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (205mg, 100%) .

Example E8.3 4- (3, 3-Dimethyl-butyl) -piperazine-1-carboxylic acid 4- (3, 6-dimethyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzylamide DIEA (0.10ml, O.βOmmol) and 1, 1' -carbonyldiimidazole (28mg, 0.17mmol) were added to a solution of (4- aminomethyl-3-fluoro-phenyl) - (3, 6-dimethyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride from Example E8.2 (57mg, 0.14mmol) in DMF (5.0ml) and the mixture was stirred at room temperature for 4h. 1- (3, 3-Dimethyl-butyl) - piperazine dihydrochloride from Example E4 (38mg, O.lβmmol) was added and the mixture was stirred at room temperature for 24h and concentrated in vacuo. The residue was dissolved in EtOAc and the resulting solu¬ tion was washed with brine and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 10% methanol: 90% dichloromethane) to give a white solid identified as the title compound (45mg, 56%) .

Example E9 4- (tert-Butoxycarbonylamino-methyl)- cyclohexanecarboxylic acid To a solution of 4-aminomethyl-cyclohexanecarboxylic acid (20.Og, 127.39mmol) in dioxan (400ml) was added IN KHCO3 (300ml, 300mmol) and di-tert-butyl dicarbonate (33.3g, 129.57mmol) . The mixture was stirred for 18h and concentrated in vacuo. The aqueous residue was washed with ether, then acidified with IN KHSO4 and ex¬ tracted with EtOAc (x 3) . The combined organic extracts were washed with water and brine and concentrated in vacuo to give a white solid identified as the title compound (31.9g, 98%) .

Example ElO Cyclopropanecarboxylic acid [4- (6-chloro-3-methyl-4,10- dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl) -cyclohexylmethyl]-amide

Example ElO.1 [4- (6-Chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -cyclohexylmethyl] -carbamic acid tert-butyl ester A solution of 4- (tert-butoxycarbonylamino-methyl) - cyclohexanecarboxylic acid from Example E9 (510mg, 2.0mmol) in dichloromethane (25 ml) at room temperature was treated with DIEA (0.70ml, 4.0mmol), PyBrop (2.4Og, 5.1mmol), and β-chloro-3-methyl-3, 4, 9, 10-tetrahydro- 2, 3, 4, 9-tetraaza-benzo [f] azulene from Example El (422mg, 1.8mmol) and the resulting solution was heated at reflux for 2Oh and allowed to cool to room tempera¬ ture. The solution was diluted with dichloromethane, washed with brine and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant EtOAc) to yield the title compound (775mg, 91%) .

Example E10.2 (4-Aiuinoinethyl-cyclohexyl) - (6-chloro-3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride A solution of [4- (6-chloro-3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - cyclohexylmethyl] -carbamic acid tert-butyl ester from Example ElO.1 (775mg, 1.63mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that de¬ scribed for Example E4.2 to yield the title compound (655mg, 100%) .

Example ElO.3 Cyclopropanecarboxylic acid [4- (6-chloro-3-methyl-4, 10- dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulene-9- carbonyl) -cyclohexylmethyl] -amide

DIEA (0.50ml, 2.90mmol) and cyclopropanecarbonyl chlo¬ ride (0.045ml, 0.50mmol) were added to a solution of (4-aminomethyl-cyclohexyl) - (6-chloro-3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride from Example ElO.2 (220mg, 0.53mmol) in dichloromethane (5ml) . The mixture was stirred for 2h then diluted with dichloromethane, washed with water and concentrated in vacuo. The resi- due was purified by preparative HPLC (eluant; 0.5% 35% ammonia/10% methanol/90% dichloromethane) to give a white solid identified as the title compound (132 mg, 60%) .

Example Ell 3-Methyl-3,4,9,10-tetrahγdro-2,3,4,9-tetraaza- benzo[f]azulene

Example Ell.l l-Methyl-5- (2-nitro-phenylamino) -lH-pyrazole-4- carboxylic acid ethyl ester Sodium hydride (60% dispersion in oil, 7.Og, 170mmol) was added portionwise to a suspension of 5-amino-l- methyl-lH-pyrazole-4-carboxylic acid ethyl ester (21. Ig, 125mmol) in anhydrous THF (300ml) at 00C. The mixture was allowed to warm to room temperature and stirred for 0.75h then cooled to 00C. l-fluoro-2- nitrobenzene (17.6g, 125mmol) was added and the resul¬ tant suspension was stirred at room temperature for 18h. EtOAc and 0.3M KHSO4 were added and separated. The aqueous layer was extracted with EtOAc and the com¬ bined organic layers were washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant 50% hex- anes/50% ethyl acetate) to yield the title compound (20.8g, 58%) .

Example Ell.2 5- (2-Amino-phenylamino) -l-methyl-lH-pyrazole-4- carboxylic acid ethyl ester l-Methyl-5- (2-nitro-phenylamino) -lH-pyrazole-4- carboxylic acid ethyl ester (20.8g, 72mmol) from Exam¬ ple Ell.l was dissolved in methanol (330ml) and hydro- genated over 10% Pd/C catalyst for 4h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to give a white solid identi¬ fied as the title compound (16.2g, 87%) .

Example Ell.3 3-Methyl-4, 9-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulen-10-one Sodium (methylsulphinyl)methanide (29.7mmol) was pre¬ pared from sodium hydride (60% dispersion in oil, 1.19g, 29.7mmol) and anhydrous dimethyl sulphoxide (7ml) by heating at 650C until a solution was observed. To this was added a solution of 5-(2-amino- phenylamino) -l-methyl-lH-pyrazole-4-carboxylic acid ethyl ester from Example Ell.2 (3.63g, 16.9mmol) in an¬ hydrous dimethyl sulphoxide (10ml) , and stirring con¬ tinued at 650C for 2.5h. The mixture was poured into ice (100ml) , and the resulting solid collected and pu- rified by recrystallisation from methanol/EtOAc/60-80 pet ether to yield the title compound (1.46g, 40%) .

Example Ell.4 3-Methyl-3, 4,9, 10-tetrahydro-2, 3,4, 9-tetraaza- benzo [f] azulene To a suspension of 3-methyl-4, 9-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulen-10-one from Example Ell.3 (3.01g, 14.1 mmol) in anhydrous THF (100ml) at 00C was added lithium aluminium hydride (2.13g, 56.2mmol), and the resulting suspension was heated at reflux for 18h, then allowed to cool to room temperature. The mixture was cooled to O0C, 35% ammonia solution (10ml) was added dropwise over 15 min and the mixture was stirred at room temperature for 30min. The resulting suspension was filtered through Celite® filter agent and the fil¬ trate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% methanol:chloroform rising to 5% methanol: chloroform) to yield the title compound (1.6Og, 57%) .

Example E12 [4- (Isobutylamino-methyl) -cyclohexyl] - (3-methyl-4,10- dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen-9-yl) - methanone

A solution of isobutyraldehyde (0.36mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) was added to a solution of (4-Aminomethyl-cyclohexyl) - (3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo[f]azulen-9-yl) -methanone hydro- chloride from Example ElO.2 (1.88mg, 0.005mmol) in 1,2- dichloroethane (0.05ml) and DIEA (0.0026ml) . The mix¬ ture was stirred at room temperature for Ih then a so¬ lution of sodium triacetoxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added. The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 396.4

Example Ξ13 [4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] -carbaitiic acid 4-nitro-benzyl ester

A solution of 4-nitrobenzyl chloroformate (1.08mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of (4-Aminomethyl-cyclohexyl) - (3, 6-dimethyl- 4, 10-dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride (Compound number 149) (1.95mg, 0.005mmol) in dichloromethane (0.05ml) and triethyl- amine (0.0035ml) . The mixture was stirred at room tem¬ perature for Ih then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 533.3

Example El4 (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulen-9-yl) - (4-hexylaminomethyl-cyclohexyl) - methanone

A solution of 1-bromohexane (0.83mg, 0.005mmol) in DMF(O.05ml) was added to a solution of (4-Aminomethyl- cyclohexyl) - (6-chloro-3-methyl-4, 10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulen-9-yl) -methanone hydrochloride from Example ElO.2 (2.05mg, 0.005mmol) in DMF (0.05ml) and triethylamine (0.0021ml) . The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 458.4

Example E15 1- (3,3-Dimethyl-butyl) -piperidine-4-carboxylic acid

Example El5.1 1- (3, 3-Dimethyl-butyl) -piperidine-4-carboxylic acid ethyl ester 3, 3-Dimethylbutyraldehyde (5.26ml, 42.0mmol) was added to a solution of ethyl isonipecotate (6.6g, 42.0mmol) in methanol/acetic acid (99:1, v/v, 50ml) and the mix- ture was stirred at room temperature for Ih. Sodium cyanoborohydride (3.43g, 54.6mmol) was added, and the mixture was stirred at room temperature for 4 days then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 25% EtOAc: 75% cyclohexane) to yield the title compound (7.16g, 71%) .

Example E15.2 1- (3, 3-Dimethyl-butyl) -piperidine-4-carboxylic acid Lithium hydroxide monohydrate (1.37g, 32.6mmol) was added to a solution of 1- (3, 3-dimethyl-butyl) - piperidine-4-carboxylic acid ethyl ester from Example E15.1 (7.16g, 29.7mmol) in THF (50ml) and water (5ml) . The mixture was stirred at room temperature for 18h then concentrated in vacuo. The residue was purified by flash chromatography on silica. gel through an isolute (eluant; 90% dichloromethane: 9% methanol:1% acetic acid) to yield the title compound (5.51g, 87%) . Example El5a l-Cyclopropylmethyl-piperidine-4-carboxylic acid

The title compound was prepared from cyclopropanecar- boxaldehyde and ethyl isonipecotate using similar pro¬ cedures to those described for Example E15.

Example El6 1- (3,3-Dimethyl-butyl) -piperidine-4-carboxylic acid [4~ (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] -amide

Example El6.1 4- (3, 3-Dimethyl-butyl) -piperazine-4-carboxylic acid [4- (3-methyl-4,10-dihydro-3H-2,3,4/9-tetraaza- benzo [f]azulene-9-carbonyl) -cyclohexylmethyl] -amide HBTU (84mg, 0.22mmol) was added to a solution of 1- (3, 3-dimethyl-butyl) -piperidine-4-carboxylic acid from Example E15 (42mg, 0.17mmol) in DMF (5ml) and DIEA (to pH9) . The mixture was stirred at room temperature for 1 h. (4-Aminomethyl-cyclohexyl) - (3-methyl-4, 10-dihydro- 3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) -methanone hy¬ drochloride (Compound Number 150) (42mg, O.llmmol) was added and the mixture was stirred at room temperature for 18h. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and con¬ centrated in vacuo. The residue was purified by prepa- rative HPLC (eluant; 10% methanol: 90% dichloromethane) to give a white solid identified as the title compound (34mg, 57%) . Example El 7 N-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[£]azulene-9-carbonyl) -cyclohexylmethyl] -2- piperidin-4-yl-acetamide hydrochloride

A solution of 4~ ( { [4- (3, 6-dimethyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo[f] azulene-9-carbonyl) - cyclohexylmethyl] -carbamoyl}-methyl) -piperidine-1- carboxylic acid tert-butyl ester (Compound Number 228) (259mg«, 0.45mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Ex¬ ample E4.2 to yield the title compound (230mg, 93%) .

Example El8 N-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[£]azulene-9-carbonyl) -cyclohexylmethyl] - methanesulfonamide

A solution of methanesulfonyl chloride (0.57mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of (4-aminomethyl-cyclohexyl) - (3, 6-dimethyl- 4, 10-dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone (Compound number 149) (1.95mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml). The mixture was stirred at room temperature for Ih then solvents were removed in vacuo to yield the title com¬ pound. (ESI)+: [M+H]+= 432.1

Example El9 N-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] -2- (1- methanesulfonyl-piperidin-4-yl) -acetamide A solution of methanesulfonyl chloride (0.57mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of N- [4- (3, β-dimethyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - cyclohexylmethyl] -2-piperidin-4-yl-acetamide hydrochlo¬ ride from Example E17 (2.57mg, 0.005mmol) in dichloro¬ methane (0.05ml) and triethylamine (0.0035ml) . The mix¬ ture was stirred at room temperature for Ih then sol¬ vents were removed in vacuo to yield the title com- pound. (ESI)+: [M+H] += 557.4

Example Ξ20 2- (l-Acetyl-piperidin-4-yl)-N- [4- (3,6-dimethyl-4,10- dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl) -cyclohexylmethyl] -acetamide

A solution of acetyl chloride (0.39mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of N- [4- (3, 6-dimethyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] -2- piperidin-4-yl-acetamide hydrochloride from Example E17 (2.57mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for Ih then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 521.5

Example E21 l-Isobutyl-piperidine-4-carboxylic acid [4-(3-methyl- 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl) -cyclohexylmethyl]-amide A solution of isobutyraldehyde (0.36mg, 0.005iπmol) in 1,2-dichloroethane (0.05ml) was added to a solution of piperidine-4-carboxylic acid [4- (3-methyl-4, 10-dihydro- 3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - cyclohexylmethyl] -amide hydrochloride (Compound number 238) (2.43mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) and DIEA (0.0026ml) . The mixture was stirred at room temperature for Ih then a solution of sodium triace- toxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added. The mixture was stirred for 2Oh at room tem¬ perature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H] += 507.4

Example E22 N-[4- (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] - 3- (l-hexyl-piperidin-4-yl) -propionamide

A solution of 1-bromohexane (0.83mg, 0.005mmol) in DMF(O.05ml) was added to a solution of N- [4- (6-chloro- 3-methyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -cyclohexylmethyl] -3- piperidin-4-yl-propionamide hydrochloride (Compound number 237) (2.57mg, 0.005mmol) in DMF (0.05ml) and triethylamine (0.0021ml) . The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 597.6/599.6

Example E23 4-({ [4-(3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] - carbamoyl}-methyl) -piperidine-1-carboxylic acid 4- nitro-benzyl ester

A solution of 4-nitrobenzyl chloroformate (l.Oδmg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of N- [4- (3, 6-Dimethyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -cyclohexylmethyl] - 2-piperidin-4-yl-acetamide hydrochloride from Example E17 (2.58mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for Ih then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H] += 658.5

Example E24 4- (3,3-Dimethyl-butyl) -piperazine-1-carboxylic acid [4- (3,6-dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -cyclohexylmethyl] -amide

DIEA (0.30ml, 1.7mmol) and 1,1'-carbonyldiimidazole (39mg, 0.24mmol) were added to a solution of (4- aminomethyl-cyclohexyl) - (3, β-dimethyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulen-9-yl) -methanone hydro¬ chloride (Compound number 149) (78mg, 0.20mmol) in DMF (4.0ml) and the mixture was stirred at room temperature for 2h. 1- (3, 3-Dimethyl-butyl) -piperazine dihydrochlo- ride from Example E4 (56mg, 0.23mmol) was added and the mixture was stirred at room temperature for 18h. The mixture was diluted with EtOAc, washed with brine, dried and concentrated in vacuo. The residue was puri¬ fied by preparative HPLC (eluant; 10% methanol: 90% di¬ chloromethane) to give a white solid identified as the title compound (32mg, 29%) . Example E25 3-Chloro-6,7,8,9-tetrahydro-5-oxa-9-aza- benzocycloheptene

Example E25.1 N- (4-Chloro-2-hydroxy-phenyl) -benzamide 2-Amino-5-chlorophenol (1.45g, lOinmol) was dissolved in EtOAc (30ml) and water (20ml) . Sodium bicarbonate (1.25g, 15mmol) then benzoyl chloride (1.42g, lOmmol) were added and the mixture was stirred at room tempera¬ ture for Ih. The layers were partitioned and the or¬ ganic layer was washed with brine, dried and concen¬ trated in vacuo. The residue was triturated with di- ethyl ether to yield the title compound (2.05g, 82%) .

Example E25.2 (3-Chloro-7, δ-dihydro-βH-S-oxa-g-aza-benzocyclohepten- 9-yl) -phenyl-methanone N- (4-Chloro-2-hydroxy-phenyl) -benzamide from Example E25.1 (1.Og, 4mmol) was dissolved in acetonitrile (10ml) and dichloromethane (15ml). 1, 3-Dibromopropane (3.26g, lβmmol) , aliquat 336 (170mg, 0.4mmol) and so¬ dium hydroxide (750mg, lβmmol) were added and the mix- ture was heated at 6O0C for 3h. The solid was filtered off and the filtrate concentrated in vacuo. The. residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc: 70% hexane) to yield the title com¬ pound (783mg, 83%) .

Example E25.3 3-Chloro-6, 7,8, 9-tetrahydro-5-oxa-9-aza- benzocycloheptene (3-Chloro-7, δ-dihydro-βH-S-oxa-g-aza-benzocyclohepten- 9-yl) -phenyl-methanone from Example E25.2 (783mg, 2.7mmol) was dissolved in dioxan (10ml) and 6M HCl aqueous solution (50ml) was added. The mixture was heated at reflux for 2Oh then concentrated in vacuo and azeotroped with toluene. The residue was dissolved in diethyl ether and water, basified with NaHCO3 and the layers were partitioned. The organic layer was washed with brine, dried and concentrated in vacuo to yield the title compound (280mg, 47%) .

Example Ξ26 N-Cyclohexyl-N'-methyl-benzene-1,2-diamine

Example E26.1 Cyclohexyl- (2-nitro-phenyl) -amine A mixture of 2-fluoronitrobenzene (5.Og, 35.4mmol), cyclohexylamine (4.5ml, 39.0mmol) and potassium carbon¬ ate (17. Ig, 124mmol) in acetonitrile (100ml) was heated at reflux for 2 days. The mixture was diluted with EtOAC, washed with water then brine, dried and par¬ tially concentrated in vacuo. The solid which precipi¬ tated was collected and washed with hexane to yield the title compound (6.7g, 86%) .

Example E26.2 N-Cyclohexyl-benzene-1, 2-diamine Cyclohexyl- (2-nitro-phenyl) -amine from Example E26.1 (3.Og, 13.6mmol) was dissolved in methanol (100ml) and tin (II) chloride (12.9g, 68.1mmol) was added. The mix¬ ture was stirred for 2Oh at room temperature then heated at reflux for 18h and concentrated in vacuo. The residue was placed in EtOAC (100ml), cooled down to 00C and pH was adjusted to 14 with cone. NH3. The precipi¬ tate was filtered off and washed with EtOAc. The fil¬ trate was washed with 2M NH3, water then brine, dried and concentrated in vacuo to yield the title compound (2.25g, 86%) .

Example E26.3 N-Cyclohexyl-N' -methyl-benzene-1,2-diamine Potassium carbonate (2.45g, 17.7mπιol) and iodomethane (0.81ml, 13. Ommol) were added to a solution of N- cyclohexyl-benzene-1, 2-diamine from Example E26.2 (2.25g, ll.δmmol) in DMF (10ml) . The mixture was stirred for βh at room temperature then poured into wa¬ ter and extracted with EtOAc. The organic layer was washed with water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% EtOAc: 95% hexane) to yield the title compound (950mg, 39%) .

Example E27 3-Fluoro-4-hydroxy-benzoic acid ethyl ester

A solution of 3-fluoro-4-hydroxy-benzoic acid (5.16g, 33.1mmol) in ethanol (100ml) was treated with cone. sulphuric acid (5ml), and the mixture heated at reflux for 4 days. The volatiles were removed in vacuo, and the aqueous residue was basified with saturated NaHCO3 and extracted twice with diethyl ether. The combined organic extracts were dried and concentrated in vacuo to yield the title compound (5.16g, 85%) .

Example E28 2-Chloro-4-hydroxy-benzoic acid ethyl ester A solution of 2-chloro-4-hydroxy-benzonitrile (5.Og, 32.6mmol) in ethanol (125ml) was treated with cone, sulphuric acid (25ml) and the mixture heated at reflux for 3 days. Cone, sulphuric acid (25ml) was added and the mixture was heated at reflux for another 2 days. The volatiles were removed in vacuo, and the aqueous residue was basified with saturated NaHCO3 and extracted 4 times with diethyl ether. The combined organic ex- tracts were dried and concentrated in vacuo to yield the title compound (2.5g, 38%) .

Example Ξ29 4-Hydroxy-3-methyl-benzoic acid methyl ester

4-Amino-3-methyl-benzoic acid methyl ester (5.25g, 32.0mmol) was treated with a 35% solution of sulphuric acid (50ml) and the mixture was stirred and heated un¬ til dissolution then cooled to 0°C. Sodium nitrite (2.82g, 41.6mmol) in water (50ml) was added dropwise and the mixture was stirred for 5min at 0°C. Urea was added to destroy the excess nitrite. Copper nitrate (12Ig, 320mmol) in water (11) was added then copper ox¬ ide (4.25g, 32.0mmol) . The mixture was warmed up to room temperature over 30 min and extracted with EtOAc (x 3) . The organics were combined, washed with brine, dried and concentrated in vacuo. The residue was puri¬ fied by flash chromatography on silica gel (eluant; 30% EtOAc:70% hexane) to yield the title compound (2.2g, 42%) .

Example E30 4- (3-Carboxy-propyl) -3-methyl-benzoic acid methyl ester

Example E30.1 4- ( (E) -2-tert-Butoxycarbonyl-vinyl) -3-methyl-benzoic acid methyl ester Tetrakis (triphenylphosphine)palladium (0) (5.Og, 4.33mmol) was added to a stirred solution of methyl 4- bromo-3-methylbenzoate (9.93g, 43.3mmol), tert-butyl acrylate (50ml, 341.3mmol) and sodium acetate (35.8g, 436.4mmol) in DMA (350ml) . The mixture was heated at 140°C for 5h, filtered through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was redissolved in EtOAc, washed with 0.3M KHSO4 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 15% EtOAc:85% hexane to 20% EtOAc: 80% hexane) to yield the title compound (4.81g, 40%) .

Example E30.2 4- (2-tert-Butoxycarbonyl-ethyl) -3-methyl-benzoic acid methyl ester 4- ( (E) -2-tert-Butoxycarbonyl-vinyl) -3-methyl-benzoic acid methyl ester from Example E30.1 (4.0Og, 14.5mmol) was dissolved in methanol (100ml) and hydrogenated over 10% Pd/C catalyst (480mg) for 5h. The mixture was fil¬ tered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (3.41g, 84%) .

Example E30.3 4- (2-Carboxy-ethyl) -3-methyl-benzoic acid methyl ester Trifluoroacetic acid (40ml) was added slowly to a stirred solution of 4- (2-tert-butoxycarbonyl-ethyl) -3- methyl-benzoic acid methyl ester from Example E30.2 (4.9g, 17.6mmol) in dichloromethane (80ml) at room tem¬ perature. The mixture was stirred for 2h then concen¬ trated in vacuo and azeotroped with dichloromethane. The residue was recrystallised in EtOAc to yield the title compound (2.11g, 71%) .

Example E30.4 4- (3-Carboxy-propyl) -3-methyl-benzoic acid methyl ester 4- (2-Carboxy-ethyl) -3-methyl-benzoic acid methyl ester from Example E30.3 (500mg, 2.25mmol) was dissolved in dry dichloromethane (10ml) and a few drops of DMF. Ox- alyl chloride (0.393ml, 4.5mmol) was added dropwise and the mixture was stirred for Ih at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in acetonitrile (20ml) and cooled to O0C. A solution of 2M (trimethyl- silyl) diazomethane in hexanes (2.25ml, 4.5mmol) was added dropwise and the reaction mixture was stirred for 5h at O0C then 2Oh at room temperature. Ethyl acetate then 10% citric acid solution were added and the layers were partitioned. The organic layer was washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% ethyl acetate: 50% cyclohex- ane) . The product obtained was dissolved in a mixture of acetonitrile and water. A solution of silver benzo- ate (103mg, 0.45mmol) in triethylamine (1.25ml, 9mmol) was added gradually while the mixture was sonicated in an ultrasound bath. After 30min at room temperature, solvents were removed in vacuo. Ethyl acetate and 10% aqueous citric acid solution were added and the layers were partitioned. The organic layer was washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc: 50% cyclohexane) to yield the title compound (378mg, 71%) .

Example E31 4-(4-Methoxycarbonyl-butyl) -3-methyl-benzoic acid

Example E31.1 4-Bromo-3-methyl-benzoic acid tert-butyl ester 4-Bromo-3-methyl-benzoic acid (2.06g, 9.6mmol) and thionyl chloride (2.2ml, 30.2mmol) in toluene (50ml) were heated at reflux for 2h then concentrated in vacuo and azeotroped with toluene. The residue was dissolved in THF (100ml) and triethylamine (2.8ml, 20.1mmol), cooled down to 00C and lithium tert-butoxide (1.24g, 15.5mmol) was added portionwise. The mixture was stirred for 18h at room temperature then concentrated in vacuo. The residue was dissolved in EtOAc, washed with IM HCl, saturated NaHCO3 then brine, dried and con¬ centrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% EtOAc: 95% pet. ether) to yield the title compound (1.8βg, 71%) .

Example E31.2 4- ( (IE, 3E) -4-Methoxycarbonyl-buta-l, 3-dienyl) -3-methyl- benzoic acid tert-butyl ester Tetrakis (triphenylphosphine)palladium (0) (852mg, 0.7mol) was added to a stirred solution of 4-bromo-3- methyl-benzoic acid tert-butyl ester from Example E31.1 (1.86g, 6.8mmol), 1-acetoxy-l, 3-butadiene (7.5ml, 64.5mmol) and sodium acetate (5.69g, 69.4mmol) in DMA (75ml) . The mixture was heated at 1400C for 3h, fil- tered through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc: 80% pet. ether) to yield the title compound (1.54g, 74%) .

Example E31.3 4- (4-Methoxycarbonyl-butyl) -3-methyl-benzoic acid tert- butyl ester 4- ( (IE, 3E) -4-Methoxycarbonyl-buta-l, 3-dienyl) -3-methyl- benzoic acid tert-butyl ester from Example E31.2 (1.54g, 5.1mmol) was dissolved in methanol (40ml) and hydrogenated over 10% Pd/C catalyst (200mg) for 5h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the ti¬ tle compound (1.43g, 92%) .

Example E31.4 4- (4-Methoxycarbonyl-butyl) -3-methyl-benzoic acid Trifluoroacetic acid (20ml) was added to a solution of 4- (4-methoxycarbonyl-butyl) -3-methyl-benzoic acid tert- butyl ester from Example E31.3 (1.43g, 4.7mmol) in di- chloromethane (40ml) and the mixture was stirred for 2h at room temperature. Solvents were concentrated in vacuo and azeotroped with dichloromethane to yield the title compound (1.07g, 92%) .

Example E32 4-Carboxymethyl-3-methyl-benzoic acid methyl ester

Example E32.1 4-tert-Butoxycarbonylmethyl-3-methyl-benzoic acid methyl ester Copper (II) fluoride (4.08g, 40.1mmol) and bis- [tri- (o- tolyl)phosphine]palladium dichloride (473mg, O.βmmol) were added to a solution of methyl 4-bromo-3-methyl benzoate (4.6Og, 20.1mmol) in THF (30ml) . The mixture was heated at reflux before silyl ketene acetal (18.5g, 80.3mmol) was added. The mixture was heated at reflux for 2 days then diluted with Et2O. Aqueous NH4Cl solution (250ml) was added and the mixture was stirred for 30min at room temperature. The layers were partitioned and the aqueous layer extracted twice with Et2O. The organics were combined, dried and concentrated In vacuo. The residue was purified by flash chromatog¬ raphy on silica gel (eluant; 5% EtOAc: 95% hexane) to yield the title compound (2.84g, 53%).

Example E32.2 4-Carboxymethyl-3-methyl-benzoic acid methyl ester Trifluoroacetic acid (15ml) was added to a solution of 4-tert-butoxycarbonylmethyl-3-methyl-benzoic acid methyl ester from Example E32.1 (2.84g, 10.7mmol) in dichloromethane (15ml) . The mixture was stirred for 90min at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was recrystallised from EtOAc and hexane to yield the title compound (1.8Ig, 81%) .

Example E33 4-[1,3]Dioxolan-2-yl-piperidine

Example E33.1 4-Hydroxymethyl-piperidine-l-carboxylic acid benzyl es- ter 4-Piperidinemethanol (5.Og, 43mmol) was dissolved in dichloromethane (100ml) and triethylamine (12ml, 86mmol) at 00C. Benzylchloroformate (6.8ml, 47.3mmol) was added and the mixture was stirred for 2Oh at room temperature then solvents were removed In vacuo. The residue was redissolved in EtOAc, washed with IM KHSO4, water then brine, dried and concentrated in vacuo to yield the title compound (8.33g, 77%) .

Example E33.2 4-Formyl-piperidine-l-carboxylic acid benzyl ester Dess-Martin reagent (17g, 39.6mmol) was added portion- wise to a solution of 4-hydroxymethyl-piperidine-l- carboxylic acid benzyl ester from Example E33.1 (8.33g, 33mmol) in dichloromethane (100ml) at room temperature. The mixture was stirred for 3h under an inert atmos¬ phere then diluted with chloroform and water and the layers were partitioned. The organic layer was washed with brine, dried and concentrated in vacuo. The resi- due was purified by flash chromatography on silica gel (eluant; 40% EtOAc: 60% hexane) to yield the title com¬ pound (5.5g, 66%) .

Example E33.3 4- [1, 3] Dioxolan-2-yl-piperidine-l-carboxylic acid ben¬ zyl ester Ethylene glycol (5ml) and a catalytic amount of p- toluenesulfonic acid were added to 4-formyl-piperidine- 1-carboxylic acid benzyl ester from Example E33.2 (5.6g, 22.6mmol) in toluene (100ml) and the mixture was heated at reflux under Dean and Stark conditions for 2.5h. Solvents were removed in vacuo and the residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 50% EtOAc: 50% pet. ether) to yield the title compound (5.14g, 78%) .

Example E33.4 4- [1, 3] Dioxolan-2-yl-piperidine 4- [1, 3] Dioxolan-2-yl-piperidine-l-carboxylic acid ben¬ zyl ester from Example E33.3 (5.14g, 17.7mmol) was dis- solved in methanol (100ml) and hydrogenated over 10% Pd/C catalyst (551mg) for 4h. The mixture was filtered through Celite® filter agent and the filtrate was con¬ centrated in vacuo to yield the title compound (2.84g, 100%) .

Example Ξ34 4- (3-Hydroxy-propyl) -piperazine-1-carboxylic acid tert- butyl ester

A solution of piperazine-1-carboxylic acid tert-butyl ester (26.5g, 142mmol) in acetone (300ml) at room tem¬ perature was treated with 3-bromo-propan-l-ol (14.5ml, 156.2mmol), potassium carbonate (5Og, 361.8mmol) and potassium iodide (2.4g, 14.2mmol), and the mixture was heated at reflux for 18h then allowed to cool to room temperature. The suspension was filtered and the fil¬ trate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol: 95% dichloromethane) to yield the title com- pound (21.Ig, 80%) .

Example E35 1-Cyclopropylmethyl-imidazolidine ditrifluoroacetate Example E35.1 [2- (Cyclopropylmethyl-amino) -ethyl] -carbamic acid tert- butyl ester Potassium hydrogen carbonate (220mg, 2.2mmol) and (bro- moethyl) cyclopropane (270mg, 2.0mmol) were added to a solution of tert-butyl-N- (2-aminoethyl) carbamate (320mg, 2.0mmol) in THF (10ml) . The mixture was heated at 66°C for 2Oh and solvents were concentrated in vacuo. The residue was dissolved in chloroform, washed with water, dried and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 1% triethylamine: 4% methanol: 95% chloroform) to yield the title compound (130mg, 30%) .

Example E35.2 l-Cyclopropylmethyl-imidazolidine ditrifluoroacetate Trifluoroacetic acid (5ml) was added to a solution of [2- (cyclopropylmethyl-amino) -ethyl] -carbamic acid tert- butyl ester from Example E35.1 (180mg, 0.84mmol) in di- chloromethane (3ml) and the mixture was stirred for 75min at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was placed in water (10ml) and formaldehyde (37% w/w solu- tion, 0.10ml, 1.36mmol) was added. The mixture was stirred for 6 days at room temperature, concentrated in vacuo, azeotroped with toluene then pet. ether to yield the title compound (255mg, 86%) .

Example E36 2-Piperaziη-l-yl-l-p-tolyl-ethanone dihydrochloride

Example E36.1 4- (2-Oxo-2-p-tolyl-ethyl) -piperazine-1-carboxylic acid tert-butyl ester 2-Bromo-4-methylacetophenone (572mg, 2.68mmol) was added to a solution of piperazine-1-carboxylic acid tert-butyl ester (500mg, 2.68mmol) in dichloromethane (5ml) and triethylamine (0.45ml, 3.22mmol) . The mixture was stirred for 3 days at room temperature and solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% hex- ane:60% EtOAc) to yield the title compound (ββlmg, 77%) .

Example E36.2 2-Piperazin-l-yl-l-p-tolyl-ethanone dihydrochloride 4- (2-Oxo-2-p-tolyl-ethyl) -piperazine-1-carboxylic acid tert-butyl ester from Example E36.1 (ββlmg, 2.08mmol) was dissolved in 4M HCl solution in dioxan (25ml) at 00C and the mixture was stirred for 45min at room tem¬ perature. Solvents were concentrated in vacuo and azeotroped with diethyl ether to yield the title com¬ pound (53βmg, 88%) .

Example E37 2-Bromo-l-[4- (3,3-dimethyl-butyl) -piperazin-1-yl] - ethanone

Bromoacetyl bromide (0.52ml, β.Ommol) was added to a solution of 1- (3, 3-dimethyl-butyl) -piperazine hydro¬ chloride from Example E4 (1.5g, 5.7mmol) in dichloromethane (20ml) and triethylamine (3.57ml, 25.6mmol) at 00C. The mixture was stirred for 2Oh at room temperature, washed with saturated NaHCO3, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% metha¬ nol: 95% dichloromethane) to yield the title compound (220mg, 13%) .

Example E38 Cyclopropyl-piperidin-4-ylmethyl-carbamic acid tert- biityl ester

Example E38.1 4-Cyclopropylaminomethyl-piperidine-l-carboxylic acid benzyl ester Cyclopropylamine (1.4g, 24.4mmol) and acetic acid (0.5ml) were added to a solution of 4-formyl- piperidine-1-carboxylic acid benzyl ester from Example E33.2 (5.5g, 22.2mmol) in methanol (49.5ml) and the mixture was stirred for Ih at room temperature. Sodium cyanoborohydride (1.84g, 28.9mmol) was added and the mixture was stirred for 2Oh at room temperature under an inert atmosphere. Solvents were removed in vacuo and azeotroped with toluene. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% metha¬ nol: 90% dichloromethane) to yield the title compound (3.Og, 47%) .

Example E38.2 4- [ (tert-Butoxycarbonyl-cyclopropyl-amino) -methyl] - piperidine-1-carboxylic acid benzyl ester DMAP (127mg, 1.04mmol) and di-tert-butyl dicarbonate (3.4g, 12.5mmol) were added to a solution of 4- cyclopropylaminomethyl-piperidine-1-carboxylic acid benzyl ester from Example E38.1 (3.0gΛ 10.4mmol) in di- chloromethane (50ml) and triethylamine (to pH9) . The mixture was stirred for 2Oh at room temperature then concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 40% EtOAc: 60% hexane) to yield the title compound (3.67g, 92%) .

Example E38.3 Cyclopropyl-piperidin-4-ylmethyl-carbamic acid tert- butyl ester 4- [ (tert-Butoxycarbonyl-cyclopropyl-amino) -methyl] - piperidine-1-carboxylic acid benzyl ester from Example E38.2 (3.67g, 9.4mmol) was dissolved in methanol (100ml) and hydrogenated over 10% Pd/C catalyst (3g) for Ih. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (2.07g, 87%) .

Example Ξ39 4- [3- (4-Carboxγ-2-£luoro-phenoxy) -propyl]-piperazine-1- carboxylic acid tert-butyl ester

Example E39.1 4- [3- (4-Ethoxycarbonyl-2-fluoro-phenoxy) -propyl] - piperazine-1-carboxylic acid tert-butyl ester Triphenylphosphine polystyrene (loading 1.0 mmol/g, Hg, ll.Ommol) and DEAD (2.45g, ll.Ommol) were added to a solution of 3-fluoro-4-hydroxy-benzoic acid ethyl es¬ ter from Example E27 (1.3g, 7.4mmol) and 4- (3-hydroxy- propyl) -piperazine-1-carboxylic acid tert-butyl ester from Example E34 (1.8g, 7.4mmol) in tetrahydrofuran (100ml) at 0°C. The suspension was allowed to warm to room temperature and stirred for 18h. The mixture was filtered and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAC) to yield the title compound (1.7g, 57%) .

Example E39.2 4- [3- (4-Carboxy-2-fluoro-phenoxy) -propyl] -piperazine-1- carboxylic acid tert-butyl ester A solution of 4- [3- (4-ethoxycarbonyl-2-fluoro-phenoxy) - propyl] -piperazine-1-carboxylic acid tert-butyl ester from Example E39.1 (1.7g, 4.1 mmol) in dioxan (25ml) was treated with 2N NaOH (3ml) and the mixture stirred at 500C for 18h. A further aliquot of 2N NaOH was added (2ml), and stirring continued at 500C for 3h. Solvents were removed in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel (eluant; 1% acetic acid: 9% methanol: 90% chloroform) to yield the title compound (1.45g, 92%) .

Example Ξ40 4-{2-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl]-ethoxy}-3- methyl-benzoic acid

Example E40.1 4- [2- (4-Methoxycarbonyl-2-methyl-phenoxy) -ethyl] - piperazine-1-carboxylic acid tert-butyl ester 4- (2-Hydroxy-ethyl) -piperazine-1-carboxylic acid tert- butyl ester (500mg, 2.2mmol) was dissolved in THF (30ml) and cooled down to O0C. Polymer-supported triphenylphosphine (2.2g, 2.2mmol), DEAD (378mg, 2.2mmol) and 4-hydroxy-3-methyl-benzoic acid methyl es- ter from Example E29 (3βlmg, 2.2mmol) were added and the mixture was stirred for 2Oh at room temperature. The resin was filtered off and the filtrate concen¬ trated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (495mg, 60%) .

Example E40.2 3-Methyl-4- (2-piperazin-l-yl-ethoxy) -benzoic acid methyl ester dihydrochloride 4-[2- (4-Methoxycarbonyl-2-methyl-phenoxy) -ethyl] - piperazine-1-carboxylic acid tert-butyl ester from Ex¬ ample E40.1 (200mg, 0.53mmol) was dissolved in 4M HCl solution in dioxan (5ml) . The mixture was stirred for 30min at room temperature, concentrated in vacuo and azeotroped with toluene to yield the title compound (185mg, 100%) .

Example E40.3 4-{2- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -ethoxy}-3- methyl-benzoic acid methyl ester 3,3-Dimethylbutyraldehyde (54mg, 0.53mmol) was added to a solution of 3-methyl-4- (2-piperazin-l-yl-ethoxy) - benzoic acid methyl ester dihydrochloride from Example E40.2 (146mg, 0.42mmol) in methanol/acetic acid (99:1, v/v, 10ml) and the mixture was stirred at room tempera¬ ture for Ih. Sodium cyanoborohydride (42mg, 0.69mmol) was added, and the mixture was stirred at room tempera¬ ture for 18h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the ti¬ tle compound (64mg, 34%) .

Example E40.4 4-{2-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -ethoxy}-3- methyl-benzoic acid 4-{2- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -ethoxy}-3- methyl-benzoic acid methyl ester from Example E40.3 (42mg, 0.12mmol) was dissolved in dioxan (5ml) and IM NaOH (ImI) was added. The mixture was heated at reflux for 2h then solvents were concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHC03, water then brine, dried and concentrated in vacuo to yield the title compound (40mg, 100%) .

Example E41 4-{2-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl]-2-oxo- ethoxy}-3-methyl-benzoic acid

Example E41.1 4-tert-Butoxycarbonylmethoxy-3-methyl-benzoic acid methyl ester Potassium carbonate (4.6g, 33mmol) , potassium iodide (0.25g, 1.5mmol) and tert-butylbromoacetate (2.5ml, 16.5mmol) were added to a solution of 4-hydroxy-3- methyl-benzoic acid methyl ester from Example E29 (2.5g, 15mmol) in acetone (150ml) and the mixture was heated at reflux for 2Oh. The solid was filtered off and the filtrate concentrated in vacuo. The residue was dissolved in EtOAc, washed with IN KHSO4, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 15% EtOAc: 85% hexane) to yield the title compound (3.8g, 90%) .

Example E41.2 4-Carboxymethoxy-3-methyl-benzoic acid methyl ester Trifluoroacetic acid (20ml) was added to a solution of 4-tert-butoxycarbonylmethoxy-3-methyl-benzoic acid methyl ester from Example E41.1 (3.8g, 13. βmmol) in di- chloromethane (40ml) and the mixture was stirred for Ih at room temperature. Volatiles were removed in vacuo and azeotroped with dichloromethane to yield the title compound (3.04g, 100%) .

Example E41.3 4-{2- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -2-oxo- ethoxy}-3-methyl-benzoic acid methyl ester WSCD (5.14g, 27.2mmol) and DMAP (1.64g, 13. βmmol) were added to a solution of 4-carboxymethoxy-3-methyl- benzoic acid methyl ester from Example E41.2 (3.04g, 13. βmmol) in dichloromethane (100ml) and triethylamine (5ml) . The mixture was stirred for Ih at room tempera¬ ture then 1- (3, 3-dimethyl-butyl) -piperazine dihydro- chloride from Example E4(3.67g, 14.9mmol) was added. The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (2.8g, 55%) .

Example E41.4 4-{2-[4- (3, 3-Dimethyl-butyl) -piperazin-1-yl]-2-oxo- ethoxy}-3-methyl-benzoic acid IM Boron tribromide solution (2.66ml, 2.66inmol) was added dropwise to a solution of 4-{2- [4- (3, 3-dimethyl- butyl) -piperazin-1-yl] -2-oxo-ethoxy}-3-methyl-benzoic acid methyl ester from Example E41.3 (500mg, 1.33mmol) in dichloromethane (20ml) at O0C under an inert atmos¬ phere. The mixture was stirred for 2Oh at room tempera¬ ture then cooled down to 0°C. IM Boron tribromide solu¬ tion (1.33ml, 1.33mmol) was added and the mixture was stirred for 2h at room temperature. Solvents were re- moved in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel (eluant; 1% acetic acid: 5% methanol: 94% chloroform) to yield the title compound (350mg, 72%) .

Example E41a 4-(2-Bromo-acetyl) -piperazine-1-carboxylic acid tert- butyl ester

A solution of bromoacetyl bromide (8.5ml, 97mmol) in DCM (250ml) at O0C was treated dropwise with a solution of 1-Boc-piperazine (15.9, 85.3mmol) and triethylamine (18.0ml, 130mmol) in DCM (150ml) . After addition was complete, the mixture was stirred at room temperature for 4 h. The solution was washed with ice-cold IM HCl, sat. aq. NaHCO3, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc: 80% cyclohexane to 50% EtOAc:50% cyclohexane) to yield the title compound (15.7g, 60.0%) .

Example E4Ib 2-Chloro-4-hydroxy-benzoic acid methyl ester Example E41b.l 4-Amino-2-chloro-benzoic acid methyl ester A solution of 4-Amino-2-chloro-benzoic acid (5.3g, 31mmol) in methanol (100 ml) was treated with acetyl chloride (5ml) and then heated at reflux for 16 hours. The solvents were evaporated in vacuo. The residue was dissolved in EtOAc, washed with saturated sodium hydro¬ gen carbonate, dried and concentrated in vacuo to yield the title compound as a purple solid, 5.45g, 95%.

Example E41b.2 2-Chloro-4-hydroxy-benzoic acid 4-Amino-2-chloro-benzoic acid methyl ester from Example E41b.l (5.45g, 29.4mmol) was treated with a 35% solu- tion of sulphuric acid (120ml) and the mixture was stirred and heated until dissolution then cooled to 0°C. Sodium nitrite (4.3Og, 62.5mmol) in water (25ml) was added dropwise and the mixture was stirred for 15min at 0°C. Urea was added to destroy the excess nitrite. Cop- per nitrate (200mg, 0.83mmol) was added and heated to 90 0C. The reaction mixture was cooled to room tempera¬ ture, extracted into ethyl acetate χ3, dried and con¬ centrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc: 70% hexane to 50% EtOAc: 49% hexane:l% AcOH) to yield the title compound (3.7g, 73%) .

Example E41b.3 2-Chloro-4-hydroxy-benzoic acid methyl ester A solution of 2-chloro-4-hydroxy-benzoic acid (3.70 g, 21.4 mmol) ) in methanol (50 ml) was treated with thio- nyl chloride (2.4 ml, 32 mmol) dropwise and stirred for 24 hours and the solvents were removed in vacuo. The residue was dissolved in ethyl acetate and washed with sat. sodium hydrogen carbonate, dried and solvents were removed in vacuo. The residue was purified by column chromatography on silica gel (eluant with 30% EtOAc:70% cyclohexane) to yield the desired product as a yellow solid, 3.68 g, 92%.

Example Ξ41c 4-[2-(4-Carboxy-3-chloro-phenoxy) -acetyl]-piperazine-1- carboxylic acid tert-butyl ester

Example E41c.l 4- [2- (3-Chloro-4-methoxycarbonyl-phenoxy) -acetyl] - piperazine-1-carboxylic acid tert-butyl ester 2-Chloro-4-hydroxy-benzoic acid methyl ester from exam¬ ple E41b (2.Og, 10.9mmol) and 4- (2-Bromo-acetyl) - piperazine-1-carboxylic acid tert-butyl ester from Ex¬ ample E41a (3.68g, 12.0mmol) in acetonitrile (30ml) were treated with potassium carbonate (l.βg, 11.5mmol), and the mixrure heated at reflux 18 h. before the sol¬ vents were removed in vacuo. The residue was adsorbed onto silica gel and purified by flash chromatography on silica gel (eluant; 20% EtOAc: 80% cyclohexane to 50% EtOAc: 50% cyclohexane to 70% EtOAc:30% cyclohexane) to yield the title compound (4.5g, 100%) .

Example E41c.2 4- [2- (4-Carboxy-3-chloro-phenoxy) -acetyl] -piperazine-1- carboxylic acid tert-butyl ester A solution of 4- [2- (3-Chloro-4-methoxycarbonyl- phenoxy) -acetyl]-piperazine-1-carboxylic acid tert- butyl ester from Example E41c.l (4.5g, lO.δmmol) in THF at O0C was treated with potassium trimethylsilanolate (l.βg, 10.9mmol), and the mixture stirred at room tem¬ perature for 18 h. A further l.βg (10.9mmol) potassium silanolate was added, and stirring continued at room temperatuire for 2h. A further 1.6g (10.9mmol) potas- sium silanolate was added, and the mixture was stirred at 45°C for 2h. The mixture was then diluted with water and THF was removed in vacuo. The residue was washed with ether, cooled in an ice-bath and adjusted to pH5 with solid KHSO4 whereupon it was extracted with CHCI3 and CHCl3/isopropanol (90:10 v/v) . The combined organ- ics were dried and solvents were removed in vacuo to yield the title compound (3.7g, 85%) .

Example E42 4-(3-tert-Butoxycarbonyl-propoxy) -3-methyl-benzoic acid

Example E42.1 4-Bromo-butyric acid tert-butyl ester IM Boron tribromide (39ml, 39mmol) was added to a solu- tion of butyrolactone (3ml, 39mmol) in dichloromethane (30ml) . The mixture was stirred for 20h at room tem¬ perature then quenched with an excess of tert- butylalcohol. The mixture was stirred for 2h at room temperature, diluted with dichloromethane, washed with saturated NaHCO3, saturated Na2S2U3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 5% EtOAc: 95% hexane) to yield the title com¬ pound (3g, 34%) .

Example E42.2 4- (3-tert-Butoxycarbonyl-propoxy) -3-methyl-benzoic acid methyl ester Potassium carbonate (580mg, 4.20mmol) and potassium io¬ dide (72mg, 0.43mmol) were added to a solution of 4- hydroxy-3-methyl-benzoic acid methyl ester from Example E29 (293mg, 1.7βmmol) and 4-bromo-butyric acid tert- butyl ester from Example E42.1 (397mg, 1.78mmol) in acetone (50ml) . The mixture was heated at reflux for 18h then the solid was filtered off and the filtrate concentrated in vacuo. The residue was dissolved in EtOAc, washed with water then brine, dried and concen- trated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 20% EtOAc: 80% pet. ether) to yield the title compound (414mg, 76%) .

Example E42.3 4- (3-tert-Butoxycarbonyl-propoxy) -3-methyl-benzoic acid Lithium hydroxide monohydrate (137mg, 3.2βmmol) was added to a solution of 4- (3-tert-butoxycarbonyl- propoxy) -3-methyl-benzoic acid methyl ester from Exam¬ ple E42.2 (414mg, 1.34mmol) in THF (10ml) and water (5ml) . The mixture was stirred for 48h at room tempera¬ ture and concentrated in vacuo. The residue was dis¬ solved in chloroform, acidified with IM HCl then washed with brine, dried and concentrated in vacuo to yield the title compound (275mg, 70%) .

Example Ξ43 4-{4-[4- (3,3-Dimethyl-butyl) -piperazin-1-γl]-4-oxo- butyl}-3-mefchyl-benzoic acid

Example E43.1 4-{4- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -4-oxo- butyl}-3-methyl-benzoic acid methyl ester

Y : '.Legal iDϋcmnentsΗsa'.OQϋOOOOO\00(X!θm 7 w» HBTU (910mg, 2.4mmol) was added to a solution of 4- (3- carboxy-propyl) -3-methyl-benzoic acid methyl ester from Example E30 (378mg, l.βmmol) and 1- (3, 3-dimethyl- butyl) -piperazine hydrochloride from Example E4 (467mg, 1.9mmol) in dichloromethane (15ml) and DIEA (0.836ml, 4.8mmol) . The mixture was stirred for 2Oh at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was puri¬ fied by flash chromatography on silica gel through an isolute (eluant; 5% methanol:95% dichloromethane) to yield the title compound (582mg, 94%) .

Example E43.2 4-{4- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -4-oxo- butyl}-3-methyl-benzoic acid Lithium hydroxide monohydrate (108mg, 2.6mmol) was added to a solution of 4-{4- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -4-oxo-butyl}-3-methyl-benzoic acid methyl ester from Example E43.1 (500mg, 1.3mmol) in THF (12ml) and water (6ml) . The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% acetic acid:4% methanol: 94% dichloromethane) then recrystallised from chloroform and pet. ether to yield the title compound (439mg, 91%) .

Example Ξ44 4-{3-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -3-oxo- propyl}-3-methyl-benzoic acid

Example E44.1 4-{3- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -3-oxo- propyl}-3-methyl-benzoic acid methyl ester Oxalyl chloride (2.6ml, 30mmol) was added slowly to a solution of 4- (2-carboxy-ethyl) -3-methyl-benzoic acid methyl ester from Example E30.3 (5.33g, 24mmol) in di- chloromethane (60ml) and few drops of DMF at 00C. The mixture was stirred for 2h at room temperature then concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (30ml) and added to a solution of 1- (3, 3-dimethyl-butyl) - piperazine hydrochloride from Example E4 (6.3g, 26mmol) in dichloromethane (45ml) and DIEA (17ml, 96mmol) at O0C. The mixture was stirred for Ih at room temperature then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% metha¬ nol: 95% dichloromethane) to yield the title compound (8.5g, 96%) .

Example E44.2 4-{3- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -3-oxo- propyl}-3-methyl-benzoic acid Lithium hydroxide monohydrate (2.4g, 56.7mmol) was added to a solution of 4-{3- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -3~oxo-propyl}-3-methyl-benzoic acid methyl ester from Example E44.1 (8.5g, 22.7mmol) in THF (200ml) and water (100ml) . The mixture was stirred for 24h at room temperature then solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% acetic acid: 4% methanol: 94% dichloromethane) to yield the title compound (8.1g, 99%) .

Example E45 3-[2-Methyl-4- (3-methyl-4,10-dihydro~3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -phenyl]-propionic acid

Example E45.1 4- ( (E) -2-tert-Butoxycarbonyl-vinyl) -3-methyl-benzoic acid Lithium hydroxide monohydrate (384mg, 9.2mmol) was added to a solution of 4- ( (E) -2-tert-butoxycarbonyl- vinyl) -3-methyl-benzoic acid methyl ester from Example E30.1 (1.27g, 4.6mmol) in THF (50ml) and water (20ml) . The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo. The residue was dissolved in EtOAc, washed with IM KHSO4, water then brine, dried and concentrated in vacuo to yield the ti¬ tle compound (l.lg, 92%) .

Example E45.2 (E) -3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo[f] azulene-9-carbonyl) -phenyl] -acrylic acid tert-butyl ester 4- ( (E) -2-tert-Butoxycarbonyl-vinyl) -3-methyl-benzoic acid from Example E45.1 (l.lg, 4.2mmol) and 3-methyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f]azulene from Example Ell (720rag, 3.6mmol) were dissolved in dichloromethane (50ml) and triethylamine (0.75ml) . DMAP (4.45g, 3.6mmol) and WSCD (1.36g, 7.1mmol) were added and the mixture was heated at re¬ flux for 2 days. The solution was diluted with di- chloromethane, washed with 0.3M KHSO4, saturated NaHCO3 then brine, dried and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (1.35g, 82%) .

Example E45.3 3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo[f] azulene-9-carbonyl) -phenyl] -propionic acid tert-butyl ester (E) -3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -acrylic acid tert-butyl ester from Example E45.2 (436mg, 0.99mmol) was dissolved in methanol (40ml) and hydro- genated over 10% Pd/C catalyst (91mg) for 5h. The mix¬ ture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo and azeotroped with dichloromethane to yield the title compound (426mg, 96%) .

Example E45.4 3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -propionic acid Trifluoroacetic acid (5ml) was added to a solution of 3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -propionic acid tert-butyl ester from Example E45.3 (413mg, 0.92mmol) in dichloromethane (10ml) and the mixture was stirred for 45min at room temperature. Solvents were removed in vacuo and azeotroped with dichloromethane. The residue was crystallised with MeOH/Et2O to yield the title compound (322mg, 90%) .

Example Ξ46 (E) -3-[2-Methyl-4- (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -phenyl]-acrylic acid

Trifluoroacetic acid (5ml) was added to a solution of (E)-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -acrylic acid tert-butyl ester from Example E45.2 (338mg, 0.76mmol) in dichloromethane (10ml) and the mixture was stirred for 45min at room temperature. Solvents were removed in vacuo and azeotroped with dichloromethane to yield the title compound (337mg, 80%) .

Example E47 3-[2-Methyl-4- (3-methyl-4,10-dihydro-3H-2 ,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -phenyl] -1- piperazin-1-yl-propan-l-one

Example E47.1 4-{3- [2-Methyl-4- (3-methyl-4,10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyll-piperazine-l-carboxylic acid tert-butyl es¬ ter PyBroP (1.54g, 3.3mmol) was added to a solution of 3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenyl]-propionic acid from Example E45 (850mg, 2.25mmol) and DMAP (275mg, 2.25mmol) in dichloromethane (20ml) and DIEA (0.90ml, 5.2mmol) . The mixture was stirred for 15 mins at room temperature then 3-methyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9- tetraaza-benzo [f] azulene from Example Ell (450mg, 2.25mmol) was added. The mixture was heateςi at reflux for 18h, diluted with dichloromethane, washed with 0.3M KHSO4 solution then saturated NaHCθ3, dried and concen¬ trated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol: 95% EtOAc) to yield the title compound (1.09g, 87%) .

Example E47.2 3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2,3,4,9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -1- piperazin-1-yl-propan-l-one 4-{3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyll-piperazine-1-carboxylic acid tert-butyl es¬ ter from Example E47.1 (1.09g, 1.95mmol) was dissolved in methanol (20ml) and 4M HCl/dioxan solution (20ml) was added. The mixture was stirred for 3h at room tem¬ perature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in methanol (30ml) and ammonia (5ml) then concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 0.5% 35% ammonia: 4.5% methanol: 95% dichloro- methane to 1% 35% ammonia: 9% methanol: 90% dichloro- methane) to yield the title compound (759mg, 73%) .

Example Ξ48 {4-[3- (4-Cyclopropyl-piperazin-l-yl) -propoxy]-3-fluoro- phenyl}- (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulen-9-yl) -methanone

Example E48.1 4- (3-Bromo-propoxy) -3-fluoro-benzoic acid ethyl ester 1, 3-Dibromopropane (2.2g, ll.Ommol), potassium carbon¬ ate (l.δβg, 13.6mmol) and potassium iodide (90mg, 0.5mmol) were added to 3-fluoro-4-hydroxy-benzoic acid ethyl ester from Example E27 (l.Og, 5.4mmol) in acetone (25ml) and the mixture was heated at reflux for 2Oh. The solid was filtered off and washed with EtOAc. The filtrate was concentrated in vacuo and azeotroped with toluene. The residue was purified by flash chromatogra¬ phy on silica gel (eluant; 20% EtOAc: 80% hexane) to yield the title compound (1.18g, 71%) .

Example E48.2 4- [3- (4-Cyclopropyl-piperazin-l-yl) -propoxy] -3-fluoro- benzoic acid ethyl ester 1-Cyclopropyl-piperazine dihydrochloride (642mg, 3.2mmol, according to the procedure described by G.S. Poindexter, M.A. Bruce, K.L. Le Boulluec, I. Monkovic, Tet. Lett., 35(44), 7331-7334, 1994), potassium carbon¬ ate (2.1g, 15.2mmol) and potassium iodide (50mg, 0.3mmol) were added to 4- (3-bromo-propoxy) -3-fluoro- benzoic acid ethyl ester from Example E48.1 (1.2g, 3.9mmol) in acetone (25ml) . The mixture was heated at reflux for 2Oh. The solid was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc then 1% 35% ammonia: 9% methanol: 90% dichloromethane) to yield the title compound (l.Og, 89%) .

Example E48.3 4- [3- (4-Cyclopropyl-piperazin-l-yl) -propoxy] -3-fluoro- benzoic acid 4- [3- (4-Cyclopropyl-piperazin-l-yl) -propoxy] -3-fluoro- benzoic acid ethyl ester from Example E48.2 (l.Og, 2.9mmol) was dissolved in dioxan (10ml) and 2N NaOH so¬ lution (3ml, β.Ommol) was added. The mixture was heated at 60°C for 18h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia: 19% methanol: 80% dichloro- methane) to yield the title compound (920mg, 100%) .

Example E48.4 {4- [3- (4-Cyclopropyl-piperazin-l-yl) -propoxy] -3-fluoro- phenyl}- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f]azulen-9-yl) -methanone HBTU (325mg, 0.9mmol) and 4M HCl in dioxan (0.45ml, l.δmmol) were added to a solution of 4- [3- (4- cyclopropyl-piperazin-1-yl) -propoxy] -3-fluoro-benzoic acid from Example E48.3 (230mg, 0.7mmol) in DMF (5ml) . The mixture was stirred at room temperature for 30min. 3-Methyl-3,4, 9,10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f]azulene from Example E65 (186mg, 0.9mmol) and DIEA (pH=9) were added and the mixture was stirred at room temperature for 18h. The mixture was heated at 60°C for 3h then HBTU (300mg, O.δmmol) was added. The mix- ture was heated at 60°C for 2 days then solvents were removed in vacuo and azeotroped with toluene. The resi¬ due was redissolved in EtOAc, washed with saturated Na- HCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a brown solid identified as the title compound (55mg, 15%) .

Example E49 [3-Fluoro-4-(3-piperazin-1-yl-propoxy) -phenyl]-(3- methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulen- 9-yl) -methanone dihydrochloride Example E49. 1 4-{3- [2-Fluoro-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo[f]azulene-9-carbonyl) -phenoxy] -propyl}- plperazine-1-carboxylic acid tert-butyl ester A solution of 4- [3- (4-carboxy-2-fluoro-phenoxy) - propyl] -piperazine-1-carboxylic acid tert-butyl ester from Example E39 (865mg, 2.3mmol) in dichloromethane (50ml) was treated with triethylamine (to pH9) , WSCD (865mg, 4.5mmol) and DMAP (276mg, 2.3mmol), and the mixture was stirred at room temperature for lOmin. 3- Methyl-3,4, 9,10-tetrahydro-2,3, 4, 9-tetraaza- benzo[f] azulene from Example Ell (541mg, 2.7mmol) was added. The mixture was heated at reflux for 18h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with saturated NaHCO3 then brine and con¬ centrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol: 90% dichloromethane) to yield the title compound (615mg, 48%) .

Example E49.2 [3-Fluoro-4- (3-piperazin-l-yl-propoxy) -phenyl] - (3- methyl-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen- 9-yl) -methanone dihydrochloride A solution of 4-{3- [2-fluoro-4- (3-methyl-4, 10-dihydro- 3H-2,3, 4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - phenoxy] -propyl}-piperazine-1-carboxylic acid tert- butyl ester from Example E49.1 (615 mg, 1.09mmol) in methanol (2ml) at 00C was treated with 4N HCl in dioxan (5ml) . The solution was allowed to warm to room tem¬ perature and stirred for Ih. Solvents were removed in vacuo to give a white foam identified as the title com¬ pound (585 mg, 100%) .

Example E50 (4-{3-[4-(3,3-Dimethyl-butyl) -piperazin-1-yl] -propoxy}- 3-fluoro-phenyl) - (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[£]azulen-9-yl) -methanone bis (trifluoroacetate)

3,3-Dimethylbutyraldehyde (120mg, 1.20mmol) and triethylamine (to pH9) were added to a solution of [3- fluoro-4- (3-piperazin-l-yl-propoxy) -phenyl] - (3-methyl- 4,10-dihydro-3H-2, 3,4, 9-tetraaza-benzo[f] azulen-9-yl) - methanone dihydrochloride from Example E49 (585mg, 1.09mmol) in methanol/acetic acid (99:1, v/v, 20ml) and the mixture was stirred at room temperature for Ih. So¬ dium cyanoborohydride (103mg, 1.30mmol) was added and the mixture was stirred at room temperature for 18h then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% metha¬ nol: 90% dichloromethane) to yield (4-{3- [4- (3, 3- dimethyl-butyl) -piperazin-1-yl] -propoxy}-3-fluoro- phenyl) - (3-methyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone, which was lyophilised from aqueous trifluoroacetic acid to give a white solid identified as the title compound (700mg, 83%) .

Example E51 (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulen-9-yl) -{4-[3- (l-isobutyl-piperidin-4-yl) - propoxy]-3-methyl-phenyl}-methanone A solution of isobutyraldehyde (0.36mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) was added to a solution of (3, 6-dimethyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulen-9-yl) - [3-methyl-4- (3-piperidin-4-yl- propoxy) -phenyl] -methanone hydrochloride (2.6mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) and DIEA (0.0026ml) . The mixture was stirred at room temperature for Ih then a solution of sodium triacetoxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added. The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo to yield the title com¬ pound. (ESI)+: [M+H]+= 530.5

Example E52 (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulen-9-yl) -{2-fluoro-4-[3- (4-hexyl-piperazin- 1-yl) -propoxy] -phenyl}-methanone

A solution of 1-bromohexane (0.83mg, 0.005mmol) in DMF(0.05ml) was added to a solution of (6-chloro-3- methy1-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen- 9-yl) - [2-fluoro-4- (3-piperazin-l-yl-propoxy) -phenyl] - methanone dihydrochloride from Example E5a (2.85mg, 0.005mmol) in DMF (0.05ml) and triethylamine (0.0021ml) . The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 583.6

Example E53 1-(4-{3- [2-Methyl-4- (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -phenoxy] -propyl}- piperazin-1-yl) -ethanone A solution of acetyl chloride (0.39mg, 0.005mπιol) in dichloromethane (0.05ml) was added to a solution of (3- methyl-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen- 9-yl) - [3-methyl-4- (3-piperazin-l-yl-propoxy) -phenyl] - methanone dihydrochloride (Compound number 408) (2.67mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for Ih then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H] += 503.2

Example Ξ54 {4-[3- (4-Methanesul£onyl-piperazin-l-yl) -propoxy]-3- methyl-phenyl}- (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulen-9-yl) -methanone

A solution of methanesulfonyl chloride (0.57mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of (3-methyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo[f] azulen-9-yl) -[3-methyl-4- (3-piperazin-l-yl- propoxy) -phenyl] -methanone dihydrochloride (Compound number 408) (2.67mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for Ih then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 539.2

Example Ξ55 1-(4-[l,3]Dioxolan-2-yl-piperidin-l-yl)-3-[2-methyl-4- (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenyl] -propan-1-one HBTU (327mg, 0.86mmol) was added to a solution of 4- [1, 3]dioxolan-2-yl-piperidine from Example E33 (143mg, 0.91mmol) and 3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo[f]azulene-9-carbonyl) -phenyl] - propionic acid from Example E45 (320mg, 0.82mmol) in dichloromethane (20ml) and DIEA (0.7ml, 4.02mmol) and the mixture was stirred for 2Oh at room temperature. Dichloromethane was added and the solution was washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatog¬ raphy on silica gel (eluant; 4% methanol: 96% dichloro¬ methane to 8% methanol: 92% dichloromethane) to give a white solid identified as the title compound (359mg, 83%) .

Example Ξ56 1-[4- (Furan-2-carbonyl)-piperazin-1-yl]-3-[2-methyl-4- (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenyl]-propan-1-one

A solution of HBTU (1.90mg, 0.005mmol) in DMF (0.05ml) was added to a solution of 3- [2-methyl-4- (3-methyl- 4, 10-dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9- carbonyl) -phenyl] -propionic acid from Example E45 (1.95mg, 0.005mmol) in DMF (0.05ml) and DIEA (0.0022ml) . The mixture was stirred at room temperature for 30min then a solution of 1- (2-furoyl)piperazine (0.90mg, 0.005mmol) in DMF (0.05ml) was added. The mix¬ ture was stirred for 18h at room temperature then sol- vents were removed in vacuo to yield the title com¬ pound. (ESI)+: [M+H]+= 553.4

Example Ξ57 (E) -3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene~9-carbonyl)-phenyl]-1-[4- (2- piperidin-1-yl-ethyl) -piperazin-1-yl] -propenone

A solution of HBTU (1.90mg, 0.005inmol) in DMF (0.05ml) was added to a solution of (E) -3- [2-Methyl-4- (3-methyl- A110-dihydro-3H-2, 3,4, 9-tetraaza-benzo[f]azulene-9- carbonyl) -phenyl] -acrylic acid from Example E46 (1.95mg, 0.005mmol) in DMF (0.05ml) and DIEA (0.0022ml) . The mixture was stirred at room temperature for 30min then a solution of 1- (2-Piperidin-l-yl- ethyl) -piperazi ne (0.99mg, 0.005mmol) in DMF (0.05ml) was added. The mixture was stirred for 18h at room temperature then solvents were removed in vacuo to yield the title com¬ pound.

Example E58 1-{4-[ (Butyl-methyl-amino)-methyl]-piperidin-1-yl}-3- [2-methyl-4- (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl)-phenyl]-propan-1-one

Example E58.1 1-{ 3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2,3,4,9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyl}-piperidine-4-carbaldehyde Pyridinium p-toluenesulfonate (85mg, 0.34mmol) was added to a solution of 1- (4- [1, 3]dioxolan-2-yl- piperidin-1-yl) -3- [2-methyl-4- (3-methyl-4,10-dihydro- 3H-2,3, 4, 9-tetraaza-benzo [f]azulene-9-carbonyl)- phenyl] -propan-1-one from Example E55 (614mg, l.lβmmol) in acetone (20ml) and water (20ml) . The mixture was heated at reflux for 7 days then solvents were removed in vacuo. The residue was redissolved in EtOAc, washed with 0.3M KHSO4 then brine, dried, concentrated in vacuo then crystallised with chloroform and pet. ether to yield the title compound (451mg, 80%) .

Example E58.2 l-{4- [ (Butyl-methyl-amino) -methyl] -piperidin-l-yl}-3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f]azulene-9-carbonyl) -phenyl] -propan-1-one A solution of l-{3- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3,4, 9-tetraaza-benzo[f] azulene-9-carbonyl) - phenyl] -propionyl}-piperidine-4-carbaldehyde from Exam¬ ple E58.1 (2.43mg, 0.005mmol) in 1, 2-dichloroethane (0.05ml) was added to a solution of butyl-methyl-anaine (0.43mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) and the mixture was heated at 50°C for 3h then stirred at room temperature for 2 days. A solution of sodium tri- acetoxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added and the mixture was stirred for 2Oh at room temperature. Solvents were removed in vacuo to yield the title compound. MS: (ESI) +: [M+H]+= 557.6

Example E59 3-[2-Methyl-4- (3-methγl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[£]azulene-9-carbonyl) -phenyl] -l-[4-(2- morpholin-4-yl-ethylamino) -piperidin-1-yl] -propan-1-one

A solution of l-{3- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - phenyl] -propionyl}-piperidin-4-one (Compound number 701) (2.36mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) was added to a solution of 2-morpholin-4-yl-ethylamine (0.65mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) and the mixture was heated at 500C for 3h then stirred at room temperature for 2 days. A solution of sodium tri- acetoxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added and the mixture was stirred for 2Oh at room temperature. Solvents were removed in vacuo to yield the title compound. MS: (ESI)+: [M+H]+= 586.6

Example Ξ60 1- (4-Hexyl-piperazin-l-yl) -3-[2-methyl-4- (3-methyl- 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl) -phenyl]-propan-1-one

A solution of 1-bromohexane (0.83mg, 0.005mmol) in DMF(O.05ml) was added to a solution of 3- [2-methyl-4- (3-methyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenyl] -1-piperazin-l-yl- propan-1-one from Example E47 (2.29mg, 0.005mmol) in DMF (0.05ml) and triethylamine (0.0021ml) . The mixture was stirred for 20h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 543.4

Example E61 3-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl)-2-methyl-phenyl]-1- (4- propyl-piperazin-1-yl)-propan-1-one

A solution of propionaldehyde (0.29mg, 0.005mmol) in 1, 2-dichloroethane (0.05ml) was added to a solution of 3- [4- (3, 6-dimethyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f]azulene-9-carbonyl) -2-methyl-phenyl] -1- piperazin-1-yl-propan-l-one (2.36mg, 0.005mmol) in 1,2- dichloroethane (0.05ml) and DIEA (0.0026ml) . The mix- ture was stirred at room temperature for Ih then a so¬ lution of sodium triacetoxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added. The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 515.5

Example E62 1- (4-Acetyl-piperazin-l-yl) -3-[4- (6-chloro-3-methyl- 4,10-dihγdro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl) -2-methyl-phenyl]-propan-1-one

A solution of acetyl chloride (0.39mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of 3- [4- (6-chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-methyl-phenyl] -1- piperazin-1-yl-propan-l-one (2.47mg, 0.005mmol) in di¬ chloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for 2Oh then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 535.5

Example E63 3-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -2-methyl-phenyl] -1-(4- methanesulfonyl-piperazin-1-yl) -propan-1-one

A solution of methanesulfonyl chloride (0.57mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of 3- [4- (3, 6-dimethyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -2-methyl-phenyl] - 1-piperazin-l-yl-propan-l-one (2.36mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for 2Oh then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 551.3

Example Ξ64 1-[4- (3,3-Diitιethyl-butyl) -piperazin-1-yl] -4- [2-methyl- 4- (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenyl] -butan-1-one

4-{4-[4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -4-oxo- butyl}-3-methyl-benzoic acid from Example E43 (139mg, 0.37mmol) and 3-methyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9- tetraaza-benzo [f] azulene from Example Ell (75mg, 0.37mmol) were dissolved in dichloromethane (5ml) and DIEA (0.195ml, l.llmmol) . WSCD (93mg, 0.48mmol) and DMAP (9mg, 0.07mmol) were added and the mixture was heated at reflux for 3 days, then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white powder identified as the title compound (llmg, 5%) .

Example Ξ65 N-Benzyl-3-[4- (2,3,4,5-tetrahydro-benzo[b]azepine-l- carbonyl) -phenyl]-propionamide

Example E65.1 4- ( (E) -2-Methoxycarbonyl-vinyl) -benzoic acid Sodium hydride (60% dispersion in oil, 1.46g, 3β.βmmol) was added to a solution of 4-formylbenzoic acid (5.Og, 33.3mmol) in toluene (200ml) and the mixture was stirred for 2h at room temperature. Methyl (triphenyl- phosphoranylidene) acetate (11.69g, 35.0mmol) was added and the mixture was heated at reflux for 2Oh. Solvents were removed in vacuo and the residue was redissolved in dichloromethane and IM NaHCU3. The layers were parti- tioned and the aqueous layer was acidified with IM HCl solution then extracted with chloroform. The organic layer was dried and concentrated in vacuo to yield the title compound (3.65g, 53%) .

Example E65.2 (E) -3- [4- (2,3,4, 5-Tetrahydro-benzo [b] azepine-1- carbonyl) -phenyl] -acrylic acid methyl ester WSCD (1.17g, β.lβmmol) was added to a solution of 4- ( (E) -2-methoxycarbonyl-vinyl) -benzoic acid from Example E65.1 (740mg, 3.59mmol), 2, 3, 4, 5-tetrahydro-lH- benzo [b] azepine (445mg, 3.02mmol) and DMAP (370mg, 3.02mmol) in dichloromethane (40ml) and triethylamine (0.7ml, 5.02mmol) . The mixture was heated at reflux for 42h then solvents were concentrated in vacuo. The resi- due was dissolved in EtOAc, washed with IM KHSO4 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 30% EtOAc:70% pet. ether) to yield the title compound (484mg, 48%) .

Example E65.3 3-[4-(2,3,4, 5-Tetrahydro-benzo [b] azepine-1-carbonyl) - phenyl] -propionic acid methyl ester (E) -3- [4- (2, 3, 4, 5-Tetrahydro-benzo [b] azepine-1- carbonyl) -phenyl] -acrylic acid methyl ester from Exam¬ ple E65.2 (485mg, 1.44mmol) was dissolved in methanol (60ml) and hydrogenated over 10% Pd/C catalyst (214mg) for 2h. The mixture was filtered through Celite® filter agent and the filtrate was concentrated in vacuo to yield the title compound (415mg, 85%) .

Example E65.4 3-[4-(2,3,4, 5-Tetrahydro-benzo [b] azepine-1-carbonyl) - phenyl] -propionic acid Lithium hydroxide monohydrate (114mg, 2.72mmol) was added to a solution of 3- [4- (2, 3, 4, 5-tetrahydro- benzo [b] azepine-1-carbonyl) -phenyl] -propionic acid methyl ester from Example E65.3 (415mg, 1.23mmol) in water (5ml) and dioxan (20ml) . The mixture was stirred for 18h at room temperature then concentrated in vacuo. The residue was dissolved in chloroform, washed with IM HCl solution then brine, dried and concentrated in vacuo to yield the title compound (241mg, 61%) .

Example E65.5 N-Benzyl-3- [4- (2, 3, 4, 5-tetrahydro-benzo [b] azepine-1- carbonyl) -phenyl] -propionamide A mixture of 3- [4- (2, 3, 4, 5-tetrahydro-benzo [b] azepine- 1-carbonyl) -phenyl] -propionic acid from Example E65.4 (57mg, O.lδmmol) and thionyl chloride (0.2ml, 2,74mmol) in dichloromethane (βml) was heated at reflux for 2h then volatiles were removed in vacuo. The residue was dissolved in dichloromethane (8ml) then benzylamine (0.022ml, 0.20mmol) and triethylamine (0.05ml, 0.36mmol) were added. The mixture was stirred for 3h at room temperature then concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 30% pet. ether: 70% EtOAc) to give a white fluffy solid identified as the title compound (36.5mg, 50%) . Example E66 1-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -3-[2-methyl- 4- (2-methyl-4,5-dihydro-lH-l,3,6-triaza- benzo[e]azulene-6-carbonyl) -phenyl] -propan-l-one

Oxalyl chloride (0.049ml, 0.55mmol) was added slowly to a solution of 4-{3- [4- (3, 3-dimethyl-butyl) -piperazin-1- yl] -3-oxo-propyl}-3-methyl-benzoic acid from Example E44 (lOOmg, 0.28mmol) in dichloromethane (10ml) and few drops of DMF. The mixture was stirred for Ih at room temperature then concentrated in vacuo and azeotroped with toluene. The residue was redissolved in dichloro¬ methane (10ml) and DIEA (0.144ml, 0.84mmol) then 2- methyl-1, 4,5, 6-tetrahydro-l, 3, 6-triaza-benzo [e] azulene from Example E5 (55mg, 0.28mmol) was added. The mixture was stirred for 2Oh at room temperature then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro- methane) to give a white fluffy solid identified as the title compound (42mg, 28%) .

Example E67 1-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl]-3- [2-methyl- 4- (6-methyl-3,4-dihydro-2H-quinoline-l-carbonyl) - phenyl] -propan-l-one

DMAP (51mg, 0.42mmol) and WSCD (lβlmg, 0.84mmol) were added to a solution of 4-{3- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -3-oxo-propyl}-3-methyl-benzoic acid from Example E44 (150mg, 0.42mmol) in dichloromethane (10ml) and triethylamine (0.176ml, 1.26mmol) and the mixture was stirred for 30min at room temperature. 6- Methyl-1,2, 3, 4-tetrahydro-quinoline (67mg, 0.46mmol) was added and the mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo. The residue was redissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white solid identified as the title compound (12mg, 6%) .

Example E68 (4-{3-[1-(3,3-Dimethyl-butyl) -piperidin-4-yl] -propoxy}- 3-methyl-phenyl) - (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulen-9-yl) -methanone

Example E68.1 4- (3-Hydroxy-propyl) -piperidine-1-carboxylic acid tert- butyl ester 4- (2-Carboxy-ethyl) -piperidine-1-carboxylic acid tert- butyl ester (l.Og, 3.9mmol, according to the procedure described in J. Med. Chem. , 41(14), 2492, 1998) was dissolved in THF (50ml) and cooled down to O0C. 2M Bo- rane solution in THF (3.9ml, 7.8mmol) was added slowly and the mixture was stirred for 2Oh at room tempera- ture. Water was added and solvents were concentrated in vacuo. The residue was dissolved in EtOAC, basified with NaHCO3, washed with brine, dried and concentrated in vacuo to yield the title compound (938mg, 99%) .

Example E68.2 4- [3- (4-Methoxycarbonyl-2-methyl-phenoxy) -propyl] - piperidine-1-carboxylic acid tert-butyl ester 4- (3-Hydroxy-propyl) -piperidine-1-carboxylic acid tert- butyl ester from Example E68.1 (400mg, 1.64itimol) and 4- hydroxy-3-methyl-benzoic acid methyl ester from Example E29 (274mg, 1.64mmol) were dissolved in THF (30ml) and cooled down to 00C. Polymer-supported triphenyl- phosphine (1.7g, 2.4βmmol) then DEAD (0.387ml, 2.4βmmol) were added and the mixture was heated at re¬ flux for 2Oh. The resin was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 20% EtOAC: 80% cyclohex- ane) to yield the title compound (340mg, 53%) .

Example E68.3 4- [3- (4-Carboxy-2-methyl-phenoxy) -propyl] -piperidine-1- carboxylic acid tert-butyl ester 2M NaOH solution (1.25ml, 2.5mmol) was added to 4- [3- (4-methoxycarbonyl-2-methyl-phenoxy) -propyl] - piperidine-1-carboxylic acid tert-butyl ester from Ex- ample E68.2 (340mg, 0.87mmol) in dioxan (10ml) and the mixture was heated at 600C for 2Oh. 2M NaOH solution (5ml, lOmmol) was added and the mixture was heated at 600C for 2Oh then concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 1% acetic acid: 9% metha¬ nol: 90% dichloromethane) to yield the title compound (303mg, 92%) .

Example E68.4 4-{3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenoxy] -propyl}- piperidine-1-carboxylic acid tert-butyl ester PyBroP (224mg, 0.48mπιol) and DMAP (39mg, 0.32mmol) were added to a solution of 4- [3- (4-carboxy-2-methyl- phenoxy) -propyl] -piperidine-1-carboxylic acid tert- butyl ester from Example E68.3 (120mg, 0.32mmol) and 3- methyl-3, 4, 9, 10-tetrahydro-2, 3,4, 9-tetraaza- benzo [f] azulene from Example Ell (70mg, 0.35mmol) in dichloromethane (5ml) and DIEA (0.111ml, 0.64mmol) . The mixture was heated at reflux for 2 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro¬ methane) to yield the title compound (71mg, 40%) .

Example E68.5 (3-Methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f] azulen-9-yl) - [3-methyl-4- (3-piperidin-4-yl- propoxy) -phenyl] -methanone hydrochloride 4M HCl solution in dioxan (ImI) was added to a solution of 4-{3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo[f]azulene-9-carbonyl) -phenoxy] -propyl}- piperidine-1-carboxylic acid tert-butyl ester from Ex¬ ample E68.4 (71mg, 0.13mmol) in methanol (3ml) . The mixture was stirred for 2Oh at room temperature then solvents were concentrated in vacuo. The residue was triturated with diethyl ether to yield the title com¬ pound (βlmg, 97%) .

Example E68.6 (4-{3- [1- (3, 3-Dimethyl-butyl) -piperidin-4-yl] -propoxy}- 3-methyl-phenyl) - (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulen-9-yl) -methanone Acetic acid (0.05ml) and 3, 3-dimethylbutyraldehyde (0.024ml, 0.19mmol) were added to a solution of (3- methyl-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen- 9-yl) - [3-methyl-4- (3-piperidin-4-yl-propoxy) -phenyl] - methanone hydrochloride from Example E68.5 (60mg, 0.12mmol) in methanol (2.45ml) and triethylamine (0.026ml, 0.19mmol) . The mixture was stirred at room temperature for Ih then sodium triacetoxyborohydride (40mg, 0.19mmol) was added. The mixture was stirred at room temperature for 18h, diluted with dichloromethane, washed with saturated NaHCC>3 then brine, dried and con- centrated in vacuo. The residue was purified by prepa¬ rative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white fluffy solid identi¬ fied as the title compound (33mg, 48%) .

Example E69 (4-{3-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-propoxy}- 3-fluoro-phenyl) - (2-methyl-4,5-dihydro-lH-l,3,6-triaza- benzo[e]azulen-6-yl)-methanone

Example E69.1 4-{3- [4- (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e]azulene-6-carbonyl) -2-fluoro-phenoxy] -propyl}- piperazine-1-carboxylic acid tert-butyl ester 4- [3- (4-Carboxy-2-fluoro-phenoxy) -propyl] -piperazine-1- carboxylic acid tert-butyl ester from Example E39 (130mg, 0.34mmol) was dissolved in dichloromethane (5ml) and a few drops of DMF. Oxalyl chloride (0.059ml, O.βδmmol) was added slowly and the mixture was stirred for 30min at room temperature. Solvents were concen- trated in vacuo and azeotroped with toluene. The resi¬ due was dissolved in dichloromethane (5ml) and 1- benzyl-2-methyl-l, 4,5, β-tetrahydro-1, 3, 6-triaza- benzo [e] azulene from Example E5a (lOOmg, 0.34mmol) then DIEA (0.176ml, 1.02mmol) were added. The mixture was stirred for 2h at room temperature, washed with saturated NaHCC>3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro- methane) to yield the title compound (llOmg, 50%) .

Example E69.2 (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo[e] azulen-6-yl) - [3~fluoro-4- (3-piperazin-l-yl- propoxy) -phenyl] -methanone dihydrochloride 4-{3- [4- (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo[e]azulene-β-carbonyl) -2-fluoro-phenoxy] -propyl}- piperazine-1-carboxylic acid tert-butyl ester from Ex- ample E69.1 (llOmg, 0.17mmol) was dissolved in methanol (5ml) and 4M HCl in dioxan (2ml) was added. The mixture was stirred for 2Oh at room temperature then concen¬ trated in vacuo to yield the title compound (105mg, 100%) .

Example E69.3 (l-Benzyl-2-methyl-4,5-dihydro-lH-l,3, 6-triaza- benzo [e] azulen-6-yl) - (4-{3- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -propoxy}-3-fluoro-phenyl) -methanone (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e] azulen-6-yl) - [3-fluoro-4- (3-piperazin-l-yl- propoxy) -phenyl] -methanone dihydrochloride from Example E69.2 (105mg, 0.17mmol) was dissolved in methanol (2.45ml) and triethylamine (0.07ml, 0.50mmol) . Acetic acid (0.05ml) then 3, 3-dimethylbutyraldehyde (0.032ml, 0.25mmol) were added and the mixture was stirred for Ih at room temperature. Sodium cyanoborohydride (16mg, 0.25mmol) was added and the mixture was stirred for 3h at room temperature then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol: 95% dichloromethane) to yield the title compound (102mg, 95%) .

Example E69.4 (4-{3- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -propoxy}- 3-fluoro-phenyl) - (2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo[e]azulen-6-yl) -methanone (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo[e]azulen-β-yl)- (4-{3- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -propoxy}-3-fluoro-phenyl) -methanone from Example E69.3 (90mg, 0.14mmol) was dissolved in methanol (5ml) and acetic acid (ImI) and hydrogenated over 20 wt.% palladium hydroxide catalyst (90mg) for 8h. The mixture was filtered through Celite® filter agent and the filtrate concentrated in vacuo. The resi- due was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro¬ methane) to give a white powder identified as the title compound (39mg, 51%) .

Example Ξ70 (4-{3-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -propoxy}- 3-methyl-phenyl) - (2-methyl-4,5-dihydro-lH-l,3,6-triaza- benzo[e]azulen-6-yl) -methanone

Example E70.1 4- { 3- [ 4- ( l-Benzyl-2-methyl-4 , 5-dihydro-lH-l , 3 , 6-triaza- benzo [e] azulene-6-carbonyl) -2-methyl-phenoxy] -propyl}- piperazine-l-carboxyllc acid tert-butyl ester 4- [3- (4-Carboxy-2-methyl-phenoxy) -propyl] -piperazine-1- carboxylic acid tert-butyl ester (350ing, 0.92mmol) was dissolved in dichloromethane (5ml) and a few drops of DMF. Oxalyl chloride (0.162ml, 1.84mmol) was added slowly and the mixture was stirred for 30min at room temperature. Solvents were concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (10ml) and l-benzyl-2-methyl-l, 4, 5, 6- tetrahydro-1, 3, β-triaza-benzo [e] azulene from Example E5a (268mg, 0.92mmol) then DIEA (0.48ml, 2.77mmol) were added. The mixture was stirred for 2 days at room temperature, washed with saturated NaHCC>3 then brine, dried and concentrated in vacuo. The residue was puri¬ fied by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to yield the title com¬ pound (230mg, 38%) .

Example E70.2 (l-Benzyl-2-methyl-4,5-dihydro-lH-l,3, 6-triaza- benzo [e] azulen-6-yl) - [3-methyl-4- (3-piperazin-l-yl- propoxy) -phenyl] -methanone dihydrochloride 4-{3- [4- (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, β-triaza- benzo [e] azulene-β-carbonyl) -2-methyl-phenoxy] -propyl}- piperazine-1-carboxylic acid tert-butyl ester from Ex¬ ample E70.1 (230mg, 0.35mmol) was dissolved in methanol (5ml) and 4M HCl in dioxan (2ml) was added. The mixture was stirred for 2h at room temperature then concen¬ trated in vacuo and triturated with diethyl ether to yield the title compound (215mg, 98%) . Example E70.3 (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e] azulen-6-yl) - (4-{3- [4- (3, 3-dimethyl-butyl) - plperazin-1-yl] -propoxyl-3-methyl-phenyl) -methanone (l-Benzyl-2-methyl-4,5-dihydro-lH-l,3, 6-triaza- benzo [e] azulen-β-yl) - [3-methyl-4- (3-piperazin-l-yl- propoxy) -phenyl] -methanone dihydrochloride from Example E70.2 (lOOmg, O.lβmmol) was dissolved in methanol (2.45ml) and triethylamine (0.068ml, 0.48mmol) . Acetic acid (0.05ml) then 3, 3-dimethylbutyraldehyde (0.031ml, 0.24mmol) were added and the mixture was stirred for Ih at room temperature. Sodium cyanoborohydride (lβmg, 0.24mmol) was added and the mixture was stirred for 2Oh at room temperature then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCC>3 then brine, dried and concentrated in vacuo to yield the title compound (98mg, 96%) .

Example E70.4 (4-{3- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -propoxyl- 3-methyl-phenyl) - (2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e] azulen-6-yl) -methanone (l-Benzyl-2-methyl-4,5-dihydro-lH-l,3, 6-triaza- benzo [e] azulen-6-yl) - (4-{3- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -propoxy}-3-methyl-phenyl) -methanone from Example E70.3 (98mg, 0.15mmol) was dissolved in methanol (5ml) and acetic acid (ImI) and hydrogenated over 20 wt. % palladium hydroxide catalyst (98mg) for 8h. The mixture was filtered through glass-fibre paper and the filtrate was concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white powder identified as the title compound (17mg, 20%) .

Example E71 N- (4-Chloro-phenyl) -4-{3-[4- (3,3-dimethyl-butyl) - piperazin-1-yl] -propoxy}-3-fluoro-N-methyl-benzamide

Example E71.1 4- (3-{4-[ (4-Chloro-phenyl) -methyl-carbamoyl] -2-fluoro- phenoxy}-propyl) -piperazine-l~carboxylic acid tert- butyl ester PyBroP (606mg, 1.3mmol) was added to a solution of 4- [3- (4-carboxy-2-fluoro-phenoxy) -propyl] -piperazine-1- carboxylic acid tert-butyl ester from Example E39 (382mg, l.Ommol) in dichloromethane (20ml) and DIEA (to pH9) . The mixture was stirred for Ih at room tempera¬ ture then (4-chloro-phenyl) -methyl amine (15βmg, l.lmmol) was added. The mixture was stirred for 2 days at room temperature then solvents were concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title com- pound (210mg, 41%) .

Example E71.2 N- (4-Chloro-phenyl) -3-fluoro-N-methyl-4- (3-piperazin-l- yl-propoxy) -benzamide dihydrochloride 4- (3-{4-[ (4-Chloro-phenyl) -methyl-carbamoyl] -2-fluoro- phenoxy}-propyl) -piperazine-1-carboxylic acid tert- butyl ester from Example E71.1 (210mg, 0.4mmol) was dissolved in 4M HCl in dioxan (5ml) and stirred for Ih at room temperature. Solvents were concentrated in vacuo and azeotroped with toluene to yield the title compound (184mg, 100%) .

Example E71.3 N- (4-Chloro-phenyl) -4-{3- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -propoxy}-3-fluoro-N-methyl-benzamide N- (4-Chloro-phenyl) -3-fluoro-N-methyl-4- (3-piperazin-l- yl-propoxy) -benzamide dihydrochloride from Example E71.2 (184mg, 0.4mmol) was dissolved in methanol (4.95ml) and triethylamine (0.167ml, 1.2mmol) . Acetic acid (0.05ml) then 3, 3-dimethylbutyraldehyde (46mg, 0.44mmol) were added and the mixture was stirred for Ih at room temperature. Sodium cyanoborohydride (31mg, 0.5mmol) was added and the mixture was stirred for 2Oh at room temperature then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 10% methanol: 90% dichloromethane) to give a white foam identified as the title compound (77mg, 37%) .

Example Ξ72 (4-{4-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -butoxy}- 3-fluoro-phenyl) - (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulen-9-yl) -methanone

Example E72.1 4- (4-Bromo-butoxy) -3-fluoro-benzoic acid ethyl ester 1, 4-Dibromobutane (2.34g, 10. δinmol) , potassium carbon- ate (1.86g, 13.5mmol) and potassium iodide (90mg, 0.5mmol) were added to a solution of 3-fluoro-4- hydroxy-benzoic acid ethyl ester from Example E27 (l.Og, 5.4mmol) in acetone (25ml) and the mixture was heated at reflux for 2Oh. The solid was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 15% EtOAc: 85% hexane) to yield the title compound (1.38g, 80%) .

Example E72.2 4-{4- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -butoxy}-3- fluoro-benzoic acid ethyl ester 1- (3, 3-Dimethyl-butyl) -piperazine hydrochloride from Example E4 (874mg, 3.7mmol), potassium carbonate (2.5g, lδ.Ommol) and potassium iodide (βOmg, 0.4mmol) were added to a solution of 4- (4-bromo-butoxy) -3-fluoro- benzoic acid ethyl ester from Example E72.1 (1.4g, 4.4mmol) in acetone (35ml) and the mixture was heated at reflux for 2Oh. The solid was filtered off, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc to 1% 35% ammonia: 10% metha- nol:89% EtOAc) to yield the title compound (1.35g, 90%) .

Example E72.3 4-{4- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -butoxy}-3- fluoro-benzoic acid Sodium hydroxide (0.5g, 13.2mmol) and water (5ml) were added to a solution of 4-{4~ [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -butoxy}-3-fluoro-benzoic acid ethyl es¬ ter from Example E72.2 (1.35g, 3.3mmol) in dioxan (20ml) . The mixture was stirred for Ih at room tempera¬ ture then heated at 600C for 2Oh. Solvents were concen¬ trated in vacuo and azeotroped with toluene. The resi¬ due was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia: 19% methanol: 80% chloroform) to yield the title compound (0.85g, 67%) .

Example E72.4 (4-{4- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -butoxy}- 3-fluoro-phenyl) - (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulen-9-yl) -methanone A mixture of 4-{4- [4- (3, 3-dimethyl-butyl) -piperazin-1- yl] -butoxy}-3-fluoro-benzoic acid from Example E72.3 (190mg, 0.5mmol) and thionyl chloride (2ml) in di- chloromethane (5ml) was heated at reflux for Ih. Sol¬ vents were concentrated in vacuo and the residue was dissolved in dichloromethane (10ml) . 3-Methyl-3, 4, 9, 10- tetrahydro-2, 3, 4, 9-tetraaza-benzo [f] azulene from Exam- pie Ell (llOmg, 0.55mmol) and DIEA (to pH9) were added. The mixture was stirred at room temperature for 2 days and concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% metha¬ nol: 90% dichloromethane) to give a colourless oil iden¬ tified as the title compound (48mg, 17%) .

Example Ξ73 (4-{2-[4-(3,3-Dimethyl-butyl) -piperazin-1-yl] -ethoxy}- 3-methyl-phenyl) - (3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulen-9-yl) -methanone

WSCD (58mg, 0.30mmol) and DMAP (20mg, 0.15mmol) were added to a solution of 3-methyl-3, 4, 9, 10-tetrahydro- 2, 3, 4, 9-tetraaza-benzo [f] azulene from Example Ell (37mg, 0.20mmol) and 4-{2- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -ethoxy}-3-methyl-benzoic acid from Ex- ample E40 (53mg, 0.15mmol) in dichloromethane (5ml) and triethylamine (to pH9) . The mixture was heated at re¬ flux for 2 days then concentrated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCθ3 then brine, dried and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 10% methanol: 90% chloroform) to give an off- white solid identified as the title compound (3.5mg, 4%) .

Example Ξ74 1-[4-(3,3-Dimethyl-butyl) -piperazin-1-yl] -2-[2-methyl- 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenoxy] -ethanone

Oxalyl chloride (42mg, 0.34mτnol) and 2 drops of DMF were added to a solution of 4-{2- [4- (3, 3-dimethyl- butyl) -piperazin-1-yl] -2-oxo-ethoxy}-3-methyl-benzoic acid from Example E41 (lOOmg, 0.28mmol) in dichloro- methane (5ml) at O0C. The mixture was stirred for Ih at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloro¬ methane (5ml) and a solution of 3-methyl-3, 4, 9, 10- tetrahydro-2, 3, 4, 9-tetraaza-benzo[f] azulene from Exam- pie Ell (βlmg, 0.31mmol) in dichloromethane (ImI) and triethylamine (to pH9) was added. The mixture was stirred for 2 days at room temperature then concen¬ trated in vacuo. The residue was dissolved in EtOAC, washed with saturated NaHCθ3 then brine, dried and concentrated in vacuo. The residue was purified twice by flash chromatography on silica gel (eluant; 5% methanol: 95% chloroform to 10% methanol: 90% chloroform then 5% methanol: 95% EtOAc to 10% methanol: 90% EtOAc) to give a white solid identified as the title compound (25mg, 17%) .

Example E75 1- [4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -2- [4- (3- methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]aztilene-9-carbonyl) -phenoxy] -ethanone

Example E75.1 (4-Benzyloxy-phenyl) - (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulen-9-yl) -methanone Oxalyl chloride (0.41ml, 4.7mmol) and a few drops of DMF were added to a solution of 4- (benzyloxy)benzoic acid (855mg, 3.7mmol) in dichloromethane (15ml) . The mixture was stirred for 2h at room temperature, concen¬ trated in vacuo and azeotroped with toluene. The resi¬ due was dissolved in dichloromethane (10ml) and a solu¬ tion of 3-methyl-3,4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f] azulene from Example Ell (500mg, 2.5mmol) in dichloromethane (10ml) and triethylamine (0.87ml, β.2mmol) was added. The mixture was stirred for 2Oh at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc to 3% methanol: 97% EtOAc) to yield the title compound (820mg, 80%) .

Example E75.2 (4-Hydroxy-phenyl) - (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulen-9-yl) -methanone (4-Benzyloxy-phenyl)- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo[f]azulen-9-yl) -methanone from Example E75.1 (800mg, 1.95mmol) was dissolved in methanol (100ml) and hydrogenated over 10% Pd/C catalyst (400mg) for 7h. The mixture was filtered through Celite® filter agent, washed with chloroform and methanol and the fil¬ trate was concentrated in vacuo to yield the title com¬ pound (140mg, 22%) .

Example E75.3 1- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -2- [4- (3- methyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenoxy] -ethanone Potassium carbonate (104mg, 0.7βmmol) was added to a mixture of 2-bromo-l- [4- (3, 3-dimethyl-butyl) -piperazin- 1-yl] -ethanone from Example E37 (llOmg, 0.38mmol) and (4-hydroxy-phenyl) - (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f]azulen-9-yl) -methanone from Example E75.2 (90mg, 0.28mmol) in acetonitrile (5ml) . The mix¬ ture was heated at reflux for 2Oh then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with 5% KHCO3 solution, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro¬ methane) to give a white powder identified as the title compound (21mg, 11%) .

Example Ξ76 1-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl]-4- [2-methyl- 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenoxy]-butan-1-one

Example E76.1 4- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenoxy] -butyric acid tert-butyl ester WSCD (391mg, 2.06mmol) and DMAP (133mg, 1.09iπmol) were added to a solution of 4- (3-tert-butoxycarbonyl- propoxy) -3-methyl-benzoic acid from Example E42 (275mg, 0.94mmol) and 3-methyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9- tetraaza-benzo[f] azulene from Example Ell (191mg, 0.95minol) in dichloromethane (30ml) and triethylamine (0.28ml, 2.01mmol) . The mixture was heated at reflux for 72h, washed with 0.3M KHSO4, saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (80mg, 18%) .

Example E76.2 4- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenoxy] -butyric acid Trifluoroacetic acid (5ml) was added to a solution of 4- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f]azulene-9-carbonyl) -phenoxy] -butyric acid tert-butyl ester from Example E76.1 (80mg, 0.17mmol) in dichloromethane (10ml) . The mixture was stirred for 2h at room temperature, concentrated in vacuo and azeotroped with dichloromethane to yield the title compound (71mg, 100%) .

Example E76.3 1-[4- (3, 3-Dimethyl-butyl) -pipe'razin-1-yl] -4- [2-methyl- 4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f]azulene-9-carbonyl) -phenoxy] -butan-1-one HBTU (lOlmg, 0.27mmol) was added to a solution of 4- [2- methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenoxy] -butyric acid from E76.2 (71mg, 0.17mmol) and 1- (3, 3-dimethyl-butyl) - piperazine dihydrochloride from Example E4 (54mg, 0.22mmol) in dichloromethane (10ml) and DIEA (0.15ml, 0.86mmol) . The mixture was stirred for 2Oh at room tem¬ perature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by- flash chromatography on silica gel (eluant; 6% metha¬ nol: 94% dichloromethane) to give a white powder identi¬ fied as the title compound (52mg, 53%) .

Example E77 3-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -phenyl] -propionic acid piperidin-4-ylmethyl ester

Example E77.1 4-{3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyloxymethyl}-piperidine-1-carboxylic acid benzyl ester WSCD (107mg, 0.54mmol) and DMAP (33mg, 0.27mmol) were added to a solution of 3- [2-methyl-4- (3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9- carbonyl) -phenyl] -propionic acid from Example E45 (106mg, 0.27mmol) and 4-hydroxymethyl-piperidine-l- carboxylic acid benzyl ester (81mg, 0.32mmol) in di¬ chloromethane (5ml) and DIEA (0.095ml, 0.54mmol) . The mixture was stirred for 3h at room temperature, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatog- raphy on silica gel through an isolute (eluant; EtOAc) to yield the title compound (44mg, 26%) .

Example E77.2 3- [ 2-Methyl-4- ( 3-methyl-4 , 10-dihydro-3H-2 , 3 , 4 , 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -propionic acid piperidin-4-ylmethyl ester 4-{3- [2-Methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyloxymethyll-piperidine-l-carboxylic acid benzyl ester from Example E77.1 (44mg, 0.07mmol) was dissolved in methanol (5ml) and hydrogenated over 10% Pd/C cata¬ lyst (5mg) for 2h. The mixture was filtered through Celite® filter agent and the filtrate concentrated in vacuo to give a white powder identified as the title compound (34mg, 98%) .

Example Ξ78 Methyl (3-chloro-4- (3,6-dimethyl-4,10-dihydro-3H- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl) - phenoxy)acetate

Diisopropylethylamine (2.1ml, 12.0mmol), dimethylamino- pyridine (0.74g, β.Ommol), PyBroP® (4.2Og, 9.0mmol) and 3, β-dimethyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo[f] azulene from Example E2 (1.28g, β.Ommol) were added to a solution of tert-butyl 4- (2- (4-carboxy-3- chloro-phenoxy) -acetyl) -piperazine-1-carboxylate from Example E41c (2.39g, β.Ommol) in dichloromethane (50ml) and the mixture was heated at reflux for 2Oh. The reac¬ tion mixture was cooled, diluted with dichloromethane (50ml) , washed with saturated aqueous sodium hydrogen carbonate, dried and concentrated in vacuo. The resi- due was dissolved in methanol (150ml) and treated with a 4M solution of hydrogen chloride in dioxan (50ml) , with cooling in an ice bath. The solution was stirred at room temperature for lβh. The reaction mixture was evaporated and the residue taken up in water and washed with chloroform. The aqueous was treated with solid sodium hydrogen carbonate until basic pH, extracted into chloroform, dried and evaporated. The residue was purified by flash chromatography on silica gel (eluant; EtOAc followed by a 2% to 10% methanol: 98% to 90% EtOAc gradient) to yield a white solid identified as the ti¬ tle compound (0.53g, 20%) .

Example E79 1- (4-Hydroxymethyl-piperidin-l-yl) -3-[2-methyl-4- (3- methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenyl]-propan-1-one

Sodium borohydride (12mg, 0.32mmol) was added to a so¬ lution of l-{3-[2-methyl-4- (3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyl}-piperidine-4-carbaldehyde from Example E58.1 (74mg, 0.15mmol) in methanol (6ml) . The mixture was stirred for Ih at room temperature, acidified with IM HCl and concentrated in vacuo. The residue was dis¬ solved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was crystallised from chloroform and pet. ether to give a white powder identified as the title compound (28mg, 38%) .

Example Ξ80 1-[4- (3,3-Dimethyl-butyl) -piperazin-1-yl] -3-[4-(3,4- dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -2-methyl-phenyl] -propan-1- one Example E80.1 3- [4- (3, 4-Dimethyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f] azulene-9-carbonyl) -2-methyl-phenyl] -propionic acid tert-butyl ester Sodium hydride (14mg, 0.34mmol) was added to a solution of 3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo[f] azulene-9-carbonyl) -phenyl] -propionic acid tert-butyl ester from Example E45 (125mg, 0.28mmol) in DMF (2ml) at 00C. The mixture was stirred for 20min at room temperature then cooled down to O0C. Methyl iodide (0.09ml, 1.4mmol) was added and the mix¬ ture was stirred for 2Oh at room temperature. EtOAc was added and the mixture was washed with 0.3M KHSO4 then brine, dried, concentrated in vacuo and azeotroped with toluene. The residue was purified by flash chromatogra¬ phy on silica gel through an isolute (eluant; EtOAc) to yield the title compound (46mg, 36%) .

Example E80.2 3- [4- (3, 4-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo [ f ] azulene-9-carbonyl ) -2-ittethyl-phenyl] -propionic acid Trifluoroacetic acid (2ml) was added to 3- [4- (3,4- dimethyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-methyl-phenyl] -propionic acid tert-butyl ester from Example E80.1 (46mg, O.lOmmol) in dichloromethane (5ml) . The mixture was stirred for 2h at room temperature then concentrated in vacuo to yield the title compound (40mg, 100%) .

Example E80.3 1- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -3- [4- (3,4- dimethyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-methyl-phenyl] -propan-1- one Oxalyl chloride (0.018ml, 0.20mmol) was added to a so¬ lution of 3- [4- (3,4-dimethyl-4,10-dihydro-3H-2,3,4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -2-methyl-phenyl] - propionic acid from Example E80.2 (40mg, O.lOmmol) in dichloromethane (5ml) and a few drops of DMF. The mix¬ ture was stirred for Ih at room temperature, concen¬ trated in vacuo and azeotroped with toluene. The resi- due was dissolved in dichloromethane (5ml) and l-(3,3- dimethyl-butyl) -piperazine dihydrochloride from Example E4 (30mg, 0.12mmol) and DIEA (0.052ml, 0.30mmol) were added. The mixture was stirred for 2Oh at room tempera¬ ture, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% metha¬ nol: 90% dichloromethane) to give a white powder identi¬ fied as the title compound (3βmg, 65%) .

Example E81 1-[4-(3,3-Dimethyl-butyl)-piperazin-1-yl]-4- [2-methyl- 4- (2,3,4,5-tetrahydro-benzo[e] [1,4]diazepine-1- carbonyl) -phenyl]-butan-1-one

Example E81.1 1- (4-{4- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -4-oxo- butyl}-3-methyl-benzoyl) -1, 2, 3, 5-tetrahydro- benzo [e] [1, 4] diazepine-4-carboxylic acid tert-butyl es¬ ter WSCD (58mg, 0.30mmol) and DMAP (18mg, 0.15mmol) were added to a solution of 4-{4- [4- (3, 3-dimethyl-butyl) - piperazin-1-yl] -4-oxo-butyl}-3-methyl-benzoic acid from Example E43 (55mg, 0.15mmol) and 1,2, 3, 5-tetrahydro- benzo [e] [1, 4]diazepine-4-carboxylic acid tert-butyl es¬ ter (73mg, 0.30mmol) in dichloromethane (3ml) and DIEA (0.052ml, 0.30mmol) . The mixture was heated at reflux for 5 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was puri¬ fied by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol-.90% dichloromethane) to yield the title com¬ pound (25mg, 28%) .

Example E81.2 1- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -4- [2-methyl- 4- (2, 3, 4, 5-tetrahydro-benzo [e] [1,4] diazepine-1- carbonyl) -phenyl]-butan-1-one 1- (4-{4-[4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -4-oxo- butyl}-3-methyl-benzoyl) -1,2,3, 5-tetrahydro- benzo [e] [1, 4]diazepine-4-carboxylic acid tert-butyl es¬ ter from Example E81.1 (25mg, 0.04mmol) was dissolved in methanol (2ml) and 4M HCl in dioxan (2ml) was added. The mixture was stirred for Ih at room temperature then concentrated in vacuo to give a white powder identified as the title compound (6mg, 28%) . (ESI)+: [M+H] += 505.5

Example E82 4-[4-(7,8-Dihydro-6H-5-oxa-9-aza-benzocycloheptene-9- carbonyl) -2-methyl-phenyl]-1-[4-(3,3-dimethyl-butyl) - piperazin-1-yl] -butan-1-one

WSCD (58mg, 0.30mmol) and DMAP (18mg, 0.15mmol) were added to a solution of 4-{4- [4- (3, 3--dimethyl-butyl) - piperazin-1-yl] -4-oxo-butyl}-3-methyl-benzoic acid from Example E43 (55mg, 0.15mmol) and 6, 7, 8, 9-tetrahydro-5- oxa-9-aza-benzocycloheptene (44mg, 0.30mmol) in di- chloromethane (3ml) and DIEA (0.052ml, 0.30mmol). The mixture was heated at reflux for 5 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro- methane) to give a white solid identified as the title compound (6mg, 10%) .

Example E83 1- [4- (3 , 3 -Dimethyl -butyl) -piperazin-1-yl] -5- [2-methyl- 4- (3-methyl-4 , 10-dihydro-3H-2 , 3 , 4 , 9-tetraaza- benzo [f ] azulene-9-carbonyl) -phenyl] -pentan-1-one

Example E83.1 5-[2-Methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -pentanoic acid methyl ester WSCD (822mg, 4.3mmol) and DMAP (273mg, 2.2mmol) were added to a solution of 4- (4-methoxycarbonyl-butyl) -3- methyl-benzoic acid from Example E31 (571mg, 2.3mmol) and 3-methyl-3,4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f] azulene from Example Ell (424mg, 2.1mmol) in dichloromethane (50ml) and triethylamine (O.βml, 4.3mmol) . The mixture was heated at reflux for 72h, di- luted with dichloromethane, washed with 0.3M KHSO4, saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc to 5% triethyamine: 95% EtOAc) to yield the title compound (424mg, 46%) .

Example E83.2 5- [ 2-Methyl-4- ( 3-methyl-4 , 10-dihydro-3H-2 , 3 , 4 , 9- tetraaza-benzo[f] azulene-9-carbonyl) -phenyl] -pentanoic acid Lithium hydroxide monohydrate (120mg, 2.8βmmol) was added to a solution of 5- [2-methyl-4- (3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9- carbonyl) -phenyl] -pentanoic acid methyl ester from Ex¬ ample E83.1 (410mg, 0.95mmol) in THF (10ml) and water (5ml) . The mixture was stirred for 24h at room tempera- ture and concentrated in vacuo. The residue was acidi¬ fied with IM HCl and extracted with chloroform. The or¬ ganic layer was washed with brine, dried and concen¬ trated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 3% acetic acid:7% methanol: 90% chloroform) to yield the title compound (105mg, 26%) .

Example E83.3 1- [4- (3, 3-Dimethyl-butyl) -piperazin-1-yl] -5- [2-methyl- 4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenyl] -pentan-1-one HBTU (104mg, 0.27mmol) was added to a solution of 5— [2— methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenyl] -pentanoic acid from E83.2 (105mg, 0.25mmol) and 1- (3, 3-dimethyl-butyl) - piperazine dihydrochloride from Example E4 (69mg, 0.28mmol) in DMF (10ml) and DIEA (0.2ml, 1.15mmol) . The mixture was stirred for 24h at room temperature then concentrated in vacuo. The residue was dissolved in di- chloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was puri¬ fied by flash chromatography on silica gel (eluant; 4% methanol: 96% dichloromethane to 8% methanol: 92% di- chloromethane) to give a white solid identified as the title compound (88mg, 62%) .

Example Ξ84 1- (4-Hydroxy-piperidin-l-yl) -3- [2-methyl-4- (3-methyl- 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl)-phenyl]-propan-1-one

Sodium borohydride (4mg, O.lmmol) was added to a solu- tion of l-{3-[2-methyl-4-(3-methyl-4,10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] - propionyl}-piperidin-4-one (Compound number 701) (50mg, O.llmmol) in methanol/acetic acid (99:1, v/v, 100ml) and the mixture was stirred at room temperature for Ih. Sodium borohydride (4mg, O.llmmol) was added again and the mixture was stirred for Ih at room temperature then concentrated in vacuo. The residue was dissolved in di- chloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to give a white powder identified as the title compound (28mg, 56%) .

Example E85 1- (4-Cyclobutylmethyl-piperazin-l-yl)-2-[2-methyl-4- (3- methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenyl]-ethanone

Example E85.1 4-[2- (4-Cyclobutylmethyl-piperazin-l-yl) -2-oxo-ethyl] - 3-methyl-benzoic acid methyl ester Oxalyl chloride (0.36ml, 3.3mmol) was added to a solution of 4-carboxymethyl-3-methyl-benzoic acid methyl ester from Example E32 (687mg, 3.3mmol) in dichloromethane (20ml) and few drops of DMF. The mixture was stirred for 3h at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (10ml) and added to a solution of 1-cyclobutylmethyl-piperazine dihydrochloride (750mg, 3.3mmol) in dichloromethane (10ml) and DIEA (1.73ml, 9.9mmol) at O0C. The mixture was stirred for 2Oh at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 3% metha- nol:97% dichloromethane) to yield the title compound (528mg, 46%) .

Example E85.2 4- [2- (4-Cyclobutylmethyl-piperazin-l-yl) -2-oxo-ethyl] - 3-methyl-benzoic acid Lithium hydroxide monohydrate (122mg, 2.9mmol) was added to a solution of 4- [2- (4-cyclobutylmethyl- piperazin-1-yl) -2-oxo-ethyl] -3-methyl-benzoic acid methyl ester from Example E85.1 (500mg, 1.4mmol) in THF (10ml) and water (5ml) . The mixture was stirred for 20h at room temperature and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 3% acetic acid: 7% methanol: 90% chloroform) to yield the title compound (300mg, 63%) .

Example E85.3 1- (4-Cyclobutylmethyl-piperazin-l-yl) -2- [2-methyl-4- (3- methyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenyl] -ethanone WSCD (7βmg, 0.39mmol) and DMAP (7mg, 0.06mmol) were added to a solution of 4- [2- (4-cyclobutylmethyl- piperazin-l-yl) -2-oxo-ethyl] -3-methyl-benzoic acid from Example E85.2 (lOOmg, 0.30mmol) and 3-methyl-3,4, 9, 10- tetrahydro-2,3,4, 9-tetraaza-bønzo [f]azulene from Example Ell (61mg, 0.30mmol) in dichloromethane (20ml) and DIEΑ (0.16ml, 0.91mmol) . The mixture was heated at reflux for 2Oh and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 4% methanol:96% dichloromethane to 6% metha¬ nol: 94% dichloromethane to 1% 35% ammonia:7% metha¬ nol: 92% dichloromethane) to give an off-white solid identified as the title compound (50mg, 32%) .

Example E86 1- (4-Cyclopropylaminomethyl-piperidin-l-yl) -3-[2- methyl-4- (3-methyl-4,10-dihydLro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -phenyl] -propan-1-one

Example E86.1 4- (3-{4- [ (tert-Butoxycarbonyl-cyclopropyl-amino) - methyl] -piperidin-1-yl}-3-oxo-propyl) -3-methyl-benzoic acid methyl ester Oxalyl chloride (1.26ml, 14.4mmol) was added to a solution of 4- (2-carboxy-ethyl) -3-methyl-benzoic acid methyl ester from Example E30.3 (1.6Og, 7.2mmol) in dichloromethane (50ml) and few drops of DMF. The mixture was stirred for Ih at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in dichloromethane (50ml) and DIEA (2.5ml, 14.4mmol) and cyclopropyl-piperidin-4- ylmethyl-carbamic acid tert—butyl ester from Example E38 (1.83g, 7.2mmol) in dichloromethane (5ml) was added. The mixture was stirred for 2h at room temperature, diluted with dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc: 50% cyclohexane) to yield the title compound (1.42g, 43%) .

Example E86.2 4- (3-{4- [ (tert-Butoxycarbonyl-cyclopropyl-amino) - methyl] -piperidin-l-yl}-3-oxo-propyl) -3-methyl-benzoic acid Lithium hydroxide monohydrate (142mg, 3.4mmol) was added to a solution of 4- (3-{4- [ (tert-butoxycarbonyl- cyclopropyl-amino) -methyl] -piperidin-l-yl}-3-oxo- propyl) -3-methyl-benzoic acid methyl ester from Example E86.1 (1.4Ig, 3.1mmol) in THF (20ml) and water (2ml) . The mixture was stirred for lβh at room temperature then IM NaOH solution (5ml) was added. The mixture was heated at 600C for 3h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with IM HCl then brine, dried and concentrated in vacuo to yield the ti¬ tle compound (1.25g, 91%) .

Example E86.3 Cyclopropyl- (l-{3- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - phenyl] -propionyl}-piperidin-4-ylmethyl) -carbamic acid tert-butyl ester WSCD (1.08g, 5.6mmol) and DMAP (343mg, 2.8mmol) were added to a solution of 4- (3-{4- [ (tert-butoxycarbonyl- cyclopropyl-amino) -methyl] -piperidin-l-yl}-3-oxo- propyl) -3-methyl-benzoic acid from Example E86.2 (1.25g, 2.8mmol) in dichloromethane (100ml) and triethylamine (0.783ml, 5.6mmol) . The mixture was stirred for Ih at room temperature then 3-methyl- 3,4,9, 10-tetrahydro-2, 3,4, 9-tetraaza-benzo [f] azulene from Example Ell (67βmg, 3.4mmol) was added. The mix- ture was heated at reflux for 2 days, washed with saturated NaHCC>3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 2% methanol: 98% EtOAc to 5% methanol: 95% EtOAc) to yield the title compound (l.lg, 62%) .

Example E86.4 1- (4-Cyclopropylaminomethyl-piperidin-l-yl) -3- [2- methyl-4- (3-methyl-4, 10-dihydro-3H-2,3, 4, 9-tetraaza- benzo[f] azulene-9-carbonyl) -phenyl] -propan-1-one Cyclopropyl- (l-{3- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - phenyl] -propionyl}-piperidin-4-ylmethyl) -carbamic acid tert-butyl ester from Example E86.3 (220mg, 0.35mmol) was dissolved in methanol (5ml) and 4M HCl solution in dioxan (5ml) was added. The mixture was stirred for 2h at room temperature then concentrated in vacuo to give an off-white solid identified as the title compound (189mg, 95%) .

Example E87 N-Cyclopropyl-3-[2-methyl-4-(3-methyl-4,10-dihydro-3H- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl) -phenyl]-N- piperidin-4-ylmethyl-propionamide hydrochloride

Example E87.1 4- [ (Cyclopropyl-{3- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - phenyl] -propionyl}-amino) -methyl] -piperidine-1- carboxylic acid tert-butyl ester PyBroP (238mg, 0.51mmol) was added to a solution of 3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -phenyl] -propionic acid from Example E45 (200mg, 0.51mmol) and 4- cyclopropylaminomethyl-piperidine-1-carboxylic acid tert-butyl ester (130mg, 0.51mmol) in dichloromethane (10ml) and DIEA (0.18ml, 1.02mmol) . The mixture was stirred for 4 days at room temperature, diluted with EtOAc, washed with 5% KHCO3 then brine, dried and con¬ centrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol: 95% dichloromethane) to yield the title compound (235mg, 73%) .

Example E87.2 N-Cyclopropyl-3- [2-methyl-4- (3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) -phenyl] -N- piperidin-4-ylmethyl-propionamide hydrochloride 4- [ (Cyclopropyl-U- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3,4, 9-tetraaza-benzo[f]azulene-9-carbonyl) - phenyl] -propionyl}-amino) -methyl] -piperidine-1- carboxylic acid tert-butyl ester from Example E87.1 (235mg, 0.37mmol) was dissolved in 4M HCl solution in dioxan (5ml) . The mixture was stirred for Ih at room temperature, concentrated in vacuo and azeotroped with toluene. The residue was dissolved in IM HCl, washed twice with dichloromethane and freeze-dried to give an off-white solid identified as the title compound (82mg, 39%) .

Example E88 l-Methyl-5-(3-methyl-2-nitro-phenylamino)-lH-pyrazole- 4-carboxylic acid ethyl ester Cesium carbonate (35.2g, lOδmmol) , 4,5- bis (diphenylphosphino) -9, 9-dimethylxanthene (0. Ag, 0.7mmol) and tris (dibenzylideneacetone) dipalladium(O) (0.2g, 0.2mmol) were added to a solution of ethyl 5- amino-l-methylpyrazole-4-carboxylate (15.3g, 90inmol) in dioxan (50ml) under an inert atmosphere. A solution of 3-bromo-2-nitrotoluene (16.2g, 75mmol) in dioxane (10ml) was added and the mixture was stirred for 30min at room temperature then heated at reflux for 72h. The suspension was filtered through Celite® filter agent, washed with EtOAc and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc: 50% pet. ether) then recrystallised from EtOAc/pet. ether to yield the title compound (12.5g, 45%) .

Example E89 5-Amino-l-ethyl-lH-pyrazole-4-carboxylic acid ethyl es- ter

Triethylamine (19.6ml, 144mmol) was added cautiously to a solution of ethyl (ethoxymethylene) cyanoacetate (10. Ig, βOmmol) and ethyl hydrazine oxalate (9.9g, ββmmol) in ethanol (200ml) . The mixture was heated at reflux for 24h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with 5% KHCO3 solution then brine, dried and concentrated in vacuo. The resi¬ due was purified by flash chromatography on silica gel (eluant; 25% pet. ether:75% EtOAc) to yield the title compound (8.8g, 80%) .

Example E90 l-Cγclopropγlmethyl-piperidine-4-carboxylic acid 3- fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzotf]azulene-9-carbonyl)-benzylamide

Example E90.1 [3-Fluoro-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f] azulene-9-carbonyl) -benzyl] -carbamic acid tert- butyl ester A mixture of 4- (tert-butoxycarbonylamino-methyl) -2- fluoro-benzoic acid from Example E2 (1.35g, 5.0mmol), 3-methyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f]azulene from Example Ell (1.Og, 5.0mmol) and PyBroP (3.03g, 6.5mmol) in dichloromethane (25ml) and DIEA (1.31ml, 7.5mmol) was heated at reflux for 18 h. After cooling to room temperature, the mixture was washed with 5% KHCO3, IM HCl then brine, dried and con¬ centrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (1.25g, 56%) .

Example E90.2 (4-Aminomethyl-2-fluoro-phenyl) - (3-methyl-4, 10-dihydro- 3H-2, 3,4, 9-tetraaza-benzo [f] azulen-9-yl) -methanone hy¬ drochloride [3-Fluoro-4- (3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -benzyl] -carbamic acid tert- butyl ester from Example E90.1 (1.25g, 2.8mmol) was re¬ acted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (1.Og, 97%) .

Example E90.3 l-Cyclopropylπιethyl-piperidine-4-carboxylic acid 3- fluoro-4- (3-methyl-4, 10-dihvdro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -benzylamide HBTU (227mg, O.βmmol) was added to a solution of 1- cyclopropylmethyl-piperidine-4-carboxylic acid from Ex¬ ample E15a (99mg, 0.45mmol) in DMF (5ml) and DIEA (to pH9) . The mixture was stirred at room temperature for 1 h. (4-Aminomethyl-2-fluoro-phenyl) - (3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo[f] azulen-9-yl) - methanone hydrochloride from Example E90.2 (llβmg, 0.3mmol) was added and the mixture was stirred at room temperature for 18h. Solvents were removed in vacuo and azeotroped with toluene. The residue was redissolved in EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% am¬ monia: 19% methanol: 80% dichloromethane) to give a white solid identified as the title compound (71.5mg, 46%) .

Example E91 N-[2-Methyl-4-(3-methyl-4,10-dihγdro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -benzyl]-2- piperidin-4-yl-acetamide hydrochloride

A solution of 4-{ [2-methyl-4- (3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - benzylcarbamoyl] -methyl}-piperidine-1-carboxylic acid tert-butyl ester (Compound number 1067) (156mg, 0.27mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (135mg, 97%) .

Example E92 2-[1- (3,3-Dimethyl-butyl) -piperidin-4-yl]-N- [2-methyl- 4- (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -benzyl] -acetamide

3,3-Dimethylbutyraldehyde (0.048ml, 0.38mmol) was added to a solution of N- [2-methyl-4- (3-methyl-4, 10-dihydro- 3H-2, 3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) - benzyl] -2-piperidin-4-yl-acetam±de from Example E91 (130mg, 0.25mmol) in methanol/acetic acid (49:1, v/v, 2.5ml) and the mixture was stirred at room temperature for Ih. Sodium cyanoborohydride (24mg, 0.38mmol) was added, and the mixture was stirred at room temperature for 18h then concentrated in vacuo. The residue was dissolved in dichloromethane, washed with saturated Na- HCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 1.5% 35% ammonia: 15% methanol: 83.5% dichloromethane) to give a white solid identified as the title compound (107mg, 75%) .

Example E93 l-Propyl-piperidine-4-carboxylic acid 2-chloro-4- (3- methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -benzylamide

A solution of propionaldehyde (0.29mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) was added to a solution of piperidine-4-carboxylic acid 2-chloro-4- (3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9- carbonyl) -benzylamide hydrochloride (Compound number 1109) (2.8mg, 0.005mmol) in 1,2-dichloroethane (0.05ml) and DIEA (0.0026ml). The mixture was stirred at room temperature for Ih then a solution of sodium triace- toxyborohydride (1.59mg, 0.0075mmol) in DMF (0.05ml) was added. The mixture was stirred for 2Oh at room tem¬ perature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 521.4

Example E94 N-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -2-fluoro-benzyl] -2-(1- hexyl-piperidin-4-yl) -acetamide

A solution of 1-bromohexane (0.83mg, 0.005mmol) in DMF(0.05ml) was added to a solution of N- [4- (3,6- dimethyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzyl] -2- piperidin-4-yl-acetamide hydrochloride (Compound number 1110) (2.82mg, 0.005mmol) in DMF (0.05ml) and triethyl- amine (0.0021ml) . The mixture was stirred for 20h at room temperature then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H] += 575.7

Example E95 N-[4- (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[£]azulene-9-carbonyl) -3-methyl-benzyl] - 3- (l-propionyl-piperidin-4-yl)-propionamide

A solution of propionyl chloride (0.46mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of N- [4- (6-chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f]azulene-9-carbonyl) -3-methyl-benzyl] -3- piperidin-4-yl-propionamide hydrochloride (Compound number 1108) (2.97mg, 0.005mmol) in dichloromethane (0.05ml) and triethylamine (0.0035ml) . The mixture was stirred at room temperature for Ih then solvents were removed in vacuo to yield the title compound. (ESI)+: [M+H]+= 577.4

Example E96 N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]aziilene-9-carbonyl) -3-methyl-benzyl]- 3- (l-ethanesulfonyl-piperidin-4-yl) -propionamide

A solution of ethanesulfonyl chloride (0.64mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of N- [4- (6-chloro-3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) -3-methyl- benzyl] -3-piperidin-4-yl-propionamide hydrochloride (Compound number 1108) (2.97mg, 0.005mmol) in dichloro- methane (0.05ml) and triethylamine (0.0035ml) . The mix¬ ture was stirred at room temperature for Ih then sol¬ vents were removed in vacuo to yield the title com¬ pound. (ESI)+: [M+H]+= 613.4

Example E97 4-{2-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -3- methylbenzylcarbamoyl] -ethyl}-piperidine-1-carboxylic acid 4-nitro-benzyl ester

A solution of 4-nitrobenzyl chloroformate (1.08mg, 0.005mmol) in dichloromethane (0.05ml) was added to a solution of N- [4- (β-chloro-3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo [f] azulene-9-carbonyl) -3-methyl- benzyl] -3-piperidin-4-yl-propionamide hydrochloride (Compound number 1108) (2.97mg, 0.005mmol) in dichloro¬ methane (0.05ml) and triethylamine (0.0035ml) . The mix¬ ture was stirred at room temperature for Ih then sol- vents were removed in va cuo to yield the title com¬ pound . (ESI ) + : [M+H] += 700 . 5 , 702 . 5

Example Ξ98 Propane-1-sulfonic acid 4- (3 , 6-dimethyl-4 , 10-dihydro- 3H-2 , 3 , 4 , 9-tetraaza-benzo [f ] azτalene-9-carbonyl) -2- fliioro-benzylamide

Example E98 . 1 [4- (3, 6-Dimethyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzyl] -carbamic acid tert-butyl ester A mixture of 4- (tert-butoxycarbonylamino-methyl) -3- fluoro-benzoic acid from Example E3 (1.38g, 5.1mmol) and 3, β-dimethyl-3, 4, 9, 10-tetrahydro-2, 3, 4, 9-tetraaza- benzo [f] azulene from Example E2 (l.Og, 4.7mmol) in di- chloromethane (20ml) at room temperature was treated with DIEA (2.44ml, 14. Ommol) , DMAP (627mg, 5.1mmol) and WSCD (l.lβg, δ.lmmol) . The solution was heated at re- flux for 2 days then washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (1.29g, 59%) .

Example E98.2 (4-Aminomethyl-3-fluoro-phenyl) - (3, 6-dimethyl-4, 10- dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride [4- (3, 6-Dimethyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzyl] -carbamic acid tert-butyl ester from Example E98.1 (1.29g, 2.8mmol) was reacted with 4N HCl/dioxan using an analo- gous procedure to that described for Example E4.2 to yield the title compound (l.lg, 99%) .

Example E98.3 Propane-1-sulfonic acid 4- (3, 6-dimethyl-4, 10-dihydro- 3H-2, 3, 4, 9-tetraaza-benzo [f] azulene-9-carbonyl) -2- fluoro-benzylamide 1-Propanesulfonyl chloride (0.016ml, 0.14mmol) was added to a solution of (4-aminomethyl-3-fluoro-phenyl) - (3, 6-dimethyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone hydrochloride from Exam¬ ple E98.2 (50mg, 0.12mmol) in dichloromethane (2ml) and triethylamine (0.038ml, 0.27mmol) at room temperature. The mixture was stirred for Ih then concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro¬ methane) to give a white solid identified as the title compound (30mg, 51%) .

Example E99 N-[4- (3,6-Dimethyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -2-fluoro-benzyl] -formamide

Formic acid (0.85ml, 22.5mmol) and acetic anhydride (1.4ml, 13.5mmol) were combined and stirred for 1 h at room temperature. (4-Aminomethyl-3-fluoro-phenyl) - (3, 6- dimethyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone hydrochloride from Exam- pie E98.2 (113mg, 0.3mmol) was added and the mixture was stirred for 1 h. Water (20ml) was added and the mixture was stirred for I h. It was diluted with chlo¬ roform, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo to yield a white solid iden¬ tified as the title compound (48mg, 40%) .

Example Ξ100 Cyclopropanecarboxylic acid 4- (3,6-dimethyl-4,10- dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl) -2-fluoro-benzylamide

DIEA (0.08ml, 0.46mmol) and cyclopropanecarbonyl chlo- ride (0.013ml, 0.14mmol) were added to a solution of (4-aminomethyl-3-fluoro-phenyl) - (3, β-dimethyl-4, 10- dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride from Example E98.2 (57mg, 0.14mmol) in dichloromethane (10ml) at O0C. The mixture was stirred for 90min at room temperature then diluted with dichloromethane, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammo¬ nia: 9.5% methanol: 90% dichloromethane) to give a white solid identified as the title compound (33mg, 54%) .

Example ElOl Cyclopropanecarboxylic acid 4- (3,6-dimethyl-4,10- dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9- carbonyl)-2-methyl-benzylamide

Example ElOl.1 4- (3, 6-Dimethyl-4,10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-methyl-benzonitrile A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (753mg, 4.7mmol) and thionyl chloride (1.02ml, 14.0mmol) in toluene (50ml) was heated at reflux for 2 h. After cooling at room temperature, solvents were re¬ moved in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (45ml) and a solu¬ tion of 3,6-dimethyl-3,4, 9, 10-tetrahydro-2, 3, 4, 9- tetraaza-benzo [f] azulene from Example E2 (1.Og, 4.7mmol) in dichloromethane (5ml) and triethylamine (1.3ml, 9.3mmol) was added slowly. The mixture was stirred at room temperature for 2Oh, washed with brine, dried and concentrated in vacuo. The residue was puri- fied by flash chromatography on silica gel through an isolute (eluant; EtOAc) to yield the title compound (1.42g, 85%).

Example ElOl.2 (4-Aminomethyl-3-methyl-phenyl) - (3, 6-dimethyl-4, 10- dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone A solution of 4- (3, 6-dimethyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -2-methyl- benzonitrile from Example ElOl.1 (1.42g, 4.0mmol) in methanol (50ml) at O0C was treated with cobalt (II) chloride hexahydrate (1.9Og, δ.Ommol) . The mixture was stirred for 15min at room temperature then sodium boro- hydride (1.51g, 40.0mmol) was added portionwise. The reaction mixture was stirred for 2h then saturated NH4Cl was added. The mixture was stirred for 30min then the solid was filtered off through Celite® filter agent and the filtrate concentrated in vacuo. The residue was re- dissolved in EtOAc and saturated NaHCO3. The layers were partitioned and the aqueous layer was extracted further with chloroform. Organics were combined, dried and con¬ centrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 1% 35% ammonia: 9% methanol: 90% dichloro- methane) to yield the title compound (511mg, 35%) .

Example ElOl.3 Cyclopropanecarboxylic acid 4- (3, 6-dimethyl-4, 10- dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulene-9- carbonyl) -2-methyl-benzylamide Triethylamine (0.145ml, 1.04mmol) and cyclopropanecar- bonyl chloride (0.041ml, 0.45mmol) were added to a so- lution of (4-aminomethyl-3-methyl-phenyl) - (3, 6- dimethyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone from Example ElOl.2 (150mg, 0.41mmol) in dichloromethane (10ml) at room temperature. The mixture was stirred for 2Oh then con- centrated in vacuo. The residue was purified by prepa¬ rative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give an off-white solid identified as the title compound (91mg, 51%) .

Example El02 Cyclopropanecarboxylic acid 4-(6-chloro-3-methyl-4,10- dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)- 2-fluoro-benzylamide

Example E102.1 [4- (6-Chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulene-9-carbonyl) -2-fluoro-benzyl] -carbamic acid tert-butyl ester A solution of 4- (tert-butoxycarbonylamino-methyl) -3- fluoro-benzoic acid from Example E3 (568mg, 2.1mmol) in dichloromethane (25ml) at room temperature was treated with DMAP (25βmg, 2.1mmol), DIEA (1.1ml, 6.3itimol) then WSCD (520mg, 2.7mmol) . The mixture was stirred for 3 h then 6-chloro-3-methγl-3, 4,9, 10-tetrahydro-2,3,4,9- tetraaza-benzo [f] azulene from Example El (450mg, 1.9mmol) was added. The mixture was stirred for 4 days then washed with saturated NaHCU3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (503mg, 54%) .

Example El02.2 (4-Aminomethyl-3-fluoro-phenyl) - (6-chloro-3-methyl- 4, 10-dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride [4- (6-Chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo[f] azulene-9-carbonyl) -2-fluoro-benzyl] -carbamic acid tert-butyl ester from Example E102.1 (503mg, 1.03mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (440mg, 100%) .

Example El02.3 Cyclopropanecarboxylic acid 4- (6-chloro-3-methyl-4, 10- dihydro-3H-2, 3,4, 9-tetraazabenzo [f] azulene-9-carbonyl) - 2-fluoro-benzylamide Cyclopropanecarbonyl chloride (0.045ml, 0.5mmol) was added to a solution of (4-aminomethyl-3-fluoro-phenyl) - (6-chloro-3-methyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone hydrochloride from Exam¬ ple E102.2 (210mg, 0.5mmol) in dichloromethane (40ml) and DIEA (0.30ml, 1.7mmol) at 0°C. The mixture was stirred for Ih at room temperature then washed with saturated NaHCO3, brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro- methane) to give a white powder identified as the title compound (134mg, 59%) .

Example El03 N-[4- (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -2-fluoro-benzyl]- propionamide

DIEA (0.27ml, 1.5βmmol) and propionyl chloride (0.048ml, 0.55mmol) were added to a solution of (4- aminomethyl-3-fluoro-phenyl) - (6-chloro-3-methyl-4, 10- dihydro-3H-2, 3,4, 9-tetraaza-benzo[f]azulen-9-yl) - methanone hydrochloride from Example E102.2 (220mg, 0.52mmol) in dichloromethane (6ml) at room temperature. The mixture was stirred for 2h, washed with saturated NaHCθ3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white powder identified as the title compound (129mg, 56%) .

Example El04 N-[4-(6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -2-fluoro-benzyl]- butyramide

DIEA (0.135ml, 0.78mmol) and butyryl chloride (0.027ml, 0.27mmol) were added to a solution of (4-aminomethyl-3- fluoro-phenyl) - (6-chloro-3-methyl-4, 10-dihydro-3H- 2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) -methanone hydro¬ chloride from Example E102.2 (llOmg, 0.26mmol) in di¬ chloromethane (3ml) at room temperature. The mixture was stirred for Ih, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammo¬ nia: 9.5% methanol: 90% dichloromethane) to give a white powder identified as the title compound (77mg, 65%) .

Example E105 N-[4- (6-Chloro-3-methγl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -2-fluoro-benzyl] - ±sobutyram±de

DIEA (0.135ml, 0.78mmol) and isobutyryl chloride (0.029ml, 0.27mmol) were added to a solution of (4- aminomethyl-3-fluoro-phenyl) - (6-chloro-3-methyl-4, 10- dihydro-3H-2, 3, 4, 9-tetraaza-benzo [f] azulen-9-yl) - methanone hydrochloride from Example E102.2 (llOmg, 0.26mmol) in dichloromethane (3ml) at room temperature. The mixture was stirred for Ih, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white powder identified as the title compound (85mg, 71%) .

Example ElO6 Cyclopropanecarboxylic acid 2-chloro-4- (6-chloro-3- methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl) -benzylamide

Example El06.1 [2-Chloro-4- (6-chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -benzyl] -carbamic acid tert-butyl ester A solution of 4- (tert-butoxycarbonylamino-methyl) -3- chloro-benzoic acid from Example E2b (568mg, 2.0mmol) in dichloromethane (25ml) at room temperature was treated with DMAP (244mg, 2.0mmol), DIEA (1.0ml, β.Ommol) then WSCD (500mg, 2.6mmol) . The mixture was stirred for 3 h then β-chloro-3-methyl-3, 4, 9, 10- tetrahydro-2, 3, 4, 9-tetraaza-benzo[f]azulene from Exam¬ ple El (430mg, 1.8mmol) was added. The mixture was stirred for 4 days then washed with saturated NaHCO3, brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; EtOAc) to yield the title compound (570mg, 63%) .

Example El06.2 (4-Aminomethyl-3-chloro-phenyl) - (6-chloro-3-methyl- 4, 10-dihydro-3H-2, 3, 4, 9-tetraaza-benzo[f]azulen-9-yl) - methanone hydrochloride [2-Chloro-4- (6-chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -benzyl] -carbamic acid tert-butyl ester from Example ElO6.1 (570mg, 1.13mmol) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (490mg, 100%) .

Example E106.3 Cyclopropanecarboxylic acid 2-chloro-4- (6-chloro-3- methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f]azulene-9-carbonyl) -benzylamide Cyclopropanecarbonyl chloride (0.045ml, 0.5mmol) was added to a solution of (4-aminomethyl-3-chloro-phenyl) - (6-chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone hydrochloride from Exam¬ ple E106.2 (220mg, 0.5mmol) in dichloromethane (40ml) and DIEA (0.30ml, 1.7mmol) at O0C. The mixture was stirred for Ih at room temperature then washed with saturated NaHCO3, brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro- methane) to give a white powder identified as the title compound (135mg, 57%) .

Example El07 N-[2-Chloro-4- (6-chloro-3-methyl-4,10-dihydro-3H- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonγl) -benzyl] - butyramide

Butyryl chloride (46mg, 0.4mmol) was added to a solu¬ tion of (4-aminomethyl-3-chloro-phenyl) - (β-chloro-3- methyl-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen- 9-yl) -methanone hydrochloride from Example E106.2 (lβlmg, 0.4mmol) in dichloromethane (10ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for 2Oh, diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloro¬ methane) to give a white solid identified as the title compound (llOmg, 58%) .

Example El08 N-[2-Chloro-4-(6-chloro-3-methyl-4,10-dihydro-3H- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl) -benzyl]- isobυtyramide

Isobutyryl chloride (46mg, 0.4mmol) was added to a solution of (4-aminomethyl-3-chloro-phenyl) - (β-chloro- 3-methyl-4, 10-dihydro-3H-2, 3, 4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone hydrochloride from Example E106.2 (lβlmg, 0.4mmol) in dichloromethane (10ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for 18h, diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and con¬ centrated in vacuo. The residue was purified by prepa- rative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white solid identified as the title compound (75mg, 40%) .

Example El09 {4- [ (Cyclopropylmethyl-amino) -methyl]-3-methyl- phenyl} (3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulen-9-yl) -methanone

Cyclopropanecarboxaldehyde (2βmg, 0.34 mmol) was added to a solution of (4-Aminomethyl-3-methyl-phenyl) - (3- methyl-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f] azulen- 9-yl) -methanone (131mg, 0.38 mmol) in MeOH/AcOH (99:1, 5ml) and the mixture was stirred at room temperature for 30 min. Sodium cyanoborohydride (31mg, 0.49 mmol) was added and the mixture was stirred at room tempera¬ ture for 18 h. The solvents were removed in vacuo and the residue was dissolved in EtOAc. The solution was washed with sat. aq. NaHCO3 and brine, then dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% metha¬ nol: 90% dichloromethane to give a white solid identi¬ fied as the title compound (70mg, 51%) .

Example ElIO [4- (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulene-9-carbonyl)-2-fluoro-benzylamino]- acetic acid methyl ester and

Example ElIl { [4- (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonγl) -2-fluoro-benzyl]- methoxycarbonylmethyl-amino}-acetic acid methyl ester

Methyl bromoacetate (0.054ml, 0.58mmol) was added to a solution of (4-aminomethyl-3-fluoro-phenyl) - (6-chloro-3- methyl-4, 10-dihydro-3H-2, 3,4, 9-tetraaza-benzo [f]azulen- 9-yl) -methanone hydrochloride from example E102.2 (107mg, 0.28mmol) and DIEA (0.26ml, 1.53mmol) in THF (25ml) and the mixture was stirred at room temperature for 2h. A further amount of methyl bromoacetate (0.10ml, l.llmmol) was added, and the mixture was stirred overnight at room temperature. The solution was quenched with water and diluted with EtOAc. The organic layer was washed with brine (x 3) , dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to yield two products. The faster eluting product was isolated as a white solid and identified as ElIl (68mg, 46%) .

The slower eluting product was isolated as a white solid and identified as EIlO (13mg, 10%) .

Example E112 (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza- benzo[f]azulen-9-yl)-{3-fluoro-4-[ (2-hydroxy- ethylamino) -methyl] -phenyl}-methanone Lithium aluminium hydride (14.5mg, 0.38mmol) was added to a solution of [4- (β-chloro-3-methyl-4, 10-dihydro-3H- 2,3,4, 9-tetraaza-benzo[f] azulene-9-carbonyl) -2-fluoro- benzylamino]-acetic acid methyl ester from example EIlO (58.5mg, 0.13mmol) in THF (5ml), and the mixture was stirred at room temperature for 30 min. Before being quenched with MeOH and extracted with EtOAc. The or¬ ganic extract was washed with brine, dried and concen¬ trated in vacuo. The residue was purified by flash chro- matography on silica gel (eluant; 10% methanol: 90% di- chloromethane then 20% methanol: 80% dichloromethane) to give a pale yellow solid identified as the title com¬ pound (15mg, 28%) .

Example E113 { [4- (6-Chloro-3-methyl-4,10-dihydro-3H-2,3,4,9- tetraaza-benzo[f]azulene-9-carbonyl) -2-fluoro- benzylcarbamoyl] -methyl}-carbamic acid tert-butyl ester

HBTU (165mg, 0.44mmol) was added to a solution of N- (tert-butoxycarbonyl) glycine (65mg, 0.37mmol) in DMF (10ml) and the mixture was stirred for 30min at room temperature. (4-Aminomethyl-3-fluoro-phenyl) - (6-chloro- 3-methyl-4, 10-dihydro-3H-2,3,4, 9-tetraaza- benzo [f] azulen-9-yl) -methanone hydrochloride from Exam¬ ple E102.2 (lOOmg, 0.22mmol) and DIEA (0.228ml, 1.31mmol) were added and the mixture was stirred for 24h at room temperature. The solution was diluted with EtOAc, washed with water then brine, dried and concen- trated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol: 95% dichloromethane then 10% methanol: 90% dichloromethane) to give a white solid identified as the title compound (123mg, 100%) .

Example E114 2-Amino-N-[4- (6-chloro-3-methyl-4,10-dihydro-3H- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl) -2-fluoro- benzyl]-acetamide hydrochloride

{ [4- (6-Chloro-3-methyl-4, 10-dihydro-3H-2, 3, 4, 9- tetraaza-benzo [f] azulene-9-carbonyl) -2-fluoro- benzylcarbamoyl] -methyl}-carbamic acid tert-butyl ester from Example E113 (120mg, 0.22minol) was reacted with 4N HCl/dioxan using an analogous procedure to that de¬ scribed for Example E4.2 to yield the title compound (95mg, 83%) .

Example E115 4-[ (3-Chloro-benzoylamino) -methyl] -N- (4-chloro-phenyl) - 3,N-dimethyl-benzamide

Example E115.1 N- (4-Chloro-phenyl) -4-cyano-3,N-dimethyl-benzamide A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (3.4g, 21mmol) and thionyl chloride (10ml, 137mmol) in dichloromethane (50ml) was heated at reflux for 2 h. After cooling at room temperature, solvents were re¬ moved in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (50ml) . (4-Chloro- phenyl) -methyl amine (3.Og, 21mmol) and triethylamine (to pH9) were added and the mixture was stirred at room temperature for 20h then concentrated in vacuo. The residue was redissolved in EtOAc, washed with IM KHSO4, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 35% EtOAc: 65% cyclohexane) to yield the title compound (5.1g, 85%) .

Example El15.2 4-Αminomethyl-N- (4-chloro-phenyl) -3,N-dimethyl- benzamide A solution of N- (4-chloro-phenyl) -4-cyano-3,N-dimethyl- benzamide from Example E115.1 (5.1g, 17.9mmol) in methanol (250ml) was treated with cobalt (II) chloride hexahydrate (8.4g, 35.8mmol) . The mixture was stirred for 15min at room temperature then cooled down to 0°C and sodium borohydride [β.lg, 179mmol) was added por- tionwise. The mixture was stirred for Ih at room tem- perature, filtered through Celite® filter agent, washed with methanol and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia:10% methanol: 89% dichloromethane) to yield the title compound (3.βg, 70%) .

Example Ell5.3 4-[ (3-Chloro-benzoylamino) -methyl] -N- (4-chloro-phenyl) - 3,N-dimethyl-benzamide 3-Chlorobenzoyl chloride (βlmg, 0.35mmol) and triethyl- amine (to pH9) were added to a solution of 4- aminomethyl-N- (4-chloro-phenyl) -3,N-dimethyl-benzamide from Example E115.2 (lOOmg, 0.35mmol) in dichloro¬ methane (5ml) at room temperature. The mixture was stirred for Ih then concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% am¬ monia: 9.5% methanol: 90% dichloromethane) to give a white solid identified as the title compound (lOlmg, 69%) .

Example Ell6 l-Cyclopropylmethyl-piperidine-4-carboxylic acid 4-[(4- chloro-phenyl) -methyl-carbamoyl] -2-methyl-benzylamide

PyBroP (212mg, 0.45mmol) and 1-cyclopropylmethyl- piperidine-4-carboxylic acid from Example El5a (76mg, 0.42mmol) were added to a solution of 4-aminomethyl-N- (4-chloro-phenyl) -3,N-dimethyl-benzamide from Example E115.2 (lOOmg, 0.35mmol) in dichloromethane (5ml) and DMF (ImI) . The mixture was stirred at room temperature for 18h then solvents were removed in vacuo and azeotroped with toluene. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% metha¬ nol: 90% dichloromethane) to give a white powder identi¬ fied as the title compound (34mg, 22%) .

Example E117 1- (3,3-Dimethyl-butyl) -piperidine-4-carboxylic acid 4- t (4-chloro-phenyl)-methyl-carbamoyl]-2-methyl- benzylamide

HBTU (29βmg, 0.78mmol) was added to a solution of 1- (3, 3-dimethyl-butyl) -piperidine-4-carboxylic acid from Example El5 (182mg, 0.73mmol) in DMF (5ml) and DIEA (0.272ml, 1.56mmol) . The mixture was stirred at room temperature for 2 h then 4-aminomethyl-N- (4-chloro- phenyl) -3,N-dimethyl-benzamide from Example E115.2 (150mg, 0.52mmol) was added. The mixture was stirred for 2 h at room temperature then diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and con- centrated in vacuo. The residue was purified by prepa¬ rative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a white powder identified as the title compound (209mg, 83%) .

Example Ell8 1-(3,3-Dimethyl-butyl) -piperidine-4-carboxylic acid 2- methyl-4-[methyl- (4-trifluoromethy1-phenyl) -carbamoyl] - benzylamide

Example El18.1 4-Cyano-3-methyl-N- (4-trifluoromethyl-phenyl) -benzamide A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (750mg, 4.βmmol) and thionyl chloride (1.02ml, 14.0inmol) in toluene (40ml) was heated at reflux for 2 h. After cooling at room temperature, solvents were re¬ moved in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (25ml) then 4- trifluoromethylaniline hydrochloride (l.llg, 5.6mmol) in dichloromethane (5ml) and triethylamine (1.95ml, 14.0mmol) was added. The mixture was stirred at room temperature for 2 days, washed with brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 20% EtOAc: 80% cyclohexane) to yield the title compound (1.13g, 80%) .

Example El18.2 4-Cyano-3,N-dimethyl-N- (4-trifluoromethyl-phenyl) - benzamide 4-Cyano-3-methyl-N- (4-trifluoromethyl-phenyl) -benzamide from Example E118.1 (l.lOg, 3.6mmol) was dissolved in DMF (10ml) and cooled down to 0°C. Sodium hydride (60% dispersion in oil, 174mg, 4.3mmol) was added and the mixture was stirred for 30min at room temperature. Methyl iodide (0.27ml, 4.3mmol) was added and the mixture was stirred for 2Oh. Solvents were removed in vacuo and azeotroped with toluene. The residue was re- dissolved in EtOAc, washed with brine, dried and con¬ centrated in vacuo to yield the title compound (l.Oδg, 94%) .

Example E118.3 4-Aminomethyl-3,N-dimethyl-N- (4-trifluoromethyl- phenyl) -benzamide A solution of 4-cyano-3,N-dimethyl-N- (4- trifluoromethyl-phenyl) -benzamide from Example E118.2 (1.08g, 3.4mmol) in methanol (40ml) at room temperature was treated with cobalt (II) chloride hexahydrate (1.6Ig, 6.8mmol) . The mixture was stirred for lOmin then sodium borohydride (1.28g, 34mmol) was added por- tionwise. The mixture was stirred for 2Oh then satu- rated NH4Cl solution (10ml) was added. The mixture was stirred for 30min, filtered through glass-fibre paper and the filtrate was concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia: 9% methanol: 90% dichloro- methane) to yield the title compound (863mg, 79%) .

Example E118.4 1- (3, 3-Dimethyl-butyl) -piperidine-4-carboxylic acid 2- methyl-4- [methyl- (4-trifluoromethyl-phenyl) -carbamoyl] - benzylamide PyBroP (188mg, 0.40mmol) and 1- (3, 3-dimethyl-butyl) - piperidine-4-carboxylic acid (82mg, 0.38mmol) were added to a solution of 4-aminomethyl-3,N-dimethyl-N- (4- trifluoromethyl-phenyl) -benzamide from Example E118.3 (lOOmg, 0.31mmol) in dichloromethane (5ml) and DIEA (0.081ml, 0.4βmmol) . The mixture was stirred at room temperature for 2 days, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The resi¬ due was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% dichloromethane) to give a off-white powder identified as the title compound (22mg, 14%) .

Example El19 Cyclopropanecarboxylic acid 2-methyl-4-(2-methy1-4,5- dihydro-l-oxa-3,6-diaza-benzo[e]aziilene-6-carbonyl)- benzylamide

Example El19.1 [2-Methyl-4- (2-methyl-4, 5-dihydro-l-oxa-3, 6-diaza- benzo [e]azulene-6-carbonyl) -benzyl] -carbamic acid tert- butyl ester A solution of 4- (tert-butoxycarbonylamino-methyl) -3- methyl-benzoic acid from Example E2h (400mg, 1.5mmol) in dichloromethane (20ml) and triethylamine (to pH9) was treated with WSCD (573mg, 3.0mmol) and DMAP (183mg, 1.5mmol) . The solution was stirred for 30min at room temperature then 2-methyl-5, 6-dihydro-4H-l-oxa-3, 6- diaza-benzo [e]azulene from Example E6 (300mg, 1.5mmol) was added and the mixture was heated at reflux for 3 days. WSCD (287mg, 1.5mmol) was added and the mixture was heated at reflux for another 24h then concentrated in vacuo. The residue was dissolved in EtOAc, washed with IN KHSO4, water then brine, dried and concentrated in vacuo. The residue was purified by flash chromatog- raphy on silica gel (eluant; EtOAc) to yield the title compound (62mg, 9%) .

Example E119.2 (4-Aminomethyl-3-methyl-phenyl) - (2-methyl-4, 5-dihydro- l-oxa-3, 6-diaza-benzo[e] azulen-6-yl) -methanone hydrochloride [2-Methyl-4- (2-methyl-4, 5~dihydro-l-oxa-3, 6-diaza- benzo[e] azulene-6-carbonyl) -benzyl]-carbamic acid tert- butyl ester from Example E119.1 (62mg, 0.14mmol) in methanol (0.5ml) was reacted with 4N HCl/dioxan using an analogous procedure to that described for Example E4.2 to yield the title compound (53mg, 100%) .

Example Ell9.3 Cyclopropanecarboxylic acid 2-methyl-4- (2-methyl-4, 5- dihydro-l-oxa-3, 6-diaza-benzo[e] azulene-6-carbonyl) - benzylamide Cyclopropanecarbonyl chloride (26mg, 0.25mmol) was added to a solution of (4-aminomethyl-3-methyl-phenyl) - (2-methyl-4, 5-dihydro-l-oxa-3, 6-diaza-benzo [e]azulen-6- yl) -methanone hydrochloride from Example E119.2 (85mg, 0.22mmol) in dichloromethane (5ml) and triethylamine (to pH9) at room temperature. The mixture was stirred for Ih then purified by flash chromatography on silica gel (eluant; 10% methanol: 90% dichloromethane) to give a white solid identified as the title compound (62mg, 67%) .

Example E120 1- (3,3-Dimethyl-butyl) -piperidine-4-carboxylic acid 2- methyl-4- (2-methyl-4,5-dihydro-l-oxa-3,6-diaza- benzo[e]azulene-6-carbonyl) -benzylamide (4-Aminomethyl-3-methyl-phenyl) - (2-methyl-4, 5-dihydro- l-oxa-3, β-diaza-benzo [e] azulen-β-yl) -methanone hydrochloride from Example E119.2 (89mg, 0.225mmol) was dissolved in dichloromethane (10ml) and triethylamine (to pH9) at room temperature. 1- (3, 3-Dimethyl-butyl) - piperidine-4-carboxylic acid (53mg, 0.25mmol), DMAP (27mg, 0.225mmol) and PyBroP (165mg, 0.36mmol) were added and the mixture was heated at reflux for 18h. The solution was diluted with EtOAc, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia: 9% methanol: 90% dichloro¬ methane) to give a white solid identified as the title compound (84mg, 69%).

Example Ξ121 1- (3,3-Dimethyl-butyl)-piperidine-4-carboxylic acid 4- (l-benzyl-2-methyl-4,5-dihydro-lH-l,3,6-triaza- benzo[e]azulene-6-carbonyl) -2-methyl-benzylamide

Example E121.1 4- (l-Benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo[e] azulene-6-carbonyl) -2-methyl-benzonitrile A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (557mg, 3.4mmol) and thionyl chloride (0.755ml, 10.3mmol) in toluene (100ml) was heated at reflux for 2 h. After cooling to room temperature, solvents were re¬ moved in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (100ml) and triethylamine (0.962ml, 6.9mmol) then l-benzyl-2- methyl-1, 4,5, β-tetrahydro-1, 3, 6-triaza-benzo[e]azulene from Example E5a (l.Og, 3.4mmol) was added. The mixture was stirred at room temperature for 2h, washed with saturated NaHCO3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 50% EtOAc: 50% pet. ether then EtOAc) to yield the title compound (844mg, 56%) .

Example E121.2 (4-Aminomethyl-3-methyl-phenyl) - (l-benzyl-2-methyl-4, 5- dihydro-lH-1, 3, 6-triaza-benzo [e] azulen-6-yl) -methanone A solution of 4- (l-benzyl-2-methyl-4, 5-dihydro-lH- 1,3, 6-triaza-benzo [e] azulene-6-carbonyl) -2-methyl- benzonitrile from Example E121.1 (830mg, 1.9mmol) in methanol (10ml) at room temperature was treated with cobalt(II) chloride hexahydrate (913mg, 3.8mmol) . The mixture was stirred for 15min then cooled down to 0°C. Sodium borohydride (726mg, 19mmol) was added portion- wise and the reaction mixture was stirred for 2h at room temperature. 35% Ammonia (5ml) was added dropwise and the mixture was stirred for 30min then concentrated in vacuo. The residue was purified by flash chromatog¬ raphy on silica gel (eluant; 1% 35% ammonia: 9% metha¬ nol: 90% dichloromethane) to yield the title compound (680mg, 81%) .

Example E121.3 1- (3, 3-Dimethyl-butyl) -piperidine-4-carboxylic acid 4- (l-benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e] azulene-6-carbonyl) -2-methyl-benzylamide HBTU (175mg, 0.46mmol) was added to a solution of 1- (3, 3-dimethyl-butyl) -piperidine-4-carboxylic acid (86mg, 0.34mmol) in DMF (5ml) . The mixture was stirred at room temperature for 2 h then (4-aminomethyl-3- methyl-phenyl) - (l-benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6- triaza-benzo [e] azulen-β-yl) -methanone from Example E121.2 (lOOmg, 0.23mmol) and DIEA (0.12ml, 0.69mmol) were added. The mixture was stirred at room temperature for 18h then solvents were removed in vacuo and azeotroped with toluene. The residue was purified by flash chromatography on silica gel through an isolute (eluant; 5% methanol: 95% dichloromethane then 10% methanol: 90% dichloromethane) to give a yellow foam identified as the title compound (114mg, 79%) .

Example E122 1- (3,3-Dimethyl-butyl) -piperidine-4-carboxylic acid 2- methyl-4-(2-methyl-4,5-dihydro-lH-l,3,6-triaza- benzo[e]azulene-6-carbonyl) -benzylamide

1- (3, 3-Dimethyl-butyl) -piperidine-4-carboxylic acid 4- (l-benzyl-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e] azulene-β-carbonyl) -2-methyl-benzylamide from Example E121 (llOmg, 0.17mmol) was dissolved in absolute ethanol (5ml) and placed under an inert atmosphere. 10% Palladium on carbon (llOmg) and cyclo- hexene (0.176ml, 1.7mmol) were added and the mixture was heated at 60°C for 3 h. The catalyst was filtered off through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% metha¬ nol: 90% dichloromethane) to give a white powder identi¬ fied as the title compound (45mg, 48%) .

Example E123 Cyclopropanecarboxylic acid 2-methyl-4- (2-methyl-4,5- dihydro-IH-I,3,6-triaza-benzo[e]azulene-6-carbonyl) - benzylamide Example E123.1 Cyclopropanecarboxyllc acid 4- (l-benzyl-2-methyl-4, 5- dihydro-lH-1, 3, 6-triaza-benzo [e] azulene-6-carbonyl) -2- methyl-benzylamide DIEA (0.176ml, 1.02mmol) and cyclopropanecarbonyl chlo¬ ride (0.033ml, 0.36mmol) were added to a solution of (4-aminomethyl-3-methyl-phenyl) - (l-benzyl-2-methyl-4, 5- dihydro-lH-1, 3, 6-triaza-benzo[e] azulen-6-yl) -methanone from Example E121.2 (150mg, 0.34mmol) in dichloro- methane (5ml) at room temperature. The mixture was stirred for 2Oh, washed with saturated NaHCC>3 then brine, dried and concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% ammo- nia:9.5% methanol: 90% dichloromethane) to give the ti¬ tle compound (155mg, 90%) .

Example E123.2 Cyclopropanecarboxylic acid 2-methyl-4- (2-methyl-4, 5- dihydro-lH-1, 3, 6-triaza-benzo [e]azulene-6-carbonyl) - benzylamide Cyclopropanecarboxylic acid 4- (l-benzyl-2-methyl-4,5- dihydro-lH-1, 3, 6-triaza-benzo [e] azulene-6-carbonyl) -2- methyl-benzylamide from Example E123.1 (155mg, 0.31mmol) was dissolved in absolute ethanol (10ml) and placed under an inert atmosphere. 10% Palladium on car¬ bon (155mg) and cyclohexene (0.311ml, 3.1mmol) were added and the mixture was heated at 60°C for 18 h. The catalyst was filtered off through Celite® filter agent and the filtrate was concentrated in vacuo. The residue was purified by preparative HPLC (eluant; 0.5% 35% am¬ monia: 9.5% methanol: 90% dichloromethane) to give a white solid identified as the title compound (67mg, 53%) .

Example E124 Cyclopropanecarboxylic acid 2-methyl-4- (2-methyl-4,5- dihydro-3-thia-l,6-diaza-benzo[e]azulene-6-carbonyl) - benzylamide

Example E124.1 2-Methyl-4- (2-methyl-4, 5-dihydro-3-thia-l, 6-diaza- benzo [e] azulene-6-carbonyl) -benzonitrile A mixture of 4-cyano-3-methyl-benzoic acid from Example E6 (147mg, 0.91mmol) was dissolved in dichloromethane (25ml) and 2 drops of DMF and cooled down to 00C. Oxalyl chloride (0.1ml) was added slowly and the mixture was stirred for 2 h at room temperature. Solvents were re¬ moved in vacuo and azeotroped with toluene. The residue was redissolved in dichloromethane (10ml) and cooled down to 00C. Triethylamine (0.5ml) and 2-methyl-5, 6- dihydro-4H-3-thia-l, 6-diaza-benzo [e] azulene from Exam¬ ple E7 (165mg, 0.76mmol) in dichloromethane (10ml) were added and the mixture was stirred for 2 days at room temperature. Another 0.91mmol of acid chloride was for¬ med as previously and added to the mixture. The solu- tion was stirred for 2Oh at room temperature, washed with saturated NaHCU3 then brine, dried and concentrated in vacuo. The residue was purified by flash chromatog¬ raphy on silica gel (eluant; 10% EtOAc: 90% cyclohexane then 20% EtOAc: 80% cyclohexane) to yield the title com- pound (220mg, 80%) .

Example E124.2 (4-Aminomethyl-3-methyl~phenyl) - (2-methyl-4, 5-dihydro- 3-thia-l, 6-diaza-benzo[e]azulen-6-yl) -methanone A solution of 2-methyl-4- (2-methyl-4, 5-dihydro-3-thia- 1, 6-diaza-benzo[e]azulene-β-carbonyl) -benzonitrile from Example E124.1 (190mg, 0.53mmol) in methanol (15ml) at room temperature was treated with cobalt (II) chloride hexahydrate (275mg, 1.15mmol) . The mixture was stirred for 20min then cooled down to 0°C. Sodium borohydride (200mg, 5.3mmol) was added portionwise and the mixture was stirred for 2Oh at room temperature. Saturated NH4Cl (2ml) was added dropwise and the mixture was stirred for 30min then concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia: 9% methanol: 90% dichloromethane) to yield the title compound (lOOmg, 52%) .

Example E124.3 Cyclopropanecarboxylic acid 2-methyl-4- (2-methyl-4, 5- dihydro-3-thia-l, 6-diaza-benzo [e]azulene-6-carbonyl) - benzylamide DIEA (0.02ml, 0.115mmol) and cyclopropanecarbonyl chlo¬ ride (0.008ml, 0.088mmol) were added to a solution of (4-aminomethyl-3-methyl-phenyl) - (2-methyl-4, 5-dihydro- 3-thia-l, 6-diaza-benzo [e]azulen-6-yl) -methanone from E124.2 (20mg, 0.055mmol) in dichloromethane (5ml) at 0°C. The mixture was stirred for 2Oh at room temperature then concentrated in vacuo and purified by preparative HPLC (eluant; 0.5% 35% ammonia: 9.5% methanol: 90% di¬ chloromethane) to give a white powder identified as the title compound (llmg, 46%) .

Example E125 N- [4- ( 9-Chloro-2-methyl-4 , 5-dihydro-lH-l , 3 , 6-triaza- benzo[e]azulene-6-carbonyl) -2-methyl-benzyl] - isobutyramide

Example E125.1 4- [1- (4-Cyano-3-methyl-benzoyl) -9-chloro-2-methyl~4, 5- dihydro-lH-1, 3, 6-triaza-benzo [e] azulene-6-carbonyl] -2- methyl-benzonitrile A mixture of 4-cyano-3-methyl-benzoic acid from Example Eβ (262mg, l.βmmol) was dissolved in dichloromethane (20ml) and 2 drops of DMF and cooled down to 0°C. Oxalyl chloride (O.βml) was added and the mixture was stirred for 0.5 h at room temperature. Solvents were removed in vacuo and azeotroped with toluene. The residue was re- dissolved in dichloromethane (10ml) and added to a so¬ lution of 9-chloro-2-methyl-l, 4, 5, 6-tetrahydro-l, 3, 6- triaza-benzo[e] azulene from Example E7 (190mg, 0.8mmol) and DIEA (0.5ml) in dichloromethane (10ml) and the mix¬ ture was stirred for 2Oh. at room temperature. The sol- vents were removed in vacuo and the residue was taken up in EtOAc, washed with saturated NaHCU3 then brine, dried and concentrated in vacuo. The residue was puri¬ fied by flash chromatography on silica gel (eluant; 40% EtOAc: 60% cyclohexane) to yield the title compound (124mg, 30%) .

Example E125.2 4- (9-Chloro-2-methyl-4,5-dihydro-lH-l,3, 6-triaza- benzo [e] azulene-6-carbonyl) -2-methyl-benzonitrile 4- [1- (4-Cyano-3-methyl-benzoyl) -9-chloro-2-methyl-4, 5- dihydro-lH-1, 3, 6-triaza-benzo [e] azulene-6-carbonyl] -2- methyl-benzonitrile from E125.1 (124mg, 0.24mmol) was dissolved in MeOH 5ml) . 2M NaOH (2ml) was added, and the mixture was stirred for 1 h. at room temperature. The solvents were removed in vacuo, and azeotroped with toluene. The residue was taken up in EtOAc, was with saturated NaHC03 then brine, dried and concentrated in vacuo to yield the title compound (80mg, 89%)

Example E125.3 (4-Aminomethyl-3-methyl-phenyl) - (9-chloro-2-methyl-4, 5- dihydro-lH-1, 3, 6-triaza-benzo[e] azulen-6-yl) -methanone A solution of 4- (9-chloro-2-methyl-4, 5-dihydro-lH- 1,3, 6-triaza-benzo [e]azulene-6-carbonyl) -2-methyl- benzonitrile from E125.2 (80mg, 0.2 mmol) in methanol (5ml) at room temperature was treated with cobalt (II) chloride hexahydrate (lOlmg, 0.4mmol) . The mixture was cooled to O0C then sodium borohydride (80mg, 2.1mmol) was added portionwise. The reaction mixture was stirred at 00C for 30 min. then for 2h at room temperature then saturated NH4Cl was added. The mixture was stirred for lOmin then the solid was filtered off through Celite® filter agent and the filtrate concentrated in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 1% 35% ammonia: 9% methanol: 90% di- chloromethane) to yield the title compound (24mg, 30%) .

Example E125.4 N- [4- (9-Chloro-2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza- benzo [e] azulene-6-carbonyl) -2-methyl-benzyl] - isobutyramide Isobutyryl chloride (0.07ml, 0.07mmol) was added to a solution of (4-aminomethyl-3-methyl-phenyl) - (9-chloro- 2-methyl-4, 5-dihydro-lH-l, 3, 6-triaza-benzo [e] azulen-6- yl) -methanone from Example E125.3 (24mg, 0.07mmol) in dichloromethane (3ml) and DIEA (0.10ml, 0.57mmol) at O0C. The mixture was stirred for 2Oh at room temperature then solvents were removed in vacuo. The residue was purified by flash chromatography on silica gel (eluant; 5% methanol: 95% dichloromethane to 10% methanol: 90% di- chloromethane) to give a colourless oil identified as the title compound 24mg, 85%) .

Example A In vitro Testing Compounds were assayed to determine their ability to inhibit the cellular consequences of AVP stimulation on intact cells. In the assay, the compounds of the inven¬ tion cause significant inhibition of cellular activa¬ tion at concentrations of 30 μM or less. Preferred com- pounds cause significant inhibition at concentrations of 300 nM.

Example B Tablet for Oral Administration Tablets containing 100 mg of the compound of Example E8 as the active agent may be prepared from the following:

Compound of Example E8 200.0 g Corn starch 71.0 g Hydroxypropylcellulose 18.0 g Carboxymethylcellulose calcium 13.0 g Magnesium stearate 3.0 g Lactose 195.0 g Total 500.0 g

The materials are blended and then pressed to give 2000 tablets of 250 mg, each containing 100 mg of the com¬ pound of Example E8. All the cited references are hereby incorporated in their entirety. SCHEMES AND STRUCTURES Example El

Example E2

Examples E2a-g

Example E2a Example Ξ2b 4 -Aminome thyl - 3 - chlor o- 4-(tert- benzoic acid tert-btityl es¬ Butoxycarbonylamino- ter methyl) -3-chloro-benzoic acid

Example Ξ2c Example E2d 4-(tert- 4-Cyano-3-methyl-benzoic Butoxycarbony1amino- acid methyl) -3-nitro-benzoic acid

Example Ξ2e Example E2f 4-Cyano-2-methyl-benzoic 4- (tert- acid Butoxycarbonylamino- methyl) -2-fluoro-benzoic acid

Example Ξ2g 4-Cyano-3,5-dimethyl- benzoic acid xample E2h

Examle E3

Example E 4

Example E5a

Example E6

Example E7

xample E 8

Example E 9

Example ElO

.HCI Example Ell

Example E12

Example E13

Example E14

Example El 5

xample El5a

Example El6

.HCI Example E17

Example El 8

Example El 9

Example E20

Example E21

Example E22 Example E23 Example E25

Example E26

Example E27

Example E28

Example E29

Example E30

Example E31

Example E32

Example E33

Example E34

Example E35

Example E36

Example E37

Example E38

Example E39

Example E40

Example E41

Example E41a

Example E41b

Example E41c

Example E42

Example E43

Example E44

Example E45

Example E46 Example E47

Example E48

Example E49

Example E50 Example E51

Example E52 Example E53

Example E54

Example E56 Example E57 Example E58 Example E59 Example E60

Example E 62 Example E63

Example E64 Example E65

Example E 68

Example E69 Example E70

Example E71

Example E72

Example E73

Example E74

Example E75

Example E76

Example E77

Example E78

Example E80

Example E81 Example E82

Example E83 Example E84 Example E87 Example E88

Example E89

Example E90

Example E91

Example E92

Example E93 Example E94

Example E95

Example E96

Example E 97 Example E98

Example E99

Example ElOO Example ElOl Example El02

Example E103 Example E104

Example El 05

Example El 06

Example E107

Example E108

Example ElO 9

Example ElIO and Example ElIl Example E112

Example E113

Example E114

Example E115

Example El16

Example E117

Example Ell8 Example El 19

.HCI Example E120

Example E121

Example E122

Example E123

Example E124

Example E125

EXAMPLE TABLES

The following compounds were prepared using methods

analogous to those described above.

Example E5 and Compound number 2 have particular util¬

ity as intermediates.

T DK2005/000540

275

K2005/000540

289

0

290

K2005/000540

005/000540

05/000540

T/DK2005/000540

T/DK2005/000540

T/DK2005/000540

303

2005/000540

304

K2005/000540

T/DK2005/000540

2005/000540

T/DK2005/000540

000540

K2005/000540

DK2005/000540

312

05 000540

314

T/DK2005/000540

540

005/000540

005/000540

00540

DK2005/000540